0001144204-18-025522.txt : 20180507 0001144204-18-025522.hdr.sgml : 20180507 20180507080110 ACCESSION NUMBER: 0001144204-18-025522 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180507 DATE AS OF CHANGE: 20180507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 18809719 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 10-Q 1 tv491769_10q.htm FORM 10-Q

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 10-Q

 

 

 

xQuarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For Quarterly Period ended March 31, 2018

 

¨Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from                      to                      .

 

Commission File Number: 001-36357

 

 

 

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 99-0370688

(State or Other Jurisdiction of

Incorporation or Organization)

(IRS Employer

Identification No.)

   

675 Arapeen Drive, Suite 202,

Salt Lake City, Utah

84108
(Address of Principal Executive Offices) (Zip Code)

 

801-994-7383

(Registrant’s telephone number, including area code)

 

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.    Yes:  x No  ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):

 

Large accelerated filer ¨
Accelerated filer x
Non-accelerated filer ¨  
Smaller reporting company ¨
Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

 

Outstanding Shares

 

As of May 4, 2018, the registrant had 21,264,539 shares of common stock outstanding.

 

 

 

 

 

TABLE OF CONTENTS

 

    Page
   
PART I—FINANCIAL INFORMATION  
     
Item 1. Financial Statements (unaudited) 3
     
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 16
     
Item 3. Quantitative and Qualitative Disclosures About Market Risks 28
     
Item 4. Controls and Procedures 28
   
PART II—OTHER INFORMATION  
     
Item 1. Legal Proceedings 28
     
Item 1A. Risk Factors 29
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32
     
Item 3. Defaults Upon Senior Securities 33
     
Item 4. Mine Safety Disclosures 33
     
Item 5. Other Information 33
     
Item 6. Exhibits 33

 

 2 

 

 

PART I—FINANCIAL INFORMATION

 

ITEM  1.FINANCIAL STATEMENTS (UNAUDITED)

 

LIPOCINE INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited)

 

   March 31,   December 31, 
   2018   2017 
Assets          
Current assets:          
Cash and cash equivalents  $8,561,313   $3,210,749 
Marketable investment securities   19,201,374    18,257,321 
Accrued interest income   47,249    23,067 
Litigation insurance recovery   3,566,649    3,319,927 
Prepaid and other current assets   247,979    408,227 
Total current assets   31,624,564    25,219,291 
           
Property and equipment, net of accumulated depreciation of $1,111,366 and $1,121,080, respectively   32,331    75,070 
Other assets   23,753    30,753 
Total assets  $31,680,648   $25,325,114 
           
Liabilities and Stockholders' Equity          
Current liabilities:          
Accounts payable  $388,356   $598,070 
Litigation settlement payable   4,250,000    4,250,000 
Accrued expenses   305,064    1,497,056 
Debt - current portion   1,340,514    - 
Total current liabilities   6,283,934    6,345,126 
           
Debt - non-current portion   8,724,452    - 
Total liabilities   15,008,386    6,345,126 
           
Commitments and contingencies (notes 7 and 10)          
           
Stockholders' equity:          
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized; zero issued and outstanding   -    - 
Common stock, par value $0.0001 per share, 100,000,000 shares authorized; 21,270,249 and 21,270,249 issued and 21,264,539 and 21,264,539 outstanding   2,127    2,127 
Additional paid-in capital   145,850,292    145,423,012 
Treasury stock at cost, 5,710 shares   (40,712)   (40,712)
Accumulated other comprehensive loss   (19,651)   (4,616)
Accumulated deficit   (129,119,794)   (126,399,823)
           
Total stockholders' equity   16,672,262    18,979,988 
           
Total liabilities and stockholders' equity  $31,680,648   $25,325,114 

 

See accompanying notes to unaudited condensed consolidated financial statements

 

 3 

 

 

LIPOCINE INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

 

   Three Months Ending March 31, 
   2018   2017 
         
Revenues:          
License revenue  $428,031   $- 
Total revenues   428,031    - 
           
Operating expenses:          
Research and development   1,377,527    3,083,739 
General and administrative   1,687,490    1,825,176 
Total operating expenses   3,065,017    4,908,915 
Operating loss   (2,636,986)   (4,908,915)
           
Other income (expense):          
Interest and investment income   110,181    48,355 
Interest expense   (192,466)   - 
Total other income (expense), net   (82,285)   48,355 
Loss before income tax expense   (2,719,271)   (4,860,560)
Income tax expense   (700)   (700)
Net loss  $(2,719,971)  $(4,861,260)
           
Basic loss per share attributable to common stock  $(0.13)  $(0.26)
Weighted average common shares outstanding, basic   21,264,539    18,711,239 
          
Diluted loss per share attributable to common stock  $(0.13)  $(0.26)
Weighted average common shares outstanding, diluted   21,264,539    18,711,239 
           
Comprehensive loss:          
Net loss  $(2,719,971)  $(4,861,260)
Net unrealized gain (loss) on available-for-sale securities   (15,035)   2,707 
           
Comprehensive loss  $(2,735,006)  $(4,858,553)

 

See accompanying notes to unaudited condensed consolidated financial statements

 

 4 

 

 

LIPOCINE INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

   Three Months Ending March 31, 
   2018   2017 
         
Cash flows from operating activities:          
           
Net loss  $(2,719,971)  $(4,861,260)
           
Adjustments to reconcile net loss to cash used in operating activities:          
           
Depreciation expense   5,261    7,093 
Loss on disposition of property and equipment   37,478    - 
Stock-based compensation expense   427,280    632,290 
Non-cash interest expense   64,966    - 
Amortization of discount on marketable investment securities   (48,863)   (6,169)
           
Changes in operating assets and liabilities:          
Accrued interest income   (24,182)   2,997 
Prepaid and other current assets   160,248    67,509 
Accounts payable   (209,714)   607,595 
Litigation insurance recovery   (246,722)   - 
Accrued expenses   (1,191,992)   411,194 
Cash used in operating activities   (3,746,211)   (3,138,751)
           
Cash flows from investing activities:          
           
Refund of rental deposit   7,000    - 
Purchases of marketable investment securities   (13,210,225)   (6,972,103)
Maturities of marketable investment securities   12,300,000    8,400,000 
Cash provided by (used in) investing activities   (903,225)   1,427,897 
           
Cash flows from financing activities:          
           
Proceeds from debt agreement   10,000,000    - 
Proceeds from stock option exercises   -    388,551 
Net proceeds from common stock offering   -    2,698,098 
           
Cash provided by financing activities   10,000,000    3,086,649 
           
Net increase in cash and cash equivalents   5,350,564    1,375,795 
           
Cash and cash equivalents at beginning of period   3,210,749    5,560,716 
           
Cash and cash equivalents at end of period  $8,561,313   $6,936,511 
           
Supplemental disclosure of cash flow information:          
Interest paid  $127,500   $- 
Income taxes paid   700    700 
           
Supplemental disclosure of non-cash investing and financing activity:          
Net unrealized gain (loss) on available-for-sale securities  $(15,035)  $2,707 
Accrued final payment charge on debt   64,966    - 

 

See accompanying notes to unaudited consolidated financial statements

 

 5 

 

 

LIPOCINE INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

(1)Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements included herein have been prepared by Lipocine Inc. (“Lipocine” or the “Company”) in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The unaudited condensed consolidated financial statements are comprised of the financial statements of Lipocine and its subsidiaries collectively referred to as the Company. In management's opinion, the interim financial data presented includes all adjustments (consisting solely of normal recurring items) necessary for fair presentation. All intercompany accounts and transactions have been eliminated. Certain information required by U.S. generally accepted accounting principles has been condensed or omitted in accordance with rules and regulations of the SEC. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for any future period or for the year ending December 31, 2018.

 

These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and the notes thereto for the year ended December 31, 2017.

 

The preparation of the unaudited condensed consolidated financial statements requires management to make estimates and assumptions relating to reporting of the assets and liabilities and the disclosure of contingent assets and liabilities to prepare these condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period in conformity with U.S. generally accepted accounting principles. Actual results could differ from these estimates.

 

(2)Earnings (Loss) per Share

 

Basic earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is based on the weighted average number of common shares outstanding plus, where applicable, the additional potential common shares that would have been outstanding related to dilutive options and unvested restricted stock units to the extent such shares are dilutive.

 

 6 

 

 

The following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the three months ended March 31, 2018 and 2017:

 

   Three Months Ended March 31, 
   2018   2017 
Basic loss per share attributable to common stock:          
Numerator          
Net loss  $(2,719,971)  $(4,861,260)
           
Denominator          
Weighted avg. common shares outstanding   21,264,539    18,711,239 
           
Basic loss per share attributable to  common stock  $(0.13)  $(0.26)
           
Diluted loss per share attributable to common stock:          
Numerator          
Net loss  $(2,719,971)  $(4,861,260)
           
Denominator          
Weighted avg. common shares outstanding   21,264,539    18,711,239 
           
Diluted loss per share attributable to common stock  $(0.13)  $(0.26)

 

The computation of diluted loss per share for the three months ended March 31, 2018 and 2017 does not include the following stock options and unvested restricted stock units to purchase shares in the computation of diluted loss per share because these instruments were antidilutive:

 

   March 31, 
   2018   2017 
Stock options   2,374,449    2,070,076 
Unvested restricted stock units   203,998    287,000 

 

(3)       Marketable Investment Securities

 

 

The Company has classified its marketable investment securities as available-for-sale securities. These securities are carried at fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend income is recognized on the ex-dividend date and interest income is recognized on an accrual basis. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at March 31, 2018 and December 31, 2017 were as follows:

 

 7 

 

 

March 31, 2018  Amortized
Cost
   Gross
unrealized
holding
gains
   Gross
unrealized
 holding
losses
   Aggregate
fair value
 
                 
Government bonds and notes  $2,992,811   $-   $(2,891)  $2,989,920 
Corporate bonds, notes and commercial paper   16,228,256    -    (16,802)   16,211,454 
   $19,221,067   $-   $(19,693)  $19,201,374 

 

December 31, 2017  Amortized
Cost
   Gross
unrealized
holding
gains
   Gross
unrealized
holding
losses
   Aggregate
fair value
 
                 
Government bonds and notes  $4,744,566   $-   $(2,876)  $4,741,690 
Corporate bonds, notes and commercial paper   13,517,371    -    (1,740)   13,515,631 
   $18,261,937   $-   $(4,616)  $18,257,321 

 

Maturities of debt securities classified as available-for-sale securities at March 31, 2018 are as follows:

 

March 31, 2018  Amortized  
Cost
   Aggregate
fair value
 
Due within one year  $19,221,067   $19,201,374 
   $19,221,067   $19,201,374 

 

There were no sales of marketable investment securities during the three months ended March 31, 2018 and 2017 and therefore no realized gains or losses. Additionally, $12.3 million and $8.4 million of marketable investment securities matured during the three months ended March 31, 2018 and 2017, respectively. The Company determined there were no other-than-temporary impairments for the three months ended March 31, 2018 and 2017.

 

(4)Fair Value

 

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

 

  Level 1 Inputs: Quoted prices for identical instruments in active markets.

 

  Level 2 Inputs: Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuation in which all significant inputs and significant value drivers are observable in active markets.

 

 8 

 

 

  Level 3 Inputs: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For accrued interest income, prepaid and other current assets, accounts payable, and accrued expenses, the carrying amounts approximate fair value because of the short maturity of these instruments. The following table presents the placement in the fair value hierarchy of assets and liabilities that are measured at fair value on a recurring basis at March 31, 2018 and December 31, 2017:

 

       Fair value measurements at reporting date using 
   March 31,
2018
   Level 1 inputs   Level 2 inputs   Level 3 inputs 
                 
Assets:                    
Cash equivalents - money market funds, commercial paper, and treasury bills  $7,793,612   $5,247,856   $2,545,756   $- 
Government bonds and notes   2,989,920    2,989,920    -    - 
Corporate bonds, notes and commercial paper   16,211,454    -    16,211,454    - 
   $26,994,986   $8,237,776   $18,757,210   $- 

 

       Fair value measurements at reporting date using 
   December 31,
2017
   Level 1 inputs   Level 2 inputs   Level 3 inputs 
                 
Assets:                    
Cash equivalents - money market funds  $2,171,814   $2,171,814   $-   $- 
Government bonds and notes   4,741,690    4,741,690    -    - 
Corporate bonds, notes and commercial paper   13,515,631    -    13,515,631    - 
   $20,429,135   $6,913,504   $13,515,631   $- 

 

The following methods and assumptions were used to determine the fair value of each class of assets and liabilities recorded at fair value in the balance sheets:

 

Cash equivalents: Cash equivalents primarily consist of highly-rated money market funds, commercial paper and treasury bills with original maturities to the Company of three months or less and are purchased daily at par value with specified yield rates. Cash equivalents related to money market funds and treasury bills are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices or broker or dealer quotations for similar assets. Cash equivalents related to commercial paper are classified within Level 2 of the fair value hierarchy because they are valued using broker/dealer quotes, bids and offers, benchmark yields and credit spreads and other observable inputs.

 

Government bonds and notes: The Company uses a third-party pricing service to value these investments. United States Treasury bonds and notes are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets for identical assets and reportable trades. Other United States government agency bonds are classified within Level 2 of the fair value hierarchy because they are valued using broker/dealer quotes, bids and offers, benchmark yields and credit spreads and other observable inputs.

 

 9 

 

 

Corporate bonds, notes, and commercial paper: The Company uses a third-party pricing service to value these investments. The pricing service utilizes broker/dealer quotes, bids and offers, benchmark yields and credit spreads and other observable inputs.

 

The Company’s accounting policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 1 or Level 2 for the three months ended March 31, 2018.

 

(5)Loan and Security Agreement

 

On January 5, 2018, the Company entered into a Loan and Security Agreement (the “Loan and Security Agreement”) with Silicon Valley Bank (“SVB”) pursuant to which SVB agreed to lend the Company $10.0 million. The principal borrowed under the Loan and Security Agreement bears a fixed interest rate equal to the Prime Rate, as reported in money rates section of The Wall Street Journal or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum, which interest is payable monthly. The loan matures on December 1, 2021. The Company is only required to make monthly interest payments until December 31, 2018, following which the Company will be required to also make equal monthly payments of principal and interest for the remainder of the term; provided, however, that if on or prior to May 31, 2018, the Company receives evidence reasonably satisfactory to SVB that the Company has received FDA approval for TLANDOTM, the interest-only payment period will be extended to June 30, 2019. The Company will also be required to pay an additional final payment at maturity equal to $650,000 (the “Final Payment Charge”). The Final Payment Charge will be due on the scheduled maturity date and is being recognized as an increase to the principal balance with a corresponding charge to interest expense over the term of the facility using the effective interest method. At its option, the Company may prepay all amounts owed under the Loan and Security Agreement (including all accrued and unpaid interest and the Final Payment Charge), subject to a prepayment charge if the loan has been outstanding for less than two years, which prepayment charge is determined based on the date the loan is prepaid.

 

In connection with the Loan and Security Agreement, the Company and the Subsidiary granted to SVB a security interest in substantially all of the Company’s assets now owned or hereafter acquired, excluding intellectual property and certain other assets. In addition, if TLANDO is not approved by the FDA on or prior to May 31, 2018, the Company will be required to maintain $5.0 million of cash collateral at SVB until such time as TLANDO is approved by the FDA.

 

While any amounts are outstanding under the Loan and Security Agreement, the Company is subject to a number of affirmative and negative covenants, including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness and transactions with affiliates, among other customary covenants. The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus 5.0% and would provide SVB, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including foreclosure against the property securing the credit facilities, including its cash. These events of default include, among other things, any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, the Company’s insolvency, a material adverse change, and one or more judgments against the Company in an amount greater than $100,000 individually or in the aggregate.

 

Principal payments on debt at March 31, 2018, are as follows:

 

(in thousands)    
Years Ending December 31,  Amount 
2018  $ 
2019   3,144 
2020   3,330 
2021   3,526 
Thereafter    
   $10,000 

 

 10 

 

 

(6)Income Taxes

 

The tax provision for interim periods is determined using an estimate of the Company’s effective tax rate for the full year adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter the Company updates its estimate of the annual effective tax rate, and if the estimated tax rate changes, the Company makes a cumulative adjustment.

 

At March 31, 2018 and December 31, 2017, the Company had a full valuation allowance against its deferred tax assets, net of expected reversals of existing deferred tax liabilities, as it believes it is more likely than not that these benefits will not be realized.

 

(7)Contractual Agreements

 

(a)Abbott Products, Inc.

 

On March 29, 2012, the Company terminated its collaborative agreement with Solvay Pharmaceuticals, Inc. (later acquired by Abbott Products, Inc.) for TLANDO. As part of the termination, the Company reacquired the rights to the intellectual property from Abbott. All obligations under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual 1% royalty on net sales. Such royalties are limited to $1.0 million in the first two calendar years following product launch, after which period there is not a cap on royalties and no maximum aggregate amount. If generic versions of any such product are introduced, then royalties are reduced by 50%. The Company did not incur any royalties during the three months ended March 31, 2018 and 2017.

 

(b)Contract Research and Development

 

The Company has entered into agreements with various contract organizations that conduct preclinical, clinical, analytical and manufacturing development work on behalf of the Company as well as a number of independent contractors, primarily clinical researchers, who serve as advisors to the Company. The Company incurred expenses of $732,000 and $2.4 million for the three months ended March 31, 2018 and 2017 under these agreements and has recorded these expenses in research and development expenses.

 

(8)Leases

On August 6, 2004, the Company assumed a non-cancelable operating lease for office space and laboratory facilities in Salt Lake City, Utah. On May 6, 2014, the Company modified and extended the lease through February 28, 2018. On February 8, 2018, the Company extended the lease through February 28, 2019. Additionally, on December 28, 2015, the Company entered into an operating lease for office space in Lawrenceville, New Jersey through January 31, 2018. The Company vacated the Lawrenceville, New Jersey office on January 31, 2018. Future minimum lease payments under non-cancellable operating leases (with initial or remaining lease terms in excess of one year) as of March 31, 2018 are:

 

   Operating 
   leases 
Year ending December 31:     
2018   240,570 
2019   53,460 
Total minimum lease payments  $294,030 

 

The Company’s rent expense was $83,000 and $95,000 for the three months ended March 31, 2018 and 2017.

 

(9)Stockholders’ Equity

 

(a)Issuance of Common Stock

 

In March 2017, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), to sell shares of our common stock, with aggregate gross sales proceeds of up to $20.0 million, from time to time, through an “at the market” (“ATM”), equity offering program, under which Cantor acts as sales agent. The shares of common stock to be sold under the Sales Agreement will be sold and issued pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-199093) (the “Existing Form S-3”), which was previously declared effective by the Securities and Exchange Commission, and the related prospectus and one or more prospectus supplements. As of March 31, 2018, we had sold an aggregate of 2,518,109 shares at a weighted-average sales price of $4.40 per share under the ATM for aggregate gross proceeds of $11.1 million and net proceeds of $10.6 million, after deducting sales agent commission and discounts and our other offering costs. We sold no shares in the three months ended March 31, 2018 and 666,853 shares at a weighted-average sales price of $4.33 per share under the ATM for aggregate gross proceeds of $2.9 million and $2.7 million in net proceeds in the three months ended March 31, 2017.

 

 11 

 

 

On October 13, 2017, the Company filed a Form S-3 (File No. 333-220942) (the “New Form S-3”) to replace the Existing Form S-3.  The New Form S-3 has been declared effective by the Securities and Exchange Commission.  The New Form S-3 registered the sale of up to $150.0 million of any combination of common stock, preferred stock, debt securities, warrants and units pursuant to a shelf registration statement.  The New Form S-3 also contains a prospectus pursuant to which we may sell, from time to time, shares of our common stock having an aggregate offering price of up to $25.0 million through Cantor as our sales agent, pursuant to the Sales Agreement.  Pursuant to Rule 415(a)(6) of the Securities Act of 1933, as amended, the offering of securities on the Existing Form S-3 are deemed terminated as of the date of effectiveness of the New Form S-3. 

 

(b)Rights Agreement

 

On November 13, 2015, the Company and American Stock Transfer & Trust Company, LLC, as Rights Agent, entered into a Rights Agreement. Also on November 12, 2015, the board of directors of the Company authorized and the Company declared a dividend of one preferred stock purchase right (each a “Right” and collectively, the “Rights”) for each outstanding share of common stock of the Company. The dividend was payable to stockholders of record as of the close of business on November 30, 2015 and entitles the registered holder to purchase from the Company one one-thousandth of a fully paid non-assessable share of Series A Junior Participating Preferred Stock of the Company at a price of $63.96 per one-thousandth share (the “Purchase Price”). The Rights will generally become exercisable upon the earlier to occur of (i) 10 business days following a public announcement that a person or group of affiliated or associated persons has become an Acquiring Person (as defined below) or (ii) 10 business days (or such later date as may be determined by action of the board of directors prior to such time as any person or group of affiliated or associated persons becomes an Acquiring Person) following the commencement of, or announcement of an intention to make, a tender offer or exchange offer the consummation of which would result in the beneficial ownership by a person or group of 15% or more of the outstanding common stock of the Company. Except in certain situations, a person or group of affiliated or associated persons becomes an “Acquiring Person” upon acquiring beneficial ownership of 15% or more of the outstanding shares of common stock of the Company.

 

In general, in the event a person becomes an Acquiring Person, then each Right not owned by such Acquiring Person will entitle its holder to purchase from the Company, at the Right’s then current exercise price, in lieu of shares of Series A Junior Participating Preferred Stock, common stock of the Company with a market value of twice the Purchase Price.

 

In addition, if after any person has become an Acquiring Person, (a) the Company is acquired in a merger or other business combination, or (b) 50% or more of the Company’s assets, or assets accounting for 50% or more of its earning power, are sold, leased, exchanged or otherwise transferred (in one or more transactions), proper provision shall be made so that each holder of a Right (other than the Acquiring Person, its affiliates and associates and certain transferees thereof, whose Rights became void) shall thereafter have the right to purchase from the acquiring corporation, for the Purchase Price, that number of shares of common stock of the acquiring corporation which at the time of such transaction would have a market value of twice the Purchase Price.

 

The Company will be entitled to redeem the Rights at $0.001 per Right at any time prior to the time an Acquiring Person becomes such. The terms of the Rights are set forth in the Rights Agreement, which is summarized in the Company's Current Report on Form 8-K dated November 13, 2015. The rights plan will expire on November 12, 2018, unless the rights are earlier redeemed or exchanged by the Company.

 

(c)Share-Based Payments

 

The Company recognizes stock-based compensation expense for grants of stock option awards, restricted stock units and restricted stock under the Company’s Incentive Plan to employees and nonemployee members of the Company’s board of directors based on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over the award’s requisite service period. In addition, the Company grants stock options to nonemployee consultants from time to time in exchange for services performed for the Company. Equity instruments granted to nonemployees are subject to periodic revaluation over their vesting terms.

 

 12 

 

 

The Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of the Company’s common stock price, (ii) the periods of time over which employees and members of the board of directors are expected to hold their options prior to exercise (expected term), (iii) expected dividend yield on the Common Stock, and (iv) risk-free interest rates. Stock-based compensation expense also includes an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation cost that has been expensed in the statements of operations amounted to $427,000 and $632,000 for the three months ended March 31, 2018 and 2017, allocated as follows:

 

   Three Months Ended
March 31,
 
   2018   2017 
         
Research and development  $149,588   $207,380 
General and administrative   277,692    424,910 
           
   $427,280   $632,290 

 

The Company did not issue any stock options during the three months ended March 31, 2018 and 2017. Additionally, the Company issued 287,000 restricted stock units during three months ended March 31, 2017 and did not issue any restricted stock units during the three months ended March 31, 2018.

 

Key assumptions used in the determination of the fair value of stock options granted are as follows:

 

Expected Term: The expected term represents the period that the stock-based awards are expected to be outstanding. Due to limited historical experience of similar awards, the expected term was estimated using the simplified method in accordance with the provisions of Staff Accounting Bulletin (“SAB”) No. 107, Share-Based Payment, for awards with stated or implied service periods. The simplified method defines the expected term as the average of the contractual term and the vesting period of the stock option. For awards with performance conditions, and that have the contractual term to satisfy the performance condition, the contractual term was used.

 

Risk-Free Interest Rate: The risk-free interest rate used was based on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term.

 

Expected Dividend: The expected dividend assumption is based on management’s current expectation about the Company’s anticipated dividend policy. The Company does not anticipate declaring dividends in the foreseeable future.

 

Expected Volatility: Since the Company did not have sufficient trading history, the volatility factor was based on the average of similar public companies through August 2014. When selecting similar companies, the Company considered the industry, stage of life cycle, size, and financial leverage. Beginning in August 2014, the volatility factor is based on a combination of the Company's trading history since March 2014 and the average of similar public companies. Beginning in July 2017, the volatility factor is based solely on the Company’s trading history since March 2014.

 

FASB ASC 718, Stock Compensation, requires the Company to recognize compensation expense for the portion of options that are expected to vest. Therefore, the Company applied estimated forfeiture rates that were derived from historical employee termination behavior. If the actual number of forfeitures differs from those estimated by management, additional adjustments to compensation expense may be required in future periods.

 

As of March 31, 2018, there was $2.4 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the Company’s stock plans. That cost is expected to be recognized over a weighted average period of 1.85 years and will be adjusted for subsequent changes in estimated forfeitures. Additionally, as of March 31, 2018, there was $736,000 of total unrecognized compensation cost related to unvested restricted stock units that have performance vesting.

 

 13 

 

 

(d)Stock Option Plan

 

In April 2014, the board of directors adopted the 2014 Stock and Incentive Plan ("2014 Plan") subject to shareholder approval which was received in June 2014. The 2014 Plan provides for the granting of nonqualified and incentive stock options, stock appreciation rights, restricted stock units, restricted stock and dividend equivalents. An aggregate of 1,000,000 shares are authorized for issuance under the 2014 Plan. Additionally, 271,906 remaining authorized shares under the 2011 Equity Incentive Plan ("2011 Plan") were issuable under the 2014 Plan at the time of the 2014 Plan adoption. Upon receiving shareholder approval in June 2016, the 2014 Plan was amended and restated to increase the authorized number of shares of common stock of the Company issuable under all awards granted under the 2014 Plan from 1,271,906 to 2,471,906. The board of directors, on an option-by-option basis, determines the number of shares, exercise price, term, and vesting period. Options granted generally have a ten-year contractual life. The Company issues shares of common stock upon the exercise of options with the source of those shares of common stock being either newly issued shares or shares held in treasury. An aggregate of 2,471,906 shares are authorized for issuance under the 2014 Plan, with 573,108 shares remaining available for grant as of March 31, 2018.

 

A summary of stock option activity is as follows:

 

   Outstanding stock options 
   Number of
shares
   Weighted average
exercise price
 
Balance at December 31, 2017   2,374,449   $5.64 
Options granted   -    - 
Options exercised   -    - 
Options forfeited   -    - 
Options cancelled   -    - 
Balance at March 31, 2018   2,374,449    5.64 

 

The following table summarizes information about stock options outstanding and exercisable at March 31, 2018:

 

Options outstanding  Options exercisable 
Number
outstanding
  Weighted
average
remaining
contractual
life
(Years)
   Weighted
average
exercise
price
   Aggregate
intrinsic
value
   Number
exerciseable
   Weighted
average
remaining
contractual
life
(Years)
   Weighted
average
exercise
price
   Aggregate
intrinsic
value
 
                                    
2,374,449   7.20   $5.64   $-    1,522,295    6.10   $6.20   $- 

 

The intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value of stock options exercised during the three months ended March 31, 2018 and 2017 was zero and $131,000. There were no stock options exercised during the three months ended March 31, 2018 and 138,274 stock options exercised during the three months ended March 31, 2017.

 

(e)Restricted Stock Units

 

A summary of restricted stock unit activity is as follows:

 

   Number of
unvested restricted
shares
 
     
Balance at December 31, 2017   203,998 
Granted   - 
Vested   - 
Cancelled   - 
Balance at March 31, 2018   203,998 

 

 14 

 

 

(10)Commitments and Contingencies

 

Litigation

 

The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business. The Company records a liability when a particular contingency is probable and estimable.

 

On February 15, 2018, the Company and the other defendants entered into a memorandum of understanding to settle the purported securities class action litigation captioned In re Lipocine Inc. Securities Litigation, 2:17CV00182 DB (D. Utah) which was originally filed against the Company on July 1, 2016. The memorandum of understanding contemplates that the parties will enter into a settlement agreement, which, if entered into, will be subject to customary conditions including court approval following notice to our stockholders, and a hearing at which time the court will consider the fairness, reasonableness and adequacy of the settlement.  If a settlement is finally approved by the court, it will resolve all of the claims that were or could have been brought in the action being settled. The Company continues to believe that the claims in the lawsuits are without merit and, to the extent the parties do not enter into a settlement agreement or the court does not approve a settlement, the Company will defend against them vigorously. The Company maintains insurance for claims of this nature. As a result of signing the memorandum of understanding and the potential liability becoming probable and estimable, the Company has recorded a litigation settlement liability for $4.3 million as of March 31, 2018. Additionally, the Company has recorded a litigation insurance settlement recovery receivable of $3.6 million as of March 31, 2018 which represents the estimated insurance claims proceeds from our insurance carrier in excess of the Company’s retention.

 

Beyond In re Lipocine Inc. Securities Litigation, 2:17CV00182 DB (D. Utah), management does not currently believe that any other matter, individually or in the aggregate, will have a material adverse effect on our financial condition, liquidity or results of operations.

 

Guarantees and Indemnifications

 

In the ordinary course of business, the Company enters into agreements, such as lease agreements, licensing agreements, clinical trial agreements, and certain services agreements, containing standard guarantee and / or indemnifications provisions. Additionally, the Company has indemnified its directors and officers to the maximum extent permitted under the laws of the State of Delaware.

 

(11)Spriaso, LLC

 

On July 23, 2013, the Company entered into an assignment/license and a services agreement with Spriaso, a related-party that is majority-owned by certain current and former directors of Lipocine Inc. and their affiliates. Under the license agreement, the Company assigned and transferred to Spriaso all of the Company’s rights, title and interest in its intellectual property to develop products for the cough and cold field. In addition, Spriaso received all rights and obligations under the Company’s product development agreement with a third-party. In exchange, the Company will receive a royalty of 20 percent of the net proceeds received by Spriaso, up to a maximum of $10.0 million. Spriaso also granted back to the Company an exclusive license to such intellectual property to develop products outside of the cough and cold field. Under the service agreement, the Company provided facilities and up to 10 percent of the services of certain employees to Spriaso for a period of 18 months which expired January 23, 2015. Effective January 23, 2015, the Company entered into an amended services agreement with Spriaso in which the Company agreed to continue providing up to 10 percent of the services of certain employees to Spriaso at a rate of $230/hour for a period of six months. The agreement was further amended on July 23, 2015, on January 23, 2016, on July 23, 2016, on January 23, 2017, on July 23, 2017 and again on January 23, 2018 to extend the term of the agreement for an additional six months. The agreement may be extended upon written agreement of Spriaso and the Company. The Company did not receive any reimbursements during the three months ended March 31, 2018 and 2017, respectively. Additionally, during the three months ended March 31, 2018 and 2017, the Company received $428,000 and zero in royalty payments from Spriaso. Spriaso filed its first NDA and as an affiliated entity of the Company, it used up the one-time waiver for user fees for a small business submitting its first human drug application to the FDA. Spriaso is considered a variable interest entity under the FASB ASC Topic 810-10, Consolidations, however the Company is not the primary beneficiary and has therefore not consolidated Spriaso.

 

 15 

 

 

(12)Recent Accounting Pronouncements

 

Accounting Pronouncements Not Yet Adopted

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses. The new standard amends guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019; early adoption is permitted for interim and annual reporting periods beginning after December 15, 2018. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (i.e., modified retrospective approach). The Company plans to adopt this pronouncement effective January 1, 2019 and does not believe it will have a material effect on the Company's financial position or results of operations.

 

In February 2016, FASB issued ASU 2016-02, Leases, which provides new guidance for lease accounting including recognizing most leases on-balance sheet. The standard becomes effective for annual and interim periods in fiscal years beginning after December 15, 2018. ASU 2016-02 mandates a modified retrospective transition method for all entities. The Company does not have any lease that extends beyond December 31, 2018 other that its facility lease that was extended in February 2018 for a period of one-year until February 28, 2019. The Company plans to adopt this pronouncement effective January 1, 2019 and does not believe it will have a material effect on the Company's financial position or results of operations.

 

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes thereto and other financial information included elsewhere in this report. For additional context with which to understand our financial condition and results of operations, see the management’s discussion and analysis included in our Form 10-K, filed with the SEC on March 12, 2018 as well as the financial statements and related notes contained therein.

 

As used in the discussion below, “we,” “our,” and “us” refers to Lipocine.

 

Forward-Looking Statements

 

This section and other parts of this report contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements may refer to such matters as products, expected product benefits, pre-clinical and clinical development timelines, results and timelines of ongoing or future studies, clinical and regulatory expectations and plans, anticipated financial performance, future revenues or earnings, business prospects, projected ventures, new products and services, anticipated market performance, future expectations for liquidity and capital resources needs and similar matters. Such words as “may”, “will”, “expect”, “continue”, “estimate”, “project”, “potential”, “ anticipate”, “believe”, “could”, “plan”, “predict”, “should”, “would” and “intend” and similar terms and expressions are intended to identify forward-looking statements. Forward-looking statements are not guarantees of future performance and our actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part II, Item 1A (Risk Factors) of this Form 10-Q or in Part I, Item 1A (Risk Factors) of our Form 10-K filed with the SEC on March 12, 2018. Except as required by applicable law, we assume no obligation to revise or update any forward-looking statements for any reason.

 

Overview of Our Business

 

We are a specialty pharmaceutical company focused on applying our oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Our proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. Our primary development programs are based on oral delivery solutions for poorly bioavailable drugs. We have a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Our lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“PDUFA”) action goal date of May 8, 2018. The FDA has deemed the resubmission a complete response to its June 2016 Complete Response Letter (“CRL”) that requested additional information related to the dosing algorithm for the proposed label. The TLANDO New Drug Application (“NDA”) is based on the results of the Dosing Validation (“DV”) study. The DV study confirmed the efficacy of TLANDO with a fixed dose regimen without need for dose adjustment. TLANDO was well tolerated upon 52-week exposure with no reports of drug related Serious Adverse Events (“SAEs”). On January 10, 2018, the Bone, Reproductive and Urologic Drugs Advisory Committee (“BRUDAC”) of the FDA voted six in favor and thirteen against the acceptability of the overall benefit/risk profile to support approval of TLANDO as a TRT. We continue to work with the FDA in addressing topics discussed by BRUDAC. We may receive another CRL. This would cause substantial delays which may include additional studies and add substantial expense to the process of seeking approval of TLANDO. Additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product with the potential for once daily dosing, that is currently in Phase 2 testing, and LPCN 1107, which has the potential to become the first oral hydroxyprogesterone caproate product indicated for the prevention of recurrent preterm birth and has completed an End-of-Phase 2 meeting with the FDA. We have not engaged in labeling discussions with the FDA regarding TLANDO.

 

 16 

 

 

To date, we have funded our operations primarily through the sale of equity securities, debt and convertible debt and through up-front payments, research funding and royalty and milestone payments from our license and collaboration arrangements. We have not generated any revenues from product sales and we do not expect to generate revenue from product sales unless and until we obtain regulatory approval of TLANDO or other products.

 

We have incurred losses in most years since our inception. As of March 31, 2018, we had an accumulated deficit of $129.1 million. Income and losses fluctuate year to year, primarily depending on the timing of recognition of revenues from our license and collaboration agreements. Our net loss was $2.7 million for the three months ended March 31, 2018, compared to $4.9 million for the three months ended March 31, 2017. Substantially all of our operating losses resulted from expenses incurred in connection with our product candidate development programs, our research activities and general and administrative costs associated with our operations.

 

We expect to continue to incur significant expenses and operating losses for the foreseeable future as we:

 

conduct the ambulatory blood pressure (“ABPM”), phlebotomy, or any other pre or post-approval clinical studies required in support of TLANDO;

 

conduct further development of our other product candidates, including LPCN 1111 and LPCN 1107;

 

continue our research efforts;

 

maintain, expand and protect our intellectual property portfolio; and

 

provide general and administrative support for our operations.

 

To fund future long-term operations, we will need to raise additional capital. The amount and timing of future funding requirements will depend on many factors, including capital market conditions, regulatory requirements and outcomes related to TLANDO including our ABPM clinical study, regulatory requirements related to our other development programs, the timing and results of our ongoing development efforts, the potential expansion of our current development programs, potential new development programs, the pursuit of various potential commercial activities and strategies associated with our development programs and related general and administrative support. We anticipate that we will seek to fund our operations through public or private equity or debt financings or other sources, such as potential license, partnering and collaboration agreements. We cannot be certain that anticipated additional financing will be available to us on favorable terms, or at all. Although we have previously been successful in obtaining financing through public and private equity securities offerings and our license and collaboration agreements, there can be no assurance that we will be able to do so in the future.

 

Our Product Candidates

 

Our current portfolio, shown below, includes our lead product candidate, TLANDO, an oral testosterone replacement therapy that is currently under review by the FDA with a PDUFA goal date of May 8, 2018. Additionally, we are in the process of establishing our pipeline of other clinical candidates including a next generation potential once daily oral testosterone replacement therapy, LPCN 1111, and an oral therapy for the prevention of preterm birth, LPCN 1107.

 

Our Development Pipeline

 

TLANDO: An Oral Product Candidate for Testosterone Replacement Therapy

 

Our lead product, TLANDO, is an oral formulation of the chemical, testosterone undecanoate (“TU”), an eleven carbon side chain attached to testosterone. TU is an ester prodrug of testosterone. An ester is chemically formed by bonding an acid and an alcohol. Upon the cleavage, or breaking, of the ester bond, testosterone is formed. TU has been approved for use outside the United States for many years for delivery via intra-muscular injection and in oral dosage form and recently TU has received regulatory approval in the United States for delivery via intra-muscular injection. We are using our proprietary technology to facilitate steady gastrointestinal solubilization and absorption of TU. Proof of concept was initially established in 2006, and subsequently TLANDO was licensed in 2009 to Solvay Pharmaceuticals, Inc. which was then acquired by Abbott Products, Inc. ("Abbott"). Following a portfolio review associated with the spin-off of AbbVie by Abbott in 2011, the rights to TLANDO were reacquired by us. All obligations under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual 1% royalty on net sales. Such royalties are limited to $1 million in the first two calendar years following product launch, after which period there is not a cap on royalties and no maximum aggregate amount. If generic versions of any such product are introduced, then royalties are reduced by 50%.

 

 17 

 

 

NDA Resubmission

 

We resubmitted our NDA to the FDA in August 2017 based on the results of the DV study. The DV study confirmed the efficacy of TLANDO with a fixed dose regimen without need for dose adjustment. TLANDO was well tolerated upon 52-week exposure with no reports of drug related Serious Adverse Events (“SAEs”). The FDA accepted our NDA as a complete response to their CRL and assigned a PDUFA goal date of May 8, 2018 for completion of the review. On January 10, 2018, the BRUDAC of the FDA voted six in favor and thirteen against the benefit/risk profile of TLANDO. Discussion topics during the BRUDAC included whether the safety of TLANDO is adequately characterized and whether additional data is need pre-approval or post approval, including the need for an ambulatory blood pressure (“ABPM”) study. Additional areas discussed included the potential to increase cardiovascular risk, lipid changes, hematocrit increase, levels of dihydro-testosterone and estradiol, cosynotropin stimulation results, Cmax excursions, the stopping criteria for use in clinical practice, and whether testosterone concentrations measured in serum tubes are reliable in patients treated with TLANDO. Particularly the FDA may be concerned with TLANDO’s potential for increased adverse cardiovascular outcomes in the population that will likely use the drug, if approved, and observed treatment emergent adverse reactions. We continue to work with the FDA in addressing topics discussed by BRUDAC. The FDA may or may not view BRUDAC’s TLANDO advice/recommendation similarly. We have submitted two protocols to the FDA under our TLANDO investigational new drug (“IND”) application. The first protocol is for the conduct of an ABPM clinical study and the second protocol is for a phlebotomy clinical study to confirm no ex-vivo conversion of TU to T. We have initiated the phlebotomy clinical study ahead of FDA feedback on the protocol. The FDA may not agree with our study design and may reject our data from such study. We plan to initiate the ABPM clinical study once we receive FDA feedback on the protocol. Although there is no guarantee of FDA approval of TLANDO, we believe the results from the DV study confirm the validity of a fixed dose approach without the need for dose titration to orally administering TLANDO. However, we may not receive approval of our NDA on our PDUFA date and we may receive another CRL. Receipt of another CRL would result in substantial delays which may include additional studies and expense before we would be in a position to re-submit an NDA responsive to such additional CRL. We have not engaged in any labeling discussions with the FDA regarding TLANDO.

 

Previously on June 28, 2016, we received a CRL from the FDA on our original NDA submission. A CRL is a communication from the FDA that informs companies that an application cannot be approved in its present form. The CRL identified deficiencies related to the dosing algorithm for the label. Specifically, the proposed titration scheme for clinical practice was significantly different from the titration scheme used in the Phase 3 trial leading to discordance in titration decisions between the Phase 3 trial and real-world clinical practice. In response to the CRL, we met with the FDA in a Post Action meeting and proposed a dosing regimen to the FDA based on analyses of existing data. The FDA noted that while the proposed dosing regimen might be acceptable, validation in a clinical trial would be needed prior to resubmission. The DV study was in response to the FDA’s request. We also initiated the Dosing Flexibility (“DF”) study to assess TLANDO in hypogonadal males on a fixed daily dose of 450 mg divided into three equal doses.

 

Results from DV and DF Studies

 

The DV and DF studies were both an open-label, fixed dose (no titration), single treatment clinical study of oral TRT in hypogonadal males with low testosterone (T) (< 300 ng/dL) that assessed TLANDO in hypogonadal males on a fixed daily dose of 450 mg divided into two equal doses (“BID”) in the DV study and into three equal doses (“TID”) in the DF study. In total, 95 and 100 subjects were enrolled into DV and DF studies, respectively, with 94 and 98 subjects completing the DV and DF studies, respectively.

 

On June 19, 2017, we announced top-line results of the DV and DF studies. Although there is no guarantee of FDA approval of TLANDO, we believe the results from the DV study confirm the validity of a fixed dose approach without the need for dose titration to orally administering TLANDO. The DV study will be considered our pivotal efficacy clinical study for the NDA resubmission. TLANDO successfully met the FDA primary efficacy guidelines in the DV study safety statistical analysis set (“SS”) where 80% of the subjects achieved average testosterone levels (“Cavg”) within the normal range with a lower bound confidence interval (“CI”) of 72%. The DF study restored 70% of the subjects’ average testosterone levels within the normal range (Cavg) confirming that twice daily (“BID”) dosing is the appropriate dosing regimen for TLANDO and was the basis for resubmission. The safety set is defined as any subject that was randomized into the study and took at least one dose (N=95 subjects in the DV study and N=100 in the DF study). A baseline carried forward approach was used to account for missing data as a result of subject discontinuation.

 

 18 

 

 

The primary efficacy endpoint is the percentage of subjects with Cavg within the normal range, which is defined as 300-1080 ng/dL. The FDA guidelines for primary efficacy success is that at least 75% of the subjects on active treatment achieve a testosterone Cavg within the normal range; and the lower bound of the 95% CI must be greater than or equal to 65%.

 

The adverse event profile of TLANDO in both the DV and DF studies was consistent with the previously conducted 52-week Phase 3 Study of Androgen Replacement (“SOAR”) clinical trial. All drug related adverse events (“AEs”) were either mild or moderate in intensity and none were severe. To date, the safety database of TLANDO includes ~525 unique hypogonadal men demonstrating a profile consistent with other TRT products.

 

The secondary endpoints assessed the maximum total testosterone concentration (“Cmax”) post dosing using predetermined limits developed by the FDA for transdermals. The FDA guidelines for secondary efficacy success is that at least 85% of the subjects achieve Cmax less than 1500 ng/dL; no greater than 5% of the subjects have Cmax between 1800 ng/dl and 2500 ng/dL; and zero percent of the subjects have Cmax greater than 2500 ng/dL. Consistent with the definition of Cmax and the pharmacokinetic profile of multiple times a day dosing, two pre-specified analyses were performed, Cmax per dose and Cmax per day.

 

In the DV study SS Cmax per dose analysis, the percentage of subjects with Cmax less than 1500 ng/dL and between 1800 ng/dL and 2500 ng/dL were 85% and 7%, respectively. Deviations from the predetermined limits in the DV study were observed in the Cmax per day dose analysis for these thresholds. Only one subject, who was a major protocol violator, exceeded the 2500 ng/dL limit independent of per dose or per day dose analyses.

 

The DF study SS met all Cmax thresholds in per dose and per day dose analyses.

 

Prior to conducting the DV study and the DF study, we completed our SOAR pivotal Phase 3 clinical study evaluating efficacy and 52-week safety of TLANDO. The SOAR study is considered our pivotal safety clinical study for the NDA resubmission.

 

Results from SOAR

 

SOAR was a randomized, open-label, parallel-group, active-controlled, Phase 3 clinical study of TLANDO in hypogonadal males with low testosterone (< 300 ng/dL). In total, 315 subjects at 40 active sites were assigned, such that 210 were randomized to TLANDO and 105 were randomized to the active control, AndroGel 1.62%®, for 52 weeks of treatment. The active control is included for safety assessment. TLANDO subjects were started at 225 mg TU (equivalent to ~ 142 mg of T) twice daily (“BID”) with a standard meal and then dose titrated, if needed, based on average T levels during the day, Cavg, and peak serumT levels, Cmax, up to 300 mg TU BID or down to 150 mg TU BID based on serum testosterone measured at weeks 3 and 7 based on PK profile with multiple blood samples drawn at each time period. The mean age of the subjects in the trial was ~53 years with ~91% of the patients < 65 years of age. The discontinuation rate for TLANDO was 38% compared to 32% for AndroGel 1.62%.

 

Primary statistical analysis was conducted using the Efficacy Population Set ("EPS"). The EPS is defined as subjects randomized into the study with at least one PK profile and no significant protocol deviations and includes imputed missing data by last observation carried forward, N=151. Further analysis was performed using the full analysis set ("FAS") (any subject randomized into the study with at least one post-baseline efficacy variable response, N=193) and the SS (any subject that was randomized into the study and took at least one dose, N=210).

 

Safety

 

The safety component of the SOAR trial was completed the last week of April 2015. The safety extension phase was designed to assess safety based on information such as metabolites, biomarkers, laboratory values, serious adverse events ("SAEs") and AEs, with subjects on their stable dose regimen in both the treatment arm and the active control arm. TLANDO treatment was well tolerated in there were no hepatic, cardiac or drug related SAEs.

 

TLANDO safety highlights include:

 

·TLANDO was well tolerated during 52 weeks of dosing;

 

·Overall AE profile for TLANDO was comparable to the active control;

 

·Cardiac AE profiles were consistent between treatment groups and none of the observed cardiac AEs occurred in greater than 1.0% of the subjects in the TLANDO arm and none were classified as severe; and

 

 19 

 

 

·All observed adverse drug reactions (“ADRs”) were classified as mild or moderate in severity and no serious ADRs occurred during the 52-week treatment period.

 

Food Effect Study

 

We also completed our labeling "food effect" study in May 2015. Results from the labeling "food effect" study indicate that bioavailability of testosterone from TLANDO is not affected by changes in meal fat content. The results demonstrate comparable testosterone levels between the standard fat meal (similar to the meal instruction provided in the Phase 3 clinical study) and both the low and high fat meals. The labeling “food effect” study was conducted per the FDA requirement and we submitted preliminary results from this study to the FDA in the second quarter of 2015 prior to submitting the NDA.

 

Other Safety Requirements

 

Based on our meetings with the FDA, we do not expect to be required to conduct a heart attack and stroke risk study or any additional safety studies prior to the potential approval of our NDA for TLANDO. We may, however, be required to conduct a heart attack and stroke risk study on our own or with a consortium of sponsors that have an approved TRT product subsequent to the potential approval of TLANDO.

 

LPCN 1111: A Next-Generation Oral Product Candidate for TRT

 

LPCN 1111 is a next-generation, novel ester prodrug of testosterone which uses the Lip’ral technology to enhance solubility and improve systemic absorption. We completed a Phase 2b dose finding study in hypogonadal men in the third quarter of 2016. The primary objectives of the Phase 2b clinical study were to determine the starting Phase 3 dose of LPCN 1111 along with safety and tolerability of LPCN 1111 and its metabolites following oral administration of single and multiple doses in hypogonadal men. The Phase 2b clinical trial was a randomized, open label, two-period, multi-dose PK study that enrolled hypogonadal males into five treatment groups. Each of the 12 subjects in a group received treatment for 14 days. Results of the Phase 2b study suggest that the primary objectives were met, including identifying the dose expected to be tested in a Phase 3 study. Good dose-response relationship was observed over the tested dose range in the Phase 2b study. Additionally, the target Phase 3 dose met primary and secondary end points. Overall, LPCN 1111 was well tolerated with no drug-related severe or serious adverse events reported in the Phase 2b study.

 

Additionally in October 2014, we completed a Phase 2a proof-of-concept study in hypogonadal men. The Phase 2a open-label, dose-escalating single and multiple dose study enrolled 12 males. Results from the Phase 2a clinical study demonstrated the feasibility of a once daily dosing with LPCN 1111 in hypogonadal men and a good dose response. Additionally, the study confirmed that steady state is achieved by day 14 with consistent inter-day performance observed on day 14, 21 and 28. No subjects exceeded Cmax of 1500 ng/dL at any time during the 28-day dosing period on multi-dose exposure. Overall, LPCN 1111 was well tolerated with no serious AE’s reported.

 

We have also completed a preclinical toxicology study with LPCN 1111 in dogs. In February 2018 we had a meeting with the FDA to discuss these preclinical results and to discuss the Phase 3 clinical study and path forward for LPCN 1111. Based on the results of this FDA meeting, additional pre-clinical and clinical trials may be required before a Phase 3 clinical study can be initiated. Additionally, the FDA requested that an ABPM clinical study be conducted as part of the Phase 3 clinical study. Based on our capital resources and the clinical status of our product candidates, we will primarily focus our efforts in 2018 on TLANDO. We do not anticipate the initiation of a Phase 3 study with LPCN 1111 to occur in 2018 unless and until additional capital is secured or the product candidate is out-licensed.

 

LPCN 1107: An Oral Product Candidate for the Prevention of Preterm Birth

 

We believe LPCN 1107 has the potential to become the first oral hydroxyprogesterone caproate (“HPC”) product indicated for the reduction of risk of preterm birth (“PTB”) in women with singleton pregnancy who have a history of singleton spontaneous PTB. Prevention of PTB is a significant unmet need as ~11.7% of all U.S. pregnancies result in PTB (delivery less than 37 weeks), a leading cause of neonatal mortality and morbidity.

 

 20 

 

 

We have completed a multi-dose PK dose selection study in pregnant women. The objective of the multi-dose PK selection study was to assess HPC blood levels in order to identify the appropriate LPCN 1107 Phase 3 dose. The multi-dose PK dose selection study was an open-label, four-period, four-treatment, randomized, single and multiple dose, PK study in pregnant women of three dose levels of LPCN 1107 and the injectable intramuscular ("IM") HPC (Makena®). The study enrolled 12 healthy pregnant women (average age of 27 years) with a gestational age of approximately 16 to 19 weeks. Subjects received three dose levels of LPCN 1107 (400 mg BID, 600 mg BID, or 800 mg BID) in a randomized, crossover manner during the first three treatment periods and then received five weekly injections of HPC during the fourth treatment period. During each of the LPCN 1107 treatment periods, subjects received a single dose of LPCN 1107 on Day 1 followed by twice daily administration from Day 2 to Day 8. Following completion of the three LPCN 1107 treatment periods and a washout period, all subjects received five weekly injections of HPC. Results from this study demonstrated that average steady state HPC levels (Cavg0-24) were comparable or higher for all three LPCN 1107 doses than for injectable HPC. Additionally, HPC levels as a function of daily dose were linear for the three LPCN 1107 doses. Also unlike the injectable HPC, steady state exposure was achieved for all three LPCN 1107 doses within seven days. We have also completed a proof-of-concept Phase 1b clinical study of LPCN 1107 in healthy pregnant women in January 2015 and a proof-of-concept Phase 1a clinical study of LPCN 1107 in healthy non-pregnant women in May 2014. These studies were designed to determine the PK and bioavailability of LPCN 1107 relative to an IM HPC, as well as safety and tolerability.

 

A traditional pharmacokinetics/pharmacodynamics (“PK/PD”) based Phase 2 clinical study in the intended patient population is not expected to be required prior to entering into Phase 3. Therefore, based on the results of our multi-dose PK study we had an End-of-Phase 2 meeting with the FDA as well as other guidance meetings with the FDA to define a Phase 3 development plan for LPCN 1107. During the End-of-Phase 2 meeting and subsequent guidance meetings, the FDA agreed to a randomized, open-label, two-arm clinical study to include a LPCN 1107 arm and a comparator IM arm with treatment up to 23 weeks. The FDA also provided preliminary feedback on other critical Phase 3 study design considerations including: positive feedback on the proposed 800 mg BID Phase 3 dose and dosing regimen; confirmation of the use of a surrogate primary endpoint focusing on rate of delivery less than 37 weeks gestation rather on clinical infant outcomes; acknowledged that the use of a gestational age endpoint would likely lead to any FDA approval, if granted, being a Subpart H approval; and, recommended a non-inferiority study margin of 7% with interim analyses. A standard statistical design for a NI study based on the FDA feedback, a NI margin of 7% for the primary endpoint may require ~1,100 subjects per treatment arm with a 90% power. However, based on the FDA’s suggestion of including an interim analysis in the NI design, an adaptive study design is under consideration that may allow for fewer subjects. We submitted the initial LPCN 1107 Phase 3 protocol to the FDA via a SPA in June 2017 and have received multiple rounds of FDA’s feedback. Agreement with the FDA on the Phase 3 protocol via SPA has not occurred and will not occur until results from a planned food-effect study with LPCN 1107 are reviewed by the FDA. Final agreement with the FDA on the Phase 3 protocol, if reached, may or may not confirm the FDA’s preliminary feedback on the Phase 3 design. Additionally, manufacturing scale-up work for LPCN 1107 has been completed. Based on our capital resources and the clinical status of our product candidates, we plan to primarily focus our efforts in 2018 on TLANDO. We do not anticipate the initiation of a Phase 3 study with LPCN 1107 to occur in 2018 unless and until additional capital is secured or the product candidate is out-licensed. We are exploring the possibility of licensing LPCN 1107 to a third party. No licensing agreement has been entered into by the Company.

 

The FDA has granted orphan drug designation to LPCN 1107 based on a major contribution to patient care. Orphan designation qualifies Lipocine for various development incentives, including tax credits for qualified clinical testing, and a waiver of the prescription drug user fee when we file our NDA.

 

Financial Operations Overview

 

Revenue

 

To date, we have not generated any revenues from product sales and do not expect to do so until one of our product candidates receives approval from the FDA. Revenues to date have been generated substantially from license fees, royalty and milestone payments and research support from our licensees. Since our inception through March 31, 2018, we have generated $27.9 million in revenue under our various license and collaboration arrangements and from government grants. We may never generate revenues from TLANDO or any of our other clinical or preclinical development programs or licensed products as we may never succeed in obtaining regulatory approval or commercializing any of these product candidates.

 

Research and Development Expenses

 

Research and development expenses consist primarily of salaries, benefits, stock-based compensation and related personnel costs, fees paid to external service providers such as contract research organizations and contract manufacturing organizations, contractual obligations for clinical development, clinical sites, manufacturing and scale-up for late-stage clinical trials, formulation of clinical drug supplies, and expenses associated with regulatory submissions. Research and development expenses also include an allocation of indirect costs, such as those for facilities, office expense, travel, and depreciation of equipment based on the ratio of direct labor hours for research and development personnel to total direct labor hours for all personnel. We expense research and development expenses as incurred. Since our inception, we have spent approximately $98.5 million in research and development expenses through March 31, 2018.

 

We expect to incur approximately $3.4 million in additional research and developments costs for TLANDO as we conduct and complete the ABPM clinical study. However, these expenditures are subject to numerous uncertainties regarding timing and cost to completion.

 

 21 

 

 

Approval, if ever, of TLANDO will require approval by the FDA of the resubmitted NDA, and we expect to continue to incur significant costs as we seek approval of TLANDO.

 

In general, the cost of clinical trials may vary significantly over the life of a project as a result of uncertainties in clinical development, including, among others:

 

the number of sites included in the trials;

 

the length of time required to enroll suitable subjects;

 

the duration of subject follow-ups;

 

the length of time required to collect, analyze and report trial results;

 

the cost, timing and outcome of regulatory review; and

 

potential changes by the FDA in clinical trial and NDA filing requirements for testosterone replacement therapies.

 

We also incurred significant manufacturing costs to prepare launch supplies for TLANDO and expect to incur additional manufacturing costs related to TLANDO. However, these expenditures are subject to numerous uncertainties regarding timing and cost to completion, including, among others:

 

the timing and outcome of regulatory filings and FDA reviews and actions for TLANDO;

 

our dependence on third-party manufacturers for the production of satisfactory finished product for registration and launch should regulatory approval be obtained;

 

the potential for future license or co-promote arrangements for TLANDO, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our future plans and capital requirements; and

 

the effect on our product development activities of actions taken by the FDA or other regulatory authorities.

 

A change of outcome for any of these variables with respect to the development of TLANDO could mean a substantial change in the costs and timing associated with these efforts, will require us to raise additional capital, and may require us to reduce operations.

 

Given the stage of clinical development and the significant risks and uncertainties inherent in the clinical development, manufacturing and regulatory approval process, we are unable to estimate with any certainty the time or cost to complete the development of LPCN 1111, LPCN 1107 and other product candidates. Clinical development timelines, the probability of success and development costs can differ materially from expectations and results from our clinical trials may not be favorable. If we are successful in progressing LPCN 1111, LPCN 1107 or other product candidates into later stage development, we will require additional capital. The amount and timing of our future research and development expenses for these product candidates will depend on the preclinical and clinical success of both our current development activities and potential development of new product candidates, as well as ongoing assessments of the commercial potential of such activities.

 

Summary of Research and Development Expense

 

We are conducting on-going clinical and regulatory activities with all three of our product candidates. Additionally, we incur costs for our other research programs. The following table summarizes our research and development expenses:

 

   Three Months Ended March 31, 
   2018   2017 
External service provider costs:          
LPCN 1021  $460,910   $2,431,357 
LPCN 1111   21,501    (24,129)
LPCN 1107   249,554    26,121 
Total external service provider costs   731,965    2,433,349 
Internal personnel costs   470,984    544,184 
Other research and development costs   174,578    106,206 
Total research and development  $1,377,527   $3,083,739 

 

 22 

 

 

We expect research and development expenses to increase in the future when and if we initiate Phase 3 clinical trials for LPCN 1111 and LPCN 1107.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation related to our executive, finance, business development, marketing, sales and support functions. Other general and administrative expenses include rent and utilities, travel expenses, professional fees for auditing, tax and legal services, litigation settlement and market research and market analytics.

 

They also include expenses for the cost of preparing, filling and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims.

 

We expect that general and administrative expenses will continue to increase as we mature as a public company. These increases will likely include legal and consulting fees, accounting and audit fees, director fees, increased directors’ and officers’ insurance premiums, fees for investor relations services and enhanced business and accounting systems, litigation costs, professional fees and other costs. However, outside spend on sales and marketing pre-commercialization activities will be consistent with spend during 2017 until we receive clarity on the regulatory path forward for TLANDO. If the FDA approves TLANDO, we will increase our outside spend on pre-commercialization and commercialization activities substantially and will need to raise additional capital to fund these expenses.

 

Other Expense (Income), Net

 

Other expense (income), net consists primarily of interest income earned on our cash, cash equivalents and marketable investment securities and interest expense incurred on our outstanding Loan and Security Agreement.

 

 

Results of Operations

 

Comparison of the Three Months Ended March 31, 2018 and 2017

 

The following table summarizes our results of operations for the three months ended March 31, 2018 and 2017:

 

   Three Months Ended March 31,     
   2018   2017   Variance 
License revenue  $(428,031)  $-    428,031 
Research and development expenses   1,377,527    3,083,739    (1,706,212)
General and administrative expenses   1,687,490    1,825,176    (137,686)
Other expense (income), net   82,285    (48,355)   130,640 
Income tax expense   700    700    - 

 

Revenue

 

License revenue was $428,000 during the three months ended March 31, 2018 compared to no license revenue during the three months ended March 31, 2017. License revenue relates to royalty payments received from Spriaso, LLC under a licensing agreement in the cough and cold field.

 

Research and Development Expenses

 

The decrease in research and development expenses during the three months ended March 31, 2018 was primarily due reduced contract research organization costs for TLANDO of $2.3 million as the DV and DF studies were complete in 2017 and lower personnel costs of $73,000 offset by increased outside service costs of $362,000 primarily related to the TLANDO BRUDAC meeting in January 2018 and increased contract manufacturing costs of $244,000 for LPCN 1107.

 

General and Administrative Expenses

 

The decrease in general and administrative expenses during the three months ended March 31, 2018 was primarily due to decreased personnel costs of $279,000 related to reduced stock compensation expense on restricted stock units as well as reduced bonus expense accrual in 2018. Additionally, overhead costs decreased $47,000 in 2018 offset by increased professional fees of $151,000 related to legal, intellectual property and commercial activities and a loss on disposition of property and equipment of $37,000 related to the lease expiration on our New Jersey facility.

 

 23 

 

 

Other Expense (Income), Net

 

The increase in other expense, net, during the three months ended March 31, 2018 was primarily due to interest expense on our Loan and Security Agreement (the “Loan and Security Agreement”) with Silicon Valley Bank (“SVB”) which was entered into January 2018. These increases in other expense were offset by increased interest income due to higher interest rates on higher average balances in cash, cash equivalents and marketable investment securities in 2018 as compared to 2017.

 

Liquidity and Capital Resources

 

Since our inception, our operations have been primarily financed through sales of our equity securities, debt and payments received under our license and collaboration arrangements. In January 2018, we secured a term loan with Silicon Valley Bank for $10.0 million. We have devoted our resources to funding research and development programs, including discovery research, preclinical and clinical development activities. We have incurred operating losses in most years since our inception and we expect to continue to incur operating losses into the foreseeable future as we seek to advance our lead product candidate, TLANDO, and further clinical development of LPCN 1111, LPCN 1107 and our other programs and continued research efforts.

 

As of March 31, 2018, we had $27.8 million of cash, cash equivalents and marketable investment securities compared to $21.5 million at December 31, 2017.

 

On January 5, 2018, we entered into the Loan and Security Agreement with SVB pursuant to which SVB agreed to lend us $10.0 million. The principal borrowed under the Loan and Security Agreement bears a fixed interest rate equal to the Prime Rate, as reported in money rates section of The Wall Street Journal or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum, which interest is payable monthly. The loan matures on December 1, 2021. We are only required to make monthly interest payments until December 31, 2018, following which we will be required to also make equal monthly payments of principal and interest for the remainder of the term; provided, however, that if on or prior to May 31, 2018, we receive evidence reasonably satisfactory to SVB that we have received FDA approval for TLANDOTM, the interest-only payment period will be extended to June 30, 2019. We will also be required to pay an additional final payment at maturity equal to $650,000 (the “Final Payment Charge”). At its option, we may prepay all amounts owed under the Loan and Security Agreement (including all accrued and unpaid interest and the Final Payment Charge), subject to a prepayment charge if the loan has been outstanding for less than two years, which prepayment charge is determined based on the date the loan is prepaid. In connection with the Loan and Security Agreement, we and the Subsidiary granted to SVB a security interest in substantially all of our assets now owned or hereafter acquired, excluding intellectual property and certain other assets. In addition, if TLANDO is not approved by the FDA on or prior to May 31, 2018, we will be required to maintain $5.0 million of cash collateral at SVB until such time as TLANDO is approved by the FDA. While any amounts are outstanding under the Loan and Security Agreement, we are subject to a number of affirmative and negative covenants, including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness and transactions with affiliates, among other customary covenants. The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus 5.0% and would provide SVB, as collateral agent, with the right to exercise remedies against us and the collateral securing the credit facility, including foreclosure against the property securing the credit facilities, including its cash. These events of default include, among other things, any failure by us to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, the Company’s insolvency, a material adverse change, and one or more judgments against us in an amount greater than $100,000 individually or in the aggregate.

 

On March 6, 2017, we entered into the Sales Agreement with Cantor pursuant to which we may issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $20.0 million through Cantor as our sales agent. Cantor may sell our common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act, including sales made directly on or through the Nasdaq Capital Market or any other existing trade market for our common stock, in negotiated transactions at market prices prevailing at the time of sale or at prices related to prevailing market prices, or any other method permitted by law.

 

The shares of our common stock to be sold under the Sales Agreement will be sold and issued pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-199093) (the “Existing Form S-3”), which was previously declared effective by the Securities and Exchange Commission, and the related prospectus and one or more prospectus supplements. Cantor will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell these shares. We will pay Cantor 3.0% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. We have also provided Cantor with customary indemnification rights.

 

 24 

 

 

On October 13, 2017, we filed a Form S-3 (File No. 333-220942) (the “New Form S-3”) to replace the Existing Form S-3.  The New Form S-3 has been declared effective by the Securities and Exchange Commission.  The New Form S-3 registered the sale of up to $150,000,000 of any combination of common stock, preferred stock, debt securities, warrants and units pursuant to a shelf registration statement.  The New Form S-3 also contains a prospectus pursuant to which we may sell, from time to time, shares of our common stock having an aggregate offering price of up to $25 million through Cantor as our sales agent, pursuant to the Sales Agreement that we currently have in place with Cantor.  The other terms of the Sales Agreement that are described above will apply to the up to $25 million “at the market offering” anticipated to be made pursuant to the prospectus in the New Form S-3.  Pursuant to Rule 415(a)(6) of the Securities Act of 1933, as amended, the offering of securities on the Existing Form S-3 were deemed terminated as of the date of effectiveness of the New Form S-3. 

 

We are not obligated to make any sales of our common stock under the Sales Agreement. The offering of our common stock pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement as permitted therein. We and Cantor may each terminate the Sales Agreement at any time upon ten days’ prior notice.

 

As of March 31, 2018, we have sold 2,518,109 shares of our common stock resulting in net proceeds of approximately $10.6 million under the Sales Agreement which is net of $260,000 commissions paid to Cantor in connection with these sales.

 

We believe that our existing capital resources, together with interest thereon, will be sufficient to meet our projected operating requirements through March 31, 2019. While we believe we have sufficient liquidity and capital resources to fund our projected operating requirements through March 31, 2019, we will need to raise additional capital at some point, either before or after March 31, 2019, to support our operations, ongoing clinical studies, compliance with regulatory requirements, long-term research and development and commercialization of TLANDO, if we receive approval of TLANDO from the FDA. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Additional clinical studies may be required to obtain approval of TLANDO and these studies would put additional demands on our limited capital resources. Further, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for product development, regulatory compliance, clinical trials and pre-commercialization activities sooner than planned. We may consume our capital resources more rapidly if the FDA approval for TLANDO is delayed or denied, or if we elect to pursue the build out of an internal sales force as part of our commercialization launch plan if our product candidates receive approval from the FDA. Conversely, our capital resources could last longer if we reduce expenses and the number of activities currently contemplated under our operating plan.

 

We can raise capital pursuant to the Sales Agreement in the ATM Offering but may choose not to issue common stock if our market price is too low to justify such sales in our discretion. There are numerous risks and uncertainties associated with the development and, subject to approval by the FDA, commercialization of our product candidates. There are numerous risks and uncertainties impacting our ability to enter into collaborations with third parties to participate in the development and potential commercialization of our product candidates. We are unable to precisely estimate the amounts of increased capital outlays and operating expenditures associated with our anticipated or unanticipated clinical studies and ongoing development and pre-commercialization efforts. All of these factors affect our need for additional capital resources. To fund future operations, we will need to ultimately raise additional capital and our requirements will depend on many factors, including the following:

 

further clinical development requirements, if any, or other requirements of the FDA related to approval of TLANDO;

 

the scope, rate of progress, results and cost of our clinical studies, preclinical testing and other related activities;

 

the scope of clinical and other work required to obtain approval of TLANDO and our other product candidates;

 

the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidates and any products that we may develop;

 

the cost and timing of establishing sales, marketing and distribution capabilities;

 

the terms and timing of any collaborative, licensing and other arrangements that we may establish;

 

the number and characteristics of product candidates that we pursue;

 

the cost, timing and outcomes of regulatory approvals;

 

the timing, receipt and amount of sales, profit sharing or royalties, if any, from our potential products;

 

the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

 

the extent to which we acquire or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions; and

 

 25 

 

 

the extent to which we grow significantly in the number of employees or the scope of our operations.

 

Funding may not be available to us on acceptable terms, or at all. Also, market conditions may prevent us from accessing the debt and equity capital markets, including sales of our common stock through the ATM Offering. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our clinical studies, research and development programs or, if any of our product candidates receive approval from the FDA, commercialization efforts. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, including the ATM Offering, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. These arrangements may not be available to us or available on terms favorable to us. To the extent that we raise additional capital through marketing and distribution arrangements, other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences, warrants or other terms that adversely affect our stockholders’ rights or further complicate raising additional capital in the future. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable, for any reason, to raise needed capital, we will have to reduce costs, delay research and development programs, liquidate assets, dispose of rights, commercialize products or product candidates earlier than planned or on less favorable terms than desired or reduce or cease operations.

 

Sources and Uses of Cash

 

The following table provides a summary of our cash flows for the three months ended March 31, 2018 and 2017: 

 

   Three Months Ended March 31, 
   2018   2017 
Cash used in operating activities  $(3,746,211)  $(3,138,751)
Cash provided by (used in) investing   (903,225)   1,427,897 
Cash provided by financing activities   10,000,000    3,086,649 

 

Net Cash Used in Operating Activities

 

During the three months ended March 31, 2018 and 2017, net cash used in operating activities was $3.7 million and $3.1 million, respectively.

 

Net cash used in operating activities during the three months ended March 31, 2018 and 2017 was primarily attributable to cash outlays to support ongoing operations, including research and development expenses and general and administrative expenses. During 2018, we were performing activities related to the BRUDAC meeting for TLANDO on January 10, 2018. Additionally, we completed manufacturing scale-up activities for LPCN 1107. During 2017, we were conducting our DV study and DF study for TLANDO and we were drafting our protocol for LPCN 1107.

 

Net Cash Provided by (Used in) Investing Activities

 

During the three months ended March 31, 2018, net cash used in investing activities was $903,000. During the three months ended March 31, 2017, net cash provided by investing activities was $1.4 million.

 

Net cash used in investing activities during the three months ended March 31, 2018 was primarily the result of purchasing additional marketable investment securities, net, of $903,000 due to proceeds from the SVB Loan and Security Agreement. Net cash provided by investing activities during the three months ended March 31, 2017 was primarily the result of utilizing marketable investment securities, net, of $1.4 million to fund operations. There were no capital expenditures for the three months ended March 31, 2018 and 2017.

 

Net Cash Provided by Financing Activities

 

During the three months ended March 31, 2018 and 2017 net cash provided by financing activities was $10.0 million and $3.1 million, respectively.

 

 26 

 

 

Net cash provided by financing activities during 2018 was attributable to $10.0 million in proceeds from the SVB Loan and Security Agreement.

 

Net cash provided by financing activities during 2017 was primarily attributable to the net proceeds from the sale of 666,853 shares of common stock pursuant to the ATM Offering resulting in net proceeds of $2.7 million as well as proceeds from the exercise of stock options.

 

Employee stock option exercises provided approximately zero and $389,000 of cash during the three months ended March 31, 2018 and 2017, respectively. Proceeds from the exercise of employee stock options vary from period to period based upon, among other factors, fluctuations in the market price of our common stock relative to the exercise price of such options.

 

Contractual Commitments and Contingencies

 

Purchase Obligations

 

We enter into contracts and issue purchase orders in the normal course of business with clinical research organizations for clinical trials and clinical and commercial supply manufacturing and with vendors for preclinical research studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination on notice and are cancellable obligations.

 

Operating Leases

 

In August 2004, we entered into an agreement to lease our facility in Salt Lake City, Utah consisting of office and laboratory space which serves as our corporate headquarters. On February 9, 2018, we modified and extended the lease through February 28, 2019. Additionally, on December 28, 2015, we entered into an agreement to lease office space in Lawrenceville, New Jersey which has an occupancy date of February 1, 2016 and an end date of January 31, 2018. We vacated the Lawrenceville, New Jersey office on January 31, 2018.

 

Other Contractual Obligations

 

We enter into contracts in the normal course of business with clinical research organizations for clinical trials and clinical supply manufacturing and with vendors for preclinical research studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination on notice, and are cancellable obligations.

 

JOBS Act Accounting Election

 

We are an “emerging growth company,” as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards, and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

 

Critical Accounting Policies and Significant Judgments and Estimates

 

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements which we have prepared in accordance with U.S. generally accepted accounting principles. In preparing our financial statements, we are required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. There have been no significant and material changes in our critical accounting policies during the three months ended March 31, 2018, as compared to those disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Critical Accounting Policies and Significant Judgments and Estimates” in our Form 10-K filed March 12, 2018.

 

New Accounting Standards

 

Refer to Note 12, in “Notes to Unaudited Condensed Consolidated Financial Statements” for a discussion of accounting standards not yet adopted.

 

 27 

 

 

Off-Balance Sheet Arrangements

 

None.

 

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are exposed to various market risks, which include potential losses arising from adverse changes in market rates and prices, such as interest rates. We do not enter into derivatives or other financial instruments for trading or speculative purposes.

 

Interest Rate Risk. Our interest rate risk exposure results from our investment portfolio. Our primary objectives in managing our investment portfolio are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields. The securities we hold in our investment portfolio are subject to interest rate risk. At any time, sharp changes in interest rates can affect the fair value of the investment portfolio and its interest earnings. After a review of our marketable investment securities, we believe that in the event of a hypothetical one percent increase in interest rates, the resulting decrease in fair value of our marketable investment securities would be insignificant to the consolidated financial statements. In addition, in the event of a hypothetical one percent decrease in interest rates, the resulting increase in fair value of our marketable investment securities would be insignificant to the consolidated financial statements. Currently, we do not hedge these interest rate exposures. We have established policies and procedures to manage exposure to fluctuations in interest rates. We place our investments with high quality issuers and limit the amount of credit exposure to any one issuer and do not use derivative financial instruments in our investment portfolio. We invest in highly liquid, investment-grade securities and money market funds of various issues, types and maturities. These securities are classified as available-for-sale and, consequently, are recorded on the balance sheet at fair value with unrealized gains or losses reported as accumulated other comprehensive income as a separate component in stockholders' deficit unless a loss is deemed other than temporary, in which case the loss is recognized in earnings.

 

ITEM  4.CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain "disclosure controls and procedures" within the meaning of Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our disclosure controls and procedures, or Disclosure Controls, are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission's rules and forms. Our Disclosure Controls include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

 

As of the end of the period covered by this Quarterly Report on Form 10-Q, we evaluated the effectiveness of the design and operation of our Disclosure Controls, which was done under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer. Based on the controls evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the date of their evaluation, our Disclosure Controls were effective as of March 31, 2018.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the most recent fiscal quarter covered by this report, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II—OTHER INFORMATION

 

ITEM  1.LEGAL PROCEEDINGS

 

On May 15, 2015, we filed a patent application with the PTO, and our application requested that the PTO declare an interference between our patent application and the Clarus 428 Patent.  Pursuant to Lipocine's request, on December 4, 2015, the Patent Trial and Appeal Board (“PTAB”) declared an interference between the Clarus 428 Patent and Lipocine's application to determine, as between Clarus and Lipocine, who was the first to invent the subject matter of the claimed invention. Lipocine was declared the Senior Party in the interference. On September 20, 2017 the PTAB issued a Decisions on Motions. The PTAB granted Lipocine’s motion to deny Clarus’ previously accorded priority date for the Clarus 428 Patent and denied Clarus’ motion for an earlier priority date based upon the filing of its provisional applications. Therefore, Clarus has a new priority date of April 16, 2014 for the Clarus 428 patent. The PTAB also granted Clarus’ motion to deny Lipocine’s accorded priority date. Therefore, Lipocine has an accorded priority date of May 15, 2015 on its application. As a consequence of this decision, the PTAB has redeclared the interference and named Clarus as the senior party and Lipocine as the junior party. All other motions were denied. A conference call with the PTAB was held on October 4, 2017 to discuss the next steps, including a priority schedule. After the conference call, the PTAB issued an order setting times in the priority phase.  The order indicated that since Lipocine is the only party that filed a priority statement, only Lipocine shall be permitted to put on a priority case. The priority statement filed by Lipocine included a claimed date of invention well prior to Clarus’ accorded benefit date. Lipocine filed its motion for priority on January 18, 2018, and thereafter, on March 26, 2018, Clarus filed a notice stating it has not filed, and will not file, a substantive opposition to Lipocine’s priority motion.

 

 28 

 

 

On July 1, 2016, the Company and certain of its officers were named as defendants in a purported shareholder class action lawsuit, David Lewis v. Lipocine Inc., et al., 3:16-cv-04009-BRM-LHG, filed in the United States District Court for the District of New Jersey. This initial action was followed by additional lawsuits also filed in the District of New Jersey. On December 2, 2016, the court granted plaintiff’s motion to consolidate the various lawsuits and appointed Pomerantz LLP as lead counsel and Lipocine Investor Group as lead plaintiff.  The court also stated that all filings shall bear the caption In re Lipocine Inc. Securities Litigation.  On March 14, 2017, the court granted our motion to transfer the action to the United States District Court for the District of Utah.  On April 27, 2017, Plaintiff filed an Amended Complaint against the Company and certain of its officers and/or directors in the United States District Court for the District of Utah.  This is a purported class action seeking relief for violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The Amended Complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose that our filing of the NDA for TLANDO to the FDA contained deficiencies and as a result the defendants’ statements about our business and operations were false and misleading and/or lacked a reasonable basis in violation of federal securities laws. Plaintiff seeks certification as a class action, compensatory damages of an unspecified amount, pre-judgment and post-judgment interest, reasonable attorneys’ fees, expert fees, and unspecified other costs, as well as any further relief the court deems just and proper.  We filed a motion to dismiss the Amended Complaint on June 12, 2017, in compliance with the scheduling order entered by the court on December 20, 2016. Oral arguments on the motion to dismiss were held on October 24, 2017, and the judge denied our motion to dismiss.  On February 15, 2018 we and the other defendants entered into a memorandum of understanding to settle the purported securities class action litigation. On March 15, 2018, plaintiff filed a motion for preliminary approval of the settlement along with a copy of the parties’ stipulation of settlement. On March 21, 2018, the court granted the motion for preliminary approval of the settlement and amended the order on March 28, 2018. As set for the in the preliminary approval order, the settlement is subject to customary conditions including court approval following notice to our stockholders, and a hearing currently set for July 2, 2018 at 2:00p.m. at which time the court will consider the fairness, reasonableness and adequacy of the settlement.  If a settlement is finally approved by the court, it will resolve all of the claims that were or could have been brought in the action being settled. We continue to believe that the claims in the lawsuits are without merit and, to the extent the court does not approve a settlement, will defend against them vigorously. We maintain insurance for claims of this nature, which management believes is adequate. Moreover, we believe, based on information currently available, that the filing and ultimate outcome of the lawsuits will not have a material impact on our financial position, although we will have to pay up to the insurance retention amount in connection with the lawsuit.

 

ITEM  1A.RISK FACTORS

 

In addition to the other information set forth in this Report, consider the risk factors discussed in Part 1, "Item 1A. Risk Factors" in the Company's Annual Report filed on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 12, 2018 and the risk factors discussed in Item 1A of this Form 10-Q, which could materially affect our business, financial condition or future results. The risks described in the aforementioned report are not the only risks facing the Company. Additional risks and uncertainties not currently known to the Company or that it currently deems to be not material also may materially adversely affect the Company's business, financial condition and or operating results.

 

The following are the risk factors that have materially changed from our risk factors included in our Form 10-K for the year ended December 31, 2017 filed with the SEC on March 12, 2018:

 

RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK

 

Our share price is expected to be volatile and may be influenced by numerous factors that are beyond our control.

 

A low share price and low market valuation may make it difficult to raise sufficient additional cash due to the significant dilution to current stockholders. Market prices for shares of biotechnology and biopharmaceutical companies such as ours are often volatile. The market price of our common stock may fluctuate significantly in response to a number of factors, most of which we cannot control, including:

 

·our ability to address the deficiencies noted in the CRL for TLANDO;

 

·the receipt of a second CRL for TLANDO;

 

 29 

 

 

·plans for, progress of and results from clinical trials of our product candidates;

 

·the failure of the FDA to approve our product candidates;

 

·regulatory uncertainty in the TRT class;

 

·FDA Advisory Committee meetings and related recommendations including meetings convened on the TRT class or on similar companies;

 

·announcements by the FDA that may impact on-going clinical studies related to safety or efficacy of TRT products;

 

·announcements of new products, technologies, commercial relationships, acquisitions or other events by us or our competitors;

 

·failure to engage with collaborators or build an internal sales force to commercialize our products;

 

·the success or failure of other TRT products or non-testosterone based testosterone therapy products;

 

·failure of our products, if approved, to achieve commercial success;

 

·fluctuations in stock market prices and trading volumes of similar companies;

 

·general market conditions and overall fluctuations in U.S. equity markets;

 

·variations in our quarterly operating results;

 

·changes in our financial guidance or securities analysts’ estimates of our financial performance;

 

·changes in accounting principles;

 

·sales of large blocks of our common stock, including sales by our executive officers, directors and significant stockholders;

 

·additions or departures of key personnel;

 

·discussion of us or our stock price by the press and by online investor communities;

 

·our cash balance; and

 

·other risks and uncertainties described in these risk factors.

 

In recent years, the stock of other biotechnology and biopharmaceutical companies has experienced extreme price fluctuations that have been unrelated to the operating performance of the affected companies. There can be no assurance that the market price of our shares of common stock will not experience significant fluctuations in the future, including fluctuations that are unrelated to our performance. These fluctuations may result due to macroeconomic and world events, national or local events, general perception of the biotechnology industry or to a lack of liquidity. In addition, other biotechnology companies or our competitors’ programs could have positive or negative results that impact their stock prices and their results, or stock fluctuations could have a positive or negative impact on our stock price regardless whether such impact is direct or not.

 

Stockholders may not agree with our business, scientific, clinical, commercial or financial strategy, including additional dilutive financings, and may decide to sell their shares or vote against such proposals. Such actions could materially impact our stock price. In addition, portfolio managers of funds or large investors can change or change their view on us and decide to sell our shares. These actions could have a material impact on our stock price. In order to complete a financing, or for other business reasons, we may elect to consolidate our shares of common stock. Investors may not agree with these actions and may sell our shares. We may have little or no ability to impact or alter such decisions.

 

The stock prices of many companies in the biotechnology industry have experienced wide fluctuations that have often been unrelated to the operating performance of these companies. Following periods of volatility in the market price of a company’s securities, securities class action litigation often has been initiated against a company. For example, on July 1, 2016, the Company and certain of its officers were named as defendants in a purported shareholder class action lawsuit, David Lewis v. Lipocine Inc., et al., filed in the United States District Court for the District of New Jersey. This initial action was followed by additional lawsuits also filed in the District of New Jersey. Due to this class action litigation initiated against us or any future class action litigation that may be initiated against us, we may incur substantial costs and our management’s attention may be diverted from our operations, which could significantly harm our business. In addition, this litigation could lead to increased volatility in our share price.

 

 30 

 

 

Our management and directors will be able to exert influence over our affairs.

 

As of March 31, 2018, our executive officers and directors beneficially owned approximately 11.3% of our common stock. These stockholders, if they act together, may be able to influence our management and affairs and all matters requiring stockholder approval, including significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control and might affect the market price of our common stock.

 

Our common stock is thinly traded, may continue to be thinly traded in the future, and our stockholders may be unable to sell at or near asking prices or at all if they need to sell their shares.

 

To date, we have a low volume of daily trades in our common stock on NASDAQ. For example, the average daily trading volume in our common stock on NASDAQ during the first quarter of 2018 was approximately 767,762 shares per day with volumes continuing to decrease. Our stockholders may be unable to sell their common stock at or near their asking prices or at all, which may result in substantial losses to our stockholders.

 

The market for our common stock may be characterized by significant price volatility when compared to seasoned issuers, and we expect that our share price will be more volatile than a seasoned issuer for the indefinite future. As noted above, our common stock may be sporadically and/or thinly traded. As a consequence of this lack of liquidity, the trading of relatively small quantities of shares by our stockholders may disproportionately influence the price of those shares in either direction. The price for our shares could, for example, decline significantly in the event that a large number of shares of our common stock are sold on the market without commensurate demand, as compared to a seasoned issuer that could better absorb those sales without adverse impact on its share price.

 

RISKS RELATING TO OUR FINANCIAL POSITION AND CAPITAL REQUIREMENTS

 

We have incurred significant operating losses in most years since our inception and anticipate that we will incur continued losses for the foreseeable future.

 

We have focused a significant portion of our efforts on developing TLANDO. We have funded our operations to date through proceeds from sales of common stock, preferred stock and convertible debt and from license and milestone revenues and research revenue from license and collaboration agreements with corporate partners. We have incurred losses in most years since our inception. As of March 31, 2018, we had an accumulated deficit of $129.1 million. Substantially all of our operating losses resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. These losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ equity and working capital. We expect our research and development expenses to significantly increase in connection with clinical trials associated with TLANDO, LPCN 1111 and LPCN 1107, if initiated. In addition, if we obtain marketing approval for TLANDO, we will incur significant sales, marketing and commercialization expenses. As a result, we expect to continue to incur significant operating losses for the foreseeable future as we advance our lead product candidate, TLANDO, and further clinical development of LPCN 1111, LPCN 1107 and our other programs and continued research efforts. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all.

 

RISKS RELATING TO OUR INTELLECTUAL PROPERTY

 

We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we may be unable to protect our rights to our products and technology.

 

If we or our collaborators choose to go to court to stop a third party from using the inventions claimed in our owned or licensed patents, that third party may ask a court to rule that the patents are invalid and should not be enforced against that third party. These lawsuits are expensive and would consume time and other resources, including financial resources, even if we were successful in stopping the infringement of these patents. In addition, there is a risk that a court will decide that these patents are not valid or not enforceable and that we do not have the right to stop others from using the inventions.

 

 31 

 

 

There is also the risk that, even if the validity of these patents is not challenged or is upheld, the court will refuse to stop the third party on the ground that such third-party’s activities do not infringe on our owned or licensed patents. In addition, the U.S. Supreme Court has recently changed some standards relating to the granting of patents and assessing the validity of patents. As a consequence, issued patents may be found to contain invalid claims according to the newly revised standards. Some of our owned or licensed patents may be subject to challenge and subsequent invalidation or significant narrowing of claim scope in a reexamination or other proceeding before the U.S. Patent and Trademark Office ("PTO"), or during litigation, under the revised criteria which make it more difficult to obtain or maintain patents.

 

While our in-licensed patents and applications are not currently used in our product candidates, should we develop other product candidates that are covered by this intellectual property, we will rely on our licensor to file and prosecute patent applications and maintain patents and otherwise protect the intellectual property we license from them. Our licensor has retained the first right, but not the obligation to initiate an infringement proceeding against a third-party infringer of the intellectual property licensed to us, and enforcement of our in-licensed patents or defense of any claims asserting the invalidity or unenforceability of these patents would also be subject to the control or cooperation of our licensor. It is possible that our licensor’s defense activities may be less vigorous than had we conducted the defense ourselves.

 

We also license our patent portfolio, including U.S. and foreign patents and patent applications that cover our TLANDO and our other product candidates, to third parties for their respective products and product candidates. Under our agreements with our licensees, we have the right, but not the obligation, to enforce our current and future licensed patents against infringers of our licensees. In certain cases, our licensees may have primary enforcement rights and we have the obligation to cooperate. In the event of an enforcement action against infringers of our licensees, our licensees might not have the interest or resources to successfully preserve the patents, the infringers may countersue, and as a result our patents may be found invalid or unenforceable or of a narrower scope of coverage and leave us with no patent protection for TLANDO and our other product candidates.

 

In addition, on May 15, 2015 we filed a patent application with the PTO, and our application requests that the PTO declare an interference between our patent application and Clarus Therapeutics’ (“Clarus”) U.S. Patent No. 8,828,428 (“the Clarus 428 Patent”). Pursuant to Lipocine's request, on December 4, 2015, the Patent Trial and Appeal Board (“PTAB”) declared an interference between the Clarus 428 Patent and Lipocine's application to determine, as between Clarus and Lipocine, who was the first to invent the subject matter of the claimed invention. Lipocine was declared the senior party in the interference. On September 20, 2017 the PTAB issued a Motions Decision based on each party’s motions in the interference case. The PTAB granted Lipocine’s motion to deny Clarus’ previously accorded priority date for the Clarus 428 Patent. Therefore, Clarus has a new priority date of April 16, 2014 for the Clarus 428 patent. The PTAB also granted Clarus’ motion to deny Lipocine’s accorded priority date. Therefore, Lipocine has an accorded priority date of May 15, 2015 on its application. As a consequence of this decision, the PTAB has redeclared the interference and named Clarus as the senior party and Lipocine as the junior party. All other motions were denied. A conference call with the PTAB was held on October 4, 2017 to discuss the next steps, including priority schedule. As a result of the conference call, the PTAB has issued an order setting priority times.  The order indicated that since Lipocine is the only party that filed a priority statement, only Lipocine shall be permitted to put on a priority case. The priority statement filed by Lipocine included an invention date prior to Clarus’ accorded benefit date. Lipocine has filed its initial motion in the priority phase while Clarus chose not to respond to Lipocine’s initial motion. Interference proceedings may fail and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party; our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. Even if we are successful in such interference, it may result in substantial costs to us and distraction to our management.

 

This interference proceeding will consume a portion of our capital resources. Moreover, we may be subject to a third party preissuance submission of prior art to the PTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our owned or licensed patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our owned or licensed patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates and impair our ability to raise needed capital.

 

If we are required to defend patent infringement actions brought by other third parties, or if we sue to protect our own patent rights or otherwise to protect our proprietary information and to prevent its disclosure, we may be required to pay substantial litigation costs and managerial attention and financial resources may be diverted from business operations even if the outcome is in our favor.

 

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

 32 

 

 

ITEM  3.DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4.MINE SAFETY DISCLOSURES

 

None.

 

ITEM  5.OTHER INFORMATION

 

None.

 

ITEM 6.EXHIBITS

 

INDEX TO EXHIBITS

 

Exhibit       Incorporation By Reference  

Number 

 

Exhibit Description 

 

Form 

 

SEC File No. 

 

Exhibit 

 

Filing Date 

 
                       
10.1   Loan and Security Agreement dated January 5, 2018   8-K   001-36357   10.1   1/8/2018  
                       
31.1*   Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                  
                       
31.2*   Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                  
                       
32.1*   Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350 (1)                  
                       
32.2*   Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350 (1)                  

 

101.INS*

 

 

XBRL Instance Document

                 

 

101.SCH*

 

 

XBRL Taxonomy Extension Schema Document

                 

 

101.CAL*

 

 

XBRL Taxonomy Extension Calculation Linkbase Document

                 

 

101.DEF*

 

 

XBRL Taxonomy Extension Definition Linkbase Document

                 

 

101.LAB*

 

 

XBRL Taxonomy Extension Labels Linkbase Document

                 

 

101.PRE*

 

 

XBRL Taxonomy Extension Presentation Linkbase Document

                 
                       
*   Filed herewith                  
                       
(1)  

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. 

                 

 

 33 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   
  Lipocine Inc.
  (Registrant)
   
Dated: May 7, 2018 /s/ Mahesh V. Patel
 

Mahesh V. Patel, President and Chief

Executive Officer

(Principal Executive Officer)

   
Dated: May 7, 2018 /s/ Morgan R. Brown
 

Morgan R. Brown, Executive Vice President

and Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 34 

EX-31.1 2 tv491769_ex31-1.htm EXHIBIT 31.1

 

EXHIBIT 31.1

 

CERTIFICATIONS

 

I, Mahesh V. Patel, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Lipocine Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: May 7, 2018     /s/ Mahesh V. Patel 
      Mahesh V. Patel, President and Chief Executive Officer
      (Principal Executive Officer)

 

 

EX-31.2 3 tv491769_ex31-2.htm EXHIBIT 31.2

 

EXHIBIT 31.2

 

CERTIFICATIONS

 

I, Morgan R. Brown, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Lipocine Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: May 7, 2018     /s/ Morgan R. Brown 
     

Morgan R. Brown, Executive Vice President and

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

EX-32.1 4 tv491769_ex32-1.htm EXHIBIT 32.1

 

EXHIBIT 32.1

 

CERTIFICATION

 

In connection with the Quarterly Report on Form 10-Q of Lipocine Inc. (the “Corporation”) for the quarter ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Mahesh V. Patel, President and Chief Executive Officer of the Corporation, hereby certifies, pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Corporation.

 

Dated: May 7, 2018     /s/ Mahesh V. Patel 
     

Mahesh V. Patel, President and Chief Executive Officer

(Principal Executive Officer)

 

 

EX-32.2 5 tv491769_ex32-2.htm EXHIBIT 32.2

 

EXHIBIT 32.2

 

CERTIFICATION

 

In connection with the Quarterly Report on Form 10-Q of Lipocine Inc. (the “Corporation”) for the quarter ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Morgan R. Brown, Executive Vice President and Chief Financial Officer of the Corporation, hereby certifies, pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Corporation.

 

Dated: May 7, 2018     /s/ Morgan R. Brown 
     

Morgan R. Brown, Executive Vice President and

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

 

EX-101.INS 6 lpcn-20180331.xml XBRL INSTANCE DOCUMENT 0001535955 2017-01-01 2017-03-31 0001535955 2018-01-01 2018-03-31 0001535955 2017-03-31 0001535955 2018-03-31 0001535955 2018-05-04 0001535955 2013-07-01 2013-07-23 0001535955 2013-07-23 0001535955 2017-10-13 0001535955 2015-11-13 0001535955 2017-12-31 0001535955 2016-12-31 0001535955 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001535955 lpcn:UnvestedRestictedStockUnitsMember 2018-01-01 2018-03-31 0001535955 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0001535955 lpcn:UnvestedRestictedStockUnitsMember 2017-01-01 2017-03-31 0001535955 us-gaap:CorporateDebtSecuritiesMember 2018-03-31 0001535955 us-gaap:USTreasuryAndGovernmentMember 2018-03-31 0001535955 us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0001535955 us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0001535955 lpcn:MoneyMarketFundsCommercialPaperAndGovernmentNotesMember 2018-03-31 0001535955 lpcn:MoneyMarketFundsCommercialPaperAndGovernmentNotesMember us-gaap:FairValueInputsLevel1Member 2018-03-31 0001535955 lpcn:MoneyMarketFundsCommercialPaperAndGovernmentNotesMember us-gaap:FairValueInputsLevel2Member 2018-03-31 0001535955 lpcn:MoneyMarketFundsCommercialPaperAndGovernmentNotesMember us-gaap:FairValueInputsLevel3Member 2018-03-31 0001535955 us-gaap:GovernmentMember 2018-03-31 0001535955 us-gaap:FairValueInputsLevel1Member us-gaap:GovernmentMember 2018-03-31 0001535955 us-gaap:FairValueInputsLevel2Member us-gaap:GovernmentMember 2018-03-31 0001535955 us-gaap:FairValueInputsLevel3Member us-gaap:GovernmentMember 2018-03-31 0001535955 us-gaap:CorporateDebtSecuritiesMember 2018-03-31 0001535955 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2018-03-31 0001535955 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2018-03-31 0001535955 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2018-03-31 0001535955 us-gaap:MoneyMarketFundsMember 2017-12-31 0001535955 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2017-12-31 0001535955 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2017-12-31 0001535955 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2017-12-31 0001535955 us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0001535955 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0001535955 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0001535955 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0001535955 us-gaap:FairValueInputsLevel3Member us-gaap:GovernmentMember 2017-12-31 0001535955 us-gaap:FairValueInputsLevel2Member us-gaap:GovernmentMember 2017-12-31 0001535955 us-gaap:FairValueInputsLevel1Member us-gaap:GovernmentMember 2017-12-31 0001535955 us-gaap:GovernmentMember 2017-12-31 0001535955 lpcn:AbbottProductsIncMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-03-31 0001535955 lpcn:ContractResearchAndDevelopmentMember 2018-01-01 2018-03-31 0001535955 lpcn:AtMarketOfferingMember 2017-03-31 0001535955 lpcn:AtMarketOfferingMember 2018-01-01 2018-03-31 0001535955 lpcn:AtMarketOfferingMember 2018-03-31 0001535955 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-03-31 0001535955 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0001535955 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-03-31 0001535955 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-03-31 0001535955 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-03-31 0001535955 us-gaap:RestrictedStockUnitsRSUMember 2018-03-31 0001535955 lpcn:StockIncentivePlan2014Member 2014-04-30 0001535955 lpcn:StockIncentivePlan2014Member 2018-03-31 0001535955 lpcn:EquityIncentivePlanMember 2014-04-30 0001535955 lpcn:StockIncentivePlan2014Member 2016-06-29 0001535955 lpcn:StockIncentivePlan2014Member 2016-06-30 0001535955 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001535955 us-gaap:EmployeeStockOptionMember 2018-03-31 0001535955 us-gaap:CommonStockMember 2017-01-01 2017-03-31 0001535955 us-gaap:RestrictedStockMember 2018-01-01 2018-03-31 0001535955 us-gaap:RestrictedStockMember 2018-03-31 0001535955 us-gaap:SettledLitigationMember 2018-03-31 0001535955 us-gaap:EmployeeStockOptionMember 2017-12-31 0001535955 us-gaap:RestrictedStockMember 2017-12-31 0001535955 us-gaap:FairValueInputsLevel1Member 2018-03-31 0001535955 us-gaap:FairValueInputsLevel2Member 2018-03-31 0001535955 us-gaap:FairValueInputsLevel3Member 2018-03-31 0001535955 us-gaap:FairValueInputsLevel1Member 2017-12-31 0001535955 us-gaap:FairValueInputsLevel2Member 2017-12-31 0001535955 us-gaap:FairValueInputsLevel3Member 2017-12-31 0001535955 lpcn:SiliconValleyBankMember lpcn:LoanAndSecurityAgreementMember 2018-01-05 0001535955 lpcn:SiliconValleyBankMember lpcn:LoanAndSecurityAgreementMember 2018-01-01 2018-01-05 0001535955 lpcn:LoanAndSecurityAgreementMember lpcn:SiliconValleyBankMember 2018-03-31 0001535955 lpcn:ContractResearchAndDevelopmentMember 2017-01-01 2017-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q false 2018-03-31 2018 Q1 Lipocine Inc. 0001535955 --12-31 Accelerated Filer LPCN 21264539 32331 75070 0 0 2127 2127 18979988 31680648 25325114 16672262 -126399823 -129119794 40712 40712 145423012 145850292 6345126 15008386 6345126 6283934 1497056 598070 388356 25325114 31680648 30753 23753 25219291 31624564 408227 247979 3210749 8561313 19201374 18257321 47249 23067 -19651 -4616 305064 -4861260 632290 -67509 607595 411194 -3138751 1427897 388551 3086649 1375795 5560716 6936511 2698098 -2997 6972103 8400000 -2719971 427280 -160248 -209714 -1191992 -3746211 -903225 0 10000000 5350564 0 24182 13210225 12300000 -15035 2707 7093 5261 -2719971 -4861260 21264539 18711239 -0.13 -0.26 -2719971 -4861260 18711239 21264539 -0.13 -0.26 2374449 203998 2070076 287000 16228256 0 16802 16211454 2992811 0 2891 2989920 4744566 13517371 0 0 2876 1740 4741690 13515631 19221067 19201374 12300000 8400000 7793612 5247856 2545756 0 2989920 2989920 0 0 16211454 0 16211454 0 2171814 2171814 0 0 13515631 0 13515631 0 0 0 4741690 4741690 1000000 0.5 2012-03-29 732000 294030 240570 53460 95000 83000 20000000 2518109 10600000 11100000 4.40 150000000 25000000 63.96 0.001 149588 277692 207380 424910 287000 2400000 P1Y10M6D 736000 1000000 573108 271906 1271906 2471906 0 0 0 2374449 0 0 0 0 5.64 0 131000 138274 0 0 0 203998 10000000 230 428000 0.2 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 27pt"> <div><b>(12)</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>Recent Accounting Pronouncements</b></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> <i>Accounting Pronouncements Not Yet Adopted</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> <i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> In June 2016, the FASB issued ASU 2016-13, <font style="FONT-FAMILY:Times New Roman, Times, Serif"><i>Financial Instruments - Credit Losses</i>. The new standard amends guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities.</font> ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019; early adoption is permitted for interim and annual reporting periods beginning after December 15, 2018. Entities will apply the standard&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (i.e., modified retrospective approach). The Company plans to adopt this pronouncement effective January 1, 2019 and does not believe it will have a material effect on the Company's financial position or results of operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif">In February 2016, FASB issued ASU 2016-02</font><i>, <font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> Leases,</font></i> <font style="FONT-FAMILY:Times New Roman, Times, Serif">which provides new guidance for lease accounting including recognizing most leases on-balance sheet. The standard becomes effective for annual and interim periods in fiscal years beginning after December 15, 2018. ASU 2016-02 mandates a modified retrospective transition method for all entities.</font> <font style="FONT-SIZE: 10pt">The Company does not have any lease that extends beyond December 31, 2018 other that its facility lease that was extended in February 2018 for a period of one-year until February 28, 2019. The Company plans to adopt this pronouncement effective January 1, 2019 and does not believe it will have a material effect on the Company's financial position or results of operations.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 27pt"> <div><b>(11)</b></div> </td> <td> <div><b>Spriaso, LLC</b></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> On July&#160;23, 2013, the Company entered into an assignment/license and a services agreement with Spriaso, a related-party that is majority-owned by certain current and former directors of Lipocine Inc. and their affiliates. Under the license agreement, the Company assigned and transferred to Spriaso all of the Company&#8217;s rights, title and interest in its intellectual property to develop products for the cough and cold field. In addition, Spriaso received all rights and obligations under the Company&#8217;s product development agreement with a third-party. In exchange, the Company will receive a royalty of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20</font> percent of the net proceeds received by Spriaso, up to a maximum of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.0</font> million. Spriaso also granted back to the Company an exclusive license to such intellectual property to develop products outside of the cough and cold field. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Under the service agreement, the Company provided facilities and up to 10 percent of the services of certain employees to Spriaso for a period of 18 months which expired</font> January 23, 2015. Effective January 23, 2015, the Company entered into an amended services agreement with Spriaso in which the Company agreed to continue providing up to 10 percent of the services of certain employees to Spriaso at a rate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">230</font>/hour for a period of six months. The agreement was further amended on July 23, 2015, on January 23, 2016, on July 23, 2016, on January 23, 2017, on July 23, 2017 and again on January 23, 2018 to extend the term of the agreement for an additional six months. The agreement may be extended upon written agreement of Spriaso and the Company. The Company did not receive any reimbursements during the three months ended March 31, 2018 and 2017, respectively. Additionally, during the three months ended March 31, 2018 and 2017, the Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">428,000</font> and zero in royalty payments from Spriaso. Spriaso filed its first NDA and as an affiliated entity of the Company, it used up the one-time waiver for user fees for a small business submitting its first human drug application to the FDA. Spriaso is considered a variable interest entity under the FASB ASC Topic 810-10, <i> Consolidations</i>, however the Company is not the primary beneficiary and has therefore not consolidated Spriaso.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 3566649 3319927 Under the service agreement, the Company provided facilities and up to 10 percent of the services of certain employees to Spriaso for a period of 18 months which expired 0 4250000 4250000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 27pt"> <div><b> (10)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></div> </td> <td> <div><b>Commitments and Contingencies</b></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Litigation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business. The Company records a liability when a particular contingency is probable and estimable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> On February 15, 2018, the Company and the other defendants entered into a memorandum of understanding to settle the purported securities class action litigation captioned <i>In re Lipocine Inc. Securities Litigation, 2:17CV00182 DB (D. Utah)</i> which was originally filed against the Company on July 1, 2016. The memorandum of understanding contemplates that the parties will enter into a settlement agreement, which, if entered into, will be subject to customary conditions including court approval following notice to our stockholders, and a hearing at which time the court will consider the fairness, reasonableness and adequacy of the settlement.&#160; If a settlement is finally approved by the court, it will resolve all of the claims that were or could have been brought in the action being settled. The Company continues to believe that the claims in the lawsuits are without merit and, to the extent the parties do not enter into a settlement agreement or the court does not approve a settlement, the Company will defend against them vigorously. The Company maintains insurance for claims of this nature. As a result of signing the memorandum of understanding and the potential liability becoming probable and estimable, the Company has recorded a litigation settlement liability for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.3</font> million as of March 31, 2018. Additionally, the Company has recorded a litigation insurance settlement recovery receivable of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.6</font> million as of March 31, 2018 which represents the estimated insurance claims proceeds from our insurance carrier in excess of the Company&#8217;s retention.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> Beyond <i>In re Lipocine Inc. Securities Litigation, 2:17CV00182 DB (D. Utah)</i>, management does not currently believe that any other matter, individually or in the aggregate, will have a material adverse effect on our financial condition, liquidity or results of operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Guarantees and Indemnifications</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> In the ordinary course of business, the Company enters into agreements, such as lease agreements, licensing agreements, clinical trial agreements, and certain services agreements, containing standard guarantee and / or indemnifications provisions. Additionally, the Company has indemnified its directors and officers to the maximum extent permitted under the laws of the State of Delaware.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1340514 0 8724452 0 4300000 3600000 1111366 1121080 0.0001 0.0001 10000000 10000000 0 0 0 0 0.0001 0.0001 100000000 100000000 21270249 21270249 21264539 21264539 5710 5710 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.01in; FONT: 10pt Times New Roman, Times, Serif"> Stock-based compensation cost that has been expensed in the statements of operations amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">427,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">632,000</font> for the three months ended March 31, 2018 and 2017, allocated as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.69in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended<br/> March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>149,588</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>207,380</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>277,692</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>424,910</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>427,280</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>632,290</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of stock option activity is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.69in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div>Outstanding&#160;stock&#160;options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="3"> <div>Number&#160;of<br/> shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted&#160;average<br/> exercise&#160;price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Balance at December 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,374,449</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Options granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Options forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Options cancelled</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Balance at March 31, 2018</div> </td> <td style="BORDER-BOTTOM: #000000 3px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,374,449</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> The following table summarizes information about stock options outstanding and exercisable at March 31, 2018:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.68in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%" colspan="12"> <div>Options&#160;outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%" colspan="11"> <div>Options&#160;exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="3"> <div>Number<br/> outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Weighted average remaining contractual life (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Weighted<br/> average<br/> exercise<br/> price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Aggregate<br/> intrinsic<br/> value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Number exerciseable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Weighted average remaining contractual life (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Weighted<br/> average<br/> exercise<br/> price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Aggregate<br/> intrinsic<br/> value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,374,449</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>7.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>5.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>1,522,295</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>6.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>6.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 45%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of<br/> unvested&#160;restricted<br/> shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>Balance&#160;at&#160;December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>203,998</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>Cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>Balance at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>203,998</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 632290 427280 2374449 5.64 P7Y2M12D 0 1522295 P6Y1M6D 6.20 0 203998 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24.5pt"> <div><b>(1)</b></div> </td> <td> <div><b>Basis of Presentation</b></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.68in; FONT: 10pt Times New Roman, Times, Serif"> The accompanying unaudited condensed consolidated financial statements included herein have been prepared by Lipocine Inc. (&#8220;Lipocine&#8221; or the &#8220;Company&#8221;) in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The unaudited condensed consolidated financial statements are comprised of the financial statements of Lipocine and its subsidiaries collectively referred to as the Company. In management's opinion, the interim financial data presented includes all adjustments (consisting solely of normal recurring items) necessary for fair presentation. All intercompany accounts and transactions have been eliminated. Certain information required by U.S. generally accepted accounting principles has been condensed or omitted in accordance with rules and regulations of the SEC. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for any future period or for the year ending December&#160;31, 2018.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.68in; FONT: 10pt Times New Roman, Times, Serif"> These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and the notes thereto for the year ended December&#160;31, 2017.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.68in; FONT: 10pt Times New Roman, Times, Serif"> The preparation of the unaudited condensed consolidated financial statements requires management to make estimates and assumptions relating to reporting of the assets and liabilities and the disclosure of contingent assets and liabilities to prepare these condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period in conformity with U.S. generally accepted accounting principles. Actual results could differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"></div> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24.5pt"> <div><strong>(2)</strong></div> </td> <td> <div><strong>Earnings (Loss) per Share</strong></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0px 0px 0px 0.68in"> Basic earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is based on the weighted average number of common shares outstanding plus, where applicable, the additional potential common shares that would have been outstanding related to dilutive options and unvested restricted stock units to the extent such shares are dilutive.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0px 0px 0px 0.5in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0px 0px 0px 0.68in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the three months ended March 31, 2018 and 2017:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0px 0px 0px 0.5in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; WIDTH: 90%; BORDER-COLLAPSE: collapse; MARGIN: 0in 0in 0in 0.67in" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="21%" colspan="5"> <div> Three&#160;Months&#160;Ended&#160;March&#160;31,</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="10%" colspan="2"> <div>2018</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="10%" colspan="2"> <div>2017</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>Basic loss per share attributable to common stock:</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 13px" width="67%"> <div>Numerator</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 26px" width="67%"> <div>Net loss</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(2,719,971)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(4,861,260)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 13px" width="67%"> <div>Denominator</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 26px" width="67%"> <div>Weighted avg. common shares outstanding</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>21,264,539</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>18,711,239</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>Basic loss per share attributable to common stock</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(0.13)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(0.26)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>Diluted loss per share attributable to common stock:</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 13px" width="67%"> <div>Numerator</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 26px" width="67%"> <div>Net loss</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(2,719,971)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(4,861,260)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 13px" width="67%"> <div>Denominator</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 26px" width="67%"> <div>Weighted avg. common shares outstanding</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>21,264,539</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>18,711,239</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>Diluted loss per share attributable to common stock</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(0.13)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(0.26)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0px 0px 0px 0.5in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0px 0px 0px 0.68in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The computation of diluted loss per share for the three months ended March 31, 2018 and 2017 does not include the following stock options and unvested restricted stock units to purchase shares in the computation of diluted loss per share because these instruments were antidilutive:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0px 0px 0px 0.5in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; WIDTH: 90%; BORDER-COLLAPSE: collapse; MARGIN: 0in 0in 0in 0.67in" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="21%" colspan="5"> <div>March&#160;31,</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="10%" colspan="2"> <div>2018</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="10%" colspan="2"> <div>2017</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>Stock options</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>2,374,449</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>2,070,076</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>Unvested restricted stock units</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>203,998</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>287,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> The following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the three months ended March 31, 2018 and 2017:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0px 0px 0px 0.5in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; WIDTH: 90%; BORDER-COLLAPSE: collapse; MARGIN: 0in 0in 0in 0.67in" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="21%" colspan="5"> <div>Three&#160;Months&#160;Ended&#160;March&#160;31,</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="10%" colspan="2"> <div>2018</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="10%" colspan="2"> <div>2017</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>Basic loss per share attributable to common stock:</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 13px" width="67%"> <div>Numerator</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 26px" width="67%"> <div>Net loss</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(2,719,971)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(4,861,260)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 13px" width="67%"> <div>Denominator</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 26px" width="67%"> <div>Weighted avg. common shares outstanding</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>21,264,539</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>18,711,239</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>Basic loss per share attributable to common stock</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(0.13)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(0.26)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>Diluted loss per share attributable to common stock:</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 13px" width="67%"> <div>Numerator</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 26px" width="67%"> <div>Net loss</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(2,719,971)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(4,861,260)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 13px" width="67%"> <div>Denominator</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 26px" width="67%"> <div>Weighted avg. common shares outstanding</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>21,264,539</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>18,711,239</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 3px double; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>Diluted loss per share attributable to common stock</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(0.13)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="9%"> <div>(0.26)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> The computation of diluted loss per share for the three months ended March 31, 2018 and 2017 does not include the following stock options and unvested restricted stock units to purchase shares in the computation of diluted loss per share because these instruments were antidilutive:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0px 0px 0px 0.5in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; WIDTH: 90%; BORDER-COLLAPSE: collapse; MARGIN: 0in 0in 0in 0.67in" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="21%" colspan="5"> <div>March&#160;31,</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="67%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="10%" colspan="2"> <div>2018</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="10%" colspan="2"> <div>2017</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>Stock options</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>2,374,449</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>2,070,076</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="67%"> <div>Unvested restricted stock units</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>203,998</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="9%"> <div>287,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> -37478 0 48863 6169 246722 0 7000 0 10000000 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Marketable Investment Securities</strong></div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> The Company has classified its marketable investment securities as available-for-sale securities. These securities are carried at fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders&#8217; equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend income is recognized on the ex-dividend date and interest income is recognized on an accrual basis. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at March 31, 2018 and December 31, 2017 were as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.67in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div>March&#160;31,&#160;2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Amortized<br/> Cost</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Gross<br/> unrealized<br/> holding<br/> gains</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Gross<br/> unrealized<br/> holding<br/> losses</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Aggregate<br/> fair&#160;value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Government bonds and notes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>2,992,811</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(2,891)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>2,989,920</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Corporate bonds, notes and commercial paper</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>16,228,256</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(16,802)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>16,211,454</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>19,221,067</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>(19,693)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>19,201,374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.67in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div>December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Amortized<br/> Cost</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Gross<br/> unrealized<br/> holding<br/> gains</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Gross<br/> unrealized<br/> holding<br/> losses</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Aggregate<br/> fair&#160;value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Government bonds and notes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>4,744,566</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(2,876)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>4,741,690</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Corporate bonds, notes and commercial paper</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>13,517,371</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(1,740)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>13,515,631</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>18,261,937</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>(4,616)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>18,257,321</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Maturities of debt securities classified as available-for-sale securities at March 31, 2018 are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.67in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div>March&#160;31,&#160;2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Amortized<br/> Cost</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Aggregate<br/> fair&#160;value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="63%"> <div>Due within one year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>19,221,067</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>19,201,374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>19,221,067</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>19,201,374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> There were no sales of marketable investment securities during the three months ended March 31, 2018 and 2017 and therefore no realized gains or losses. Additionally, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12.3</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.4</font> million of marketable investment securities matured during the three months ended March 31, 2018 and 2017, respectively. The Company determined there were no other-than-temporary impairments for the three months ended March 31, 2018 and 2017.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at March 31, 2018 and December 31, 2017 were as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.67in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div>March&#160;31,&#160;2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Amortized<br/> Cost</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Gross<br/> unrealized<br/> holding<br/> gains</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Gross<br/> unrealized<br/> holding<br/> losses</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Aggregate<br/> fair&#160;value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Government bonds and notes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>2,992,811</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(2,891)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>2,989,920</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Corporate bonds, notes and commercial paper</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>16,228,256</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(16,802)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>16,211,454</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>19,221,067</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>(19,693)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>19,201,374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.67in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div>December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Amortized<br/> Cost</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Gross<br/> unrealized<br/> holding<br/> gains</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Gross<br/> unrealized<br/> holding<br/> losses</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Aggregate<br/> fair&#160;value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Government bonds and notes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>4,744,566</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(2,876)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>4,741,690</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Corporate bonds, notes and commercial paper</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>13,517,371</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(1,740)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>13,515,631</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>18,261,937</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>(4,616)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>18,257,321</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> Maturities of debt securities classified as available-for-sale securities at March 31, 2018 are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.67in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div>March&#160;31,&#160;2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Amortized<br/> Cost</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Aggregate<br/> fair&#160;value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="63%"> <div>Due within one year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>19,221,067</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>19,201,374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>19,221,067</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>19,201,374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 19221067 0 19693 19201374 0 18261937 0 4616 18257321 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24.45pt"> <div><strong>(8)</strong></div> </td> <td> <div><strong>Leases</strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> On August&#160;6, 2004, the Company assumed a non-cancelable operating lease for office space and laboratory facilities in Salt Lake City, Utah. On May 6, 2014, the Company modified and extended the lease through February 28, 2018. On February 8, 2018, the Company extended the lease through February 28, 2019. Additionally, on December 28, 2015, the Company entered into an operating lease for office space in Lawrenceville, New Jersey through January 31, 2018. The Company vacated the Lawrenceville, New Jersey office on January 31, 2018. Future minimum lease payments under non-cancellable operating leases (with initial or remaining lease terms in excess of one year) as of March 31, 2018 are: <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.67in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"> <div>Operating</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"> <div>leases</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Year ending December 31:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>240,570</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>53,460</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Total minimum lease payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>294,030</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company&#8217;s rent expense was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">83,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">95,000</font> for the three months ended March 31, 2018 and 2017.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.67in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"> <div>Operating</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"> <div>leases</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Year ending December 31:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>240,570</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>53,460</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Total minimum lease payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>294,030</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 19221067 19201374 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24.45pt"> <div><strong>(4)</strong></div> </td> <td> <div><strong>Fair Value</strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -24.5pt; MARGIN: 0pt 0px 0pt 24.45pt; FONT: 10pt Times New Roman, Times, Serif"> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 48.5pt"> <div>&#160;</div> </td> <td style="WIDTH: 25pt"> <div><font style="FONT-SIZE: 10pt">&#8226;</font></div> </td> <td> <div><font style="FONT-SIZE: 10pt">Level&#160;1 Inputs: Quoted prices for identical instruments in active markets.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 48.5pt"> <div>&#160;</div> </td> <td style="WIDTH: 25pt"> <div><font style="FONT-SIZE: 10pt">&#8226;</font></div> </td> <td> <div><font style="FONT-SIZE: 10pt">Level&#160;2 Inputs: Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuation in which all significant inputs and significant value drivers are observable in active markets.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 48.5pt"> <div>&#160;</div> </td> <td style="WIDTH: 25pt"> <div><font style="FONT-SIZE: 10pt">&#8226;</font></div> </td> <td> <div><font style="FONT-SIZE: 10pt">Level&#160;3 Inputs: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> All of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For accrued interest income, prepaid and other current assets, accounts payable, and accrued expenses, the carrying amounts approximate fair value because of the short maturity of these instruments. The following table presents the placement in the fair value hierarchy of assets and liabilities that are measured at fair value on a recurring basis at March 31, 2018 and December 31, 2017: <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.67in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%" colspan="8"> <div> Fair&#160;value&#160;measurements&#160;at&#160;reporting&#160;date&#160;using</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>March&#160;31,<br/> 2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level&#160;1&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level&#160;2&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level&#160;3&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Cash equivalents - money market funds, commercial paper, and treasury bills</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>7,793,612</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>5,247,856</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2,545,756</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Government bonds and notes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2,989,920</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2,989,920</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Corporate bonds, notes and commercial paper</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>16,211,454</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>16,211,454</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>26,994,986</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>8,237,776</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>18,757,210</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.67in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%" colspan="8"> <div> Fair&#160;value&#160;measurements&#160;at&#160;reporting&#160;date&#160;using</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>December&#160;31,<br/> 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level&#160;1&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level&#160;2&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level&#160;3&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Cash equivalents - money market funds</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2,171,814</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2,171,814</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Government bonds and notes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4,741,690</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4,741,690</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Corporate bonds, notes and commercial paper</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>13,515,631</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>13,515,631</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>20,429,135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>6,913,504</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>13,515,631</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> The following methods and assumptions were used to determine the fair value of each class of assets and liabilities recorded at fair value in the balance sheets:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> Cash equivalents: Cash equivalents primarily consist of highly-rated money market funds, commercial paper and treasury bills with original maturities to the Company of three months or less and are purchased daily at par value with specified yield rates. Cash equivalents related to money market funds and treasury bills are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices or broker or dealer quotations for similar assets. Cash equivalents related to commercial paper are classified within Level 2 of the fair value hierarchy because they are valued using broker/dealer quotes, bids and offers, benchmark yields and credit spreads and other observable inputs.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> Government bonds and notes: The Company uses a third-party pricing service to value these investments. United States Treasury bonds and notes are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets for identical assets and reportable trades. Other United States government agency bonds are classified within Level 2 of the fair value hierarchy because they are valued using broker/dealer quotes, bids and offers, benchmark yields and credit spreads and other observable inputs.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> Corporate bonds, notes, and commercial paper: The Company uses a third-party pricing service to value these investments. The pricing service utilizes broker/dealer quotes, bids and offers, benchmark yields and credit spreads and other observable inputs.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif" align="center">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> The Company&#8217;s accounting policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 1 or Level 2 for the three months ended March 31, 2018.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.67in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%" colspan="8"> <div> Fair&#160;value&#160;measurements&#160;at&#160;reporting&#160;date&#160;using</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>March&#160;31,<br/> 2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level&#160;1&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level&#160;2&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level&#160;3&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Cash equivalents - money market funds, commercial paper, and treasury bills</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>7,793,612</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>5,247,856</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2,545,756</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Government bonds and notes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2,989,920</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2,989,920</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Corporate bonds, notes and commercial paper</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>16,211,454</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>16,211,454</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>26,994,986</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>8,237,776</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>18,757,210</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.67in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%" colspan="8"> <div> Fair&#160;value&#160;measurements&#160;at&#160;reporting&#160;date&#160;using</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>December&#160;31,<br/> 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level&#160;1&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level&#160;2&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level&#160;3&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Cash equivalents - money market funds</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2,171,814</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2,171,814</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Government bonds and notes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4,741,690</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4,741,690</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Corporate bonds, notes and commercial paper</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>13,515,631</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>13,515,631</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>20,429,135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>6,913,504</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>13,515,631</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0in; FONT: 10pt Times New Roman, Times, Serif"> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24.45pt"> <div><b>(7)</b></div> </td> <td> <div><b>Contractual Agreements</b></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -24.5pt; MARGIN: 0pt 0px 0pt 48.95pt; FONT: 10pt Times New Roman, Times, Serif"> <b><i>&#160;</i></b></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24.45pt"></td> <td style="WIDTH: 24.5pt"> <div><b><i>(a)</i></b></div> </td> <td> <div><b><i>Abbott Products, Inc.</i></b></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.68in; FONT: 10pt Times New Roman, Times, Serif"> On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">March 29, 2012</font>, the Company terminated its collaborative agreement with Solvay Pharmaceuticals, Inc. (later acquired by Abbott Products, Inc.) for TLANDO. As part of the termination, the Company reacquired the rights to the intellectual property from Abbott. All obligations under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual 1% royalty on net sales. Such royalties are limited to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million in the first two calendar years following product launch, after which period there is not a cap on royalties and no maximum aggregate amount. If generic versions of any such product are introduced, then royalties are reduced by <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>%. The Company did not incur any royalties during the three months ended March 31, 2018 and 2017.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24.45pt"></td> <td style="WIDTH: 24.5pt"> <div><b><i>(b)</i></b></div> </td> <td> <div><b><i>Contract Research and Development</i></b></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.68in; FONT: 10pt Times New Roman, Times, Serif"> The Company has entered into agreements with various contract organizations that conduct preclinical, clinical, analytical and manufacturing development work on behalf of the Company as well as a number of independent contractors, primarily clinical researchers, who serve as advisors to the Company. The Company incurred expenses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">732,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.4</font> million for the three months ended March 31, 2018 and 2017 under these agreements and has recorded these expenses in research and development expenses.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> All obligations under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual 1% royalty on net sales. <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24.45pt"> <div><b>(6)</b></div> </td> <td> <div><b>Income Taxes</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 48.95pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 48.95pt; FONT: 10pt Times New Roman, Times, Serif"> The tax provision for interim periods is determined using an estimate of the Company&#8217;s effective tax rate for the full year adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter the Company updates its estimate of the annual effective tax rate, and if the estimated tax rate changes, the Company makes a cumulative adjustment.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 48.95pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 48.95pt; FONT: 10pt Times New Roman, Times, Serif"> At March 31, 2018 and December&#160;31, 2017, the Company had a full valuation allowance against its deferred tax assets, net of expected reversals of existing deferred tax liabilities, as it believes it is more likely than not that these benefits will not be realized.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 26994986 8237776 18757210 0 20429135 6913504 13515631 0 0 3144000 3330000 3526000 0 10000000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><strong>(5)</strong></div> </td> <td> <div><strong>Loan and Security Agreement</strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> On January 5, 2018, the Company entered into a Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;) with Silicon Valley Bank (&#8220;SVB&#8221;) pursuant to which SVB agreed to lend the Company $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.0</font> million. The principal borrowed under the Loan and Security Agreement bears <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">a fixed interest rate equal to the Prime Rate, as reported in money rates section of The Wall Street Journal or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum, which interest is payable monthly.</font> The loan matures on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 1, 2021</font>. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Company is only required to make monthly interest payments until December 31, 2018, following which the Company will be required to also make equal monthly payments of principal and interest for the remainder of the term; provided, however, that if on or prior to May 31, 2018, the Company receives evidence reasonably satisfactory to SVB that the Company has received FDA approval for TLANDO<sup style="font-style:normal">TM</sup>, the interest-only payment period will be extended to June 30, 2019.</font> The Company will also be required to pay an additional final payment at maturity equal to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">650,000</font> (the &#8220;Final Payment Charge&#8221;). The Final Payment Charge will be due on the scheduled maturity date and is being recognized as an increase to the principal balance with a corresponding charge to interest expense over the term of the facility using the effective interest method. At its option, the Company may prepay all amounts owed under the Loan and Security Agreement (including all accrued and unpaid interest and the Final Payment Charge), subject to a prepayment charge if the loan has been outstanding for less than two years, which prepayment charge is determined based on the date the loan is prepaid.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> In connection with the Loan and Security Agreement, the Company and the Subsidiary granted to SVB a security interest in substantially all of the Company&#8217;s assets now owned or hereafter acquired, excluding intellectual property and certain other assets. In addition, if TLANDO is not approved by the FDA on or prior to May 31, 2018, the Company will be required to maintain $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.0</font> million of cash collateral at SVB until such time as TLANDO is approved by the FDA.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> While any amounts are outstanding under the Loan and Security Agreement, the Company is subject to a number of affirmative and negative covenants, including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness and transactions with affiliates, among other customary covenants. The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5.0</font>% and would provide SVB, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including foreclosure against the property securing the credit facilities, including its cash. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> These events of default include, among other things, any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, the Company&#8217;s insolvency, a material adverse change, and one or more judgments against the Company in an amount greater than $100,000 individually or in the aggregate.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.69in; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Principal payments on debt at March 31, 2018,&#160;are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 1in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>Years&#160;Ending&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="71%"> <div>2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3,144</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3,330</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3,526</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> Principal payments on debt at March 31, 2018,&#160;are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 1in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>Years&#160;Ending&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="71%"> <div>2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3,144</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3,330</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3,526</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 10000000 2021-12-01 0.01 650000 0.050 5000000 a fixed interest rate equal to the Prime Rate, as reported in money rates section of The Wall Street Journal or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum, which interest is payable monthly. The Company is only required to make monthly interest payments until December 31, 2018, following which the Company will be required to also make equal monthly payments of principal and interest for the remainder of the term; provided, however, that if on or prior to May 31, 2018, the Company receives evidence reasonably satisfactory to SVB that the Company has received FDA approval for TLANDOTM, the interest-only payment period will be extended to June 30, 2019. These events of default include, among other things, any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, the Companys insolvency, a material adverse change, and one or more judgments against the Company in an amount greater than $100,000 individually or in the aggregate. 2400000 428031 0 428031 0 1377527 3083739 1687490 1825176 3065017 4908915 -2636986 -4908915 110181 48355 192466 0 -82285 48355 -2719271 -4860560 700 700 -15035 2707 -2735006 -4858553 666853 4.33 2900000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24.45pt"> <div><b>(9)</b></div> </td> <td> <div><b>Stockholders&#8217; Equity</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt; TEXT-INDENT: -24.5pt"> <b><i>&#160;</i></b></div> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24.45pt"></td> <td style="WIDTH: 24.5pt"> <div><b><i>(a)</i></b></div> </td> <td> <div><b><i>Issuance of Common Stock</i></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 49.5pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 49.5pt"> In March 2017, the Company entered into a Controlled Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &#38; Co. (&#8220;Cantor&#8221;), to sell shares of our common stock, with aggregate gross sales proceeds of up to $20.0 million, from time to time, through an &#8220;at the market&#8221; (&#8220;ATM&#8221;), equity offering program, under which Cantor acts as sales agent. The shares of common stock to be sold under the Sales Agreement will be sold and issued pursuant to the Company&#8217;s Registration Statement on Form S-3 (File No. 333-199093) (the &#8220;Existing Form S-3&#8221;), which was previously declared effective by the Securities and Exchange Commission, and the related prospectus and one or more prospectus supplements. As of March 31, 2018, we had sold an aggregate of 2,518,109 shares at a weighted-average sales price of $4.40 per share under the ATM for aggregate gross proceeds of $11.1 million and net proceeds of $10.6 million, after deducting sales agent commission and discounts and our other offering costs. We sold no shares in the three months ended March 31, 2018 and 666,853 shares at a weighted-average sales price of $4.33 per share under the ATM for aggregate gross proceeds of $2.9 million and $2.7 million in net proceeds in the three months ended March 31, 2017.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 49.5pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 49.5pt"> On October 13, 2017, the Company filed a Form S-3 (File No. 333-220942) (the &#8220;New Form S-3&#8221;) to replace the Existing Form S-3.&#160; The New Form S-3 has been declared effective by the Securities and Exchange Commission.&#160; The New Form S-3 registered the sale of up to $150.0 million of any combination of common stock, preferred stock, debt securities, warrants and units pursuant to a shelf registration statement.&#160; The New Form S-3 also contains a prospectus pursuant to which we may sell, from time to time, shares of our common stock having an aggregate offering price of up to $25.0 million through Cantor as our sales agent, pursuant to the Sales Agreement.&#160; Pursuant to Rule 415(a)(6) of the Securities Act of 1933, as amended, the offering of securities on the Existing Form S-3 are deemed terminated as of the date of effectiveness of the New Form S-3.&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> &#160;</div> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 22.5pt"></td> <td style="WIDTH: 27pt"> <div><b><i>(b)</i></b></div> </td> <td> <div><b><i>Rights Agreement</i></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 49.5pt"> On November 13, 2015, the Company and American Stock Transfer &#38; Trust Company, LLC, as Rights Agent, entered into a Rights Agreement. Also on November 12, 2015, the board of directors of the Company authorized and the Company declared a dividend of one preferred stock purchase right (each a &#8220;Right&#8221; and collectively, the &#8220;Rights&#8221;) for each outstanding share of common stock of the Company. The dividend was payable to stockholders of record as of the close of business on November 30, 2015 and entitles the registered holder to purchase from the Company one one-thousandth of a fully paid non-assessable share of Series A Junior Participating Preferred Stock of the Company at a price of $63.96 per one-thousandth share (the &#8220;Purchase Price&#8221;). The Rights will generally become exercisable upon the earlier to occur of (i) 10 business days following a public announcement that a person or group of affiliated or associated persons has become an Acquiring Person (as defined below) or (ii) 10 business days (or such later date as may be determined by action of the board of directors prior to such time as any person or group of affiliated or associated persons becomes an Acquiring Person) following the commencement of, or announcement of an intention to make, a tender offer or exchange offer the consummation of which would result in the beneficial ownership by a person or group of 15% or more of the outstanding common stock of the Company. Except in certain situations, a person or group of affiliated or associated persons becomes an &#8220;Acquiring Person&#8221; upon acquiring beneficial ownership of 15% or more of the outstanding shares of common stock of the Company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 49.5pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 49.5pt"> In general, in the event a person becomes an Acquiring Person, then each Right not owned by such Acquiring Person will entitle its holder to purchase from the Company, at the Right&#8217;s then current exercise price, in lieu of shares of Series A Junior Participating Preferred Stock, common stock of the Company with a market value of twice the Purchase Price.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 49.5pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 49.5pt"> In addition, if after any person has become an Acquiring Person, (a) the Company is acquired in a merger or other business combination, or (b) 50% or more of the Company&#8217;s assets, or assets accounting for 50% or more of its earning power, are sold, leased, exchanged or otherwise transferred (in one or more transactions), proper provision shall be made so that each holder of a Right (other than the Acquiring Person, its affiliates and associates and certain transferees thereof, whose Rights became void) shall thereafter have the right to purchase from the acquiring corporation, for the Purchase Price, that number of shares of common stock of the acquiring corporation which at the time of such transaction would have a market value of twice the Purchase Price.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 49.5pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 49.5pt"> The Company will be entitled to redeem the Rights at $0.001 per Right at any time prior to the time an Acquiring Person becomes such. The terms of the Rights are set forth in the Rights Agreement, which is summarized in the Company's Current Report on Form 8-K dated November 13, 2015. The rights plan will expire on November 12, 2018, unless the rights are earlier redeemed or exchanged by the Company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 49.5pt"> <b><i>&#160;</i></b></div> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24.45pt"></td> <td style="WIDTH: 24.5pt"> <div><b><i>(c)</i></b></div> </td> <td> <div><b><i>Share-Based Payments</i></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> The Company recognizes stock-based compensation expense for grants of stock option awards, restricted stock units and restricted stock under the Company&#8217;s Incentive Plan to employees and nonemployee members of the Company&#8217;s board of directors based on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over the award&#8217;s requisite service period. In addition, the Company grants stock options to nonemployee consultants from time to time in exchange for services performed for the Company. Equity instruments granted to nonemployees are subject to periodic revaluation over their vesting terms.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> The Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Using this model, fair value is calculated based on assumptions with respect to (i)&#160;expected volatility of the Company&#8217;s common stock price, (ii)&#160;the periods of time over which employees and members of the board of directors are expected to hold their options prior to exercise (expected term), (iii)&#160;expected dividend yield on the Common Stock, and (iv)&#160;risk-free interest rates. Stock-based compensation expense also includes an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation cost that has been expensed in the statements of operations amounted to $427,000 and $632,000 for the three months ended March 31, 2018 and 2017, allocated as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> &#160;</div> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 49.5pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6"> <div>Three Months Ended<br/> March 31,</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"> <div>2018</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"> <div>2017</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center" colspan="2"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center" colspan="2"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,238,255)"> <td style="WIDTH: 70%; TEXT-ALIGN: left"> <div>Research and development</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>$</div> </td> <td style="WIDTH: 12%; TEXT-ALIGN: right"> <div>149,588</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>$</div> </td> <td style="WIDTH: 12%; TEXT-ALIGN: right"> <div>207,380</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left"> <div>General and administrative</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>277,692</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>424,910</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,238,255)"> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>427,280</div> </td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>632,290</div> </td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> The Company did not issue any stock options during the three months ended March 31, 2018 and 2017. Additionally, the Company issued 287,000 restricted stock units during three months ended March 31, 2017 and did not issue any restricted stock units during the three months ended March 31, 2018.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> Key assumptions used in the determination of the fair value of stock options granted are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> <i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> <i>Expected Term</i>: The expected term represents the period that the stock-based awards are expected to be outstanding. Due to limited historical experience of similar awards, the expected term was estimated using the simplified method in accordance with the provisions of Staff Accounting Bulletin (&#8220;SAB&#8221;) No.&#160;107, <i>Share-Based Payment,</i> for awards with stated or implied service periods. The simplified method defines the expected term as the average of the contractual term and the vesting period of the stock option. For awards with performance conditions, and that have the contractual term to satisfy the performance condition, the contractual term was used.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> <i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> <i>Risk-Free Interest Rate</i>: The risk-free interest rate used was based on the implied yield currently available on U.S.&#160;Treasury issues with an equivalent remaining term.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> <i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> <i>Expected Dividend</i>: The expected dividend assumption is based on management&#8217;s current expectation about the Company&#8217;s anticipated dividend policy. The Company does not anticipate declaring dividends in the foreseeable future.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> <i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> <i>Expected Volatility</i>: Since the Company did not have sufficient trading history, the volatility factor was based on the average of similar public companies through August 2014. When selecting similar companies, the Company considered the industry, stage of life cycle, size, and financial leverage. Beginning in August 2014, the volatility factor is based on a combination of the Company's trading history since March 2014 and the average of similar public companies. Beginning in July 2017, the volatility factor is based solely on the Company&#8217;s trading history since March 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> FASB ASC 718, <i>Stock Compensation,</i> requires the Company to recognize compensation expense for the portion of options that are expected to vest. Therefore, the Company applied estimated forfeiture rates that were derived from historical employee termination behavior. If the actual number of forfeitures differs from those estimated by management, additional adjustments to compensation expense may be required in future periods.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> As of March 31, 2018, there was $2.4 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the Company&#8217;s stock plans. That cost is expected to be recognized over a weighted average period of 1.85 years and will be adjusted for subsequent changes in estimated forfeitures. Additionally, as of March 31, 2018, there was $736,000 of total unrecognized compensation cost related to unvested restricted stock units that have performance vesting.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> &#160;</div> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24.45pt"></td> <td style="WIDTH: 24.5pt"> <div><b><i>(d)</i></b></div> </td> <td> <div><b><i>Stock Option Plan</i></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 49.5pt"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 49.5pt"> In April 2014, the board of directors adopted the 2014 Stock and Incentive Plan ("2014 Plan") subject to shareholder approval which was received in June 2014. The 2014 Plan provides for the granting of nonqualified and incentive stock options, stock appreciation rights, restricted stock units, restricted stock and dividend equivalents. An aggregate of 1,000,000 shares are authorized for issuance under the 2014 Plan. Additionally, 271,906 remaining authorized shares under the 2011 Equity Incentive Plan ("2011 Plan") were issuable under the 2014 Plan at the time of the 2014 Plan adoption. Upon receiving shareholder approval in June 2016, the 2014 Plan was amended and restated to increase the authorized number of shares of common stock of the Company issuable under all awards granted under the 2014 Plan from 1,271,906 to 2,471,906. The board of directors, on an option-by-option basis, determines the number of shares, exercise price, term, and vesting period. Options granted generally have a ten-year contractual life. The Company issues shares of common stock upon the exercise of options with the source of those shares of common stock being either newly issued shares or shares held in treasury. An aggregate of 2,471,906 shares are authorized for issuance under the 2014 Plan, with 573,108 shares remaining available for grant as of March 31, 2018.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt; TEXT-INDENT: -24.5pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> A summary of stock option activity is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt; TEXT-INDENT: -24.5pt"> &#160;</div> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 49.5pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6"> <div>Outstanding stock options</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"> <div>Number of<br/> shares</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"> <div>Weighted average<br/> exercise price</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,238,255)"> <td style="WIDTH: 70%"> <div>Balance at December 31, 2017</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 12%; TEXT-ALIGN: right"> <div>2,374,449</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>$</div> </td> <td style="WIDTH: 12%; TEXT-ALIGN: right"> <div>5.64</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"> <div>Options granted</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,238,255)"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"> <div>Options exercised</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"> <div>Options forfeited</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,238,255)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 9pt"> <div>Options cancelled</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>-</div> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>-</div> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt"> <div>Balance at March 31, 2018</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>2,374,449</div> </td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>5.64</div> </td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> The following table summarizes information about stock options outstanding and exercisable at March 31, 2018:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> &#160;</div> <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 49.5pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="13"> <div>Options outstanding</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="14"> <div>Options exercisable</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"> <div>Number<br/> outstanding</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"> <div>Weighted<br/> average<br/> remaining<br/> contractual<br/> life<br/> (Years)</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"> <div>Weighted<br/> average<br/> exercise<br/> price</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"> <div>Aggregate<br/> intrinsic<br/> value</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"> <div>Number<br/> exerciseable</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"> <div>Weighted<br/> average<br/> remaining<br/> contractual<br/> life<br/> (Years)</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"> <div>Weighted<br/> average<br/> exercise<br/> price</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"> <div>Aggregate<br/> intrinsic<br/> value</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: center"> <div>&#160;</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 12%; TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 12%; TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 12%; TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 12%; TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 12%; TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 12%; TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 12%; TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,238,255)"> <td style="TEXT-ALIGN: right"> <div>2,374,449</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>7.20</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>$</div> </td> <td style="TEXT-ALIGN: right"> <div>5.64</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>$</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>1,522,295</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>6.10</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>$</div> </td> <td style="TEXT-ALIGN: right"> <div>6.20</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>$</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> The intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value of stock options exercised during the three months ended March 31, 2018 and 2017 was zero and $131,000. There were no stock options exercised during the three months ended March 31, 2018 and 138,274 stock options exercised during the three months ended March 31, 2017.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt; TEXT-INDENT: -24.5pt"> <b><i>&#160;</i></b></div> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24.45pt"></td> <td style="WIDTH: 24.5pt"> <div><b><i>(e)</i></b></div> </td> <td> <div><b><i>Restricted Stock Units</i></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> A summary of restricted stock unit activity is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 48.95pt"> &#160;</div> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 49.5pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"> <div>Number of<br/> unvested restricted<br/> shares</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center" colspan="2"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,238,255)"> <td style="WIDTH: 85%"> <div>Balance at December 31, 2017</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="WIDTH: 12%; TEXT-ALIGN: right"> <div>203,998</div> </td> <td style="WIDTH: 1%; TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-LEFT: 9pt"> <div>Granted</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,238,255)"> <td style="PADDING-LEFT: 9pt"> <div>Vested</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"> <div>Cancelled</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>-</div> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,238,255)"> <td style="PADDING-BOTTOM: 2.5pt"> <div>Balance at March 31, 2018</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>203,998</div> </td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 700 700 64966 0 64966 0 EX-101.SCH 7 lpcn-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Earnings (Loss) per Share link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Marketable Investment Securities link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Fair Value link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Loan and Security Agreement link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Contractual Agreements link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Spriaso, LLC link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Earnings (Loss) per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Marketable Investment Securities (Tables) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Fair Value (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Loan and Security Agreement (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Earnings (Loss) per Share (Details) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Earnings (Loss) per Share (Details 1) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Marketable Investment Securities (Details) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Marketable Investment Securities (Details 1) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Marketable Investment Securities (Details Textual) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Fair Value (Details) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Loan and Security Agreement (Details) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Loan and Security Agreement (Details Textual) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Contractual Agreements (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Leases (Details Textual) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Stockholders' Equity (Details 1) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - Stockholders' Equity (Details 2) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Stockholders' Equity (Details 3) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - Spriaso, LLC (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 lpcn-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 lpcn-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 lpcn-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 lpcn-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2018
May 04, 2018
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q1  
Entity Registrant Name Lipocine Inc.  
Entity Central Index Key 0001535955  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Trading Symbol LPCN  
Entity Common Stock, Shares Outstanding   21,264,539
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 8,561,313 $ 3,210,749
Marketable investment securities 19,201,374 18,257,321
Accrued interest income 47,249 23,067
Litigation insurance recovery 3,566,649 3,319,927
Prepaid and other current assets 247,979 408,227
Total current assets 31,624,564 25,219,291
Property and equipment, net of accumulated depreciation of $1,111,366 and $1,121,080, respectively 32,331 75,070
Other assets 23,753 30,753
Total assets 31,680,648 25,325,114
Current liabilities:    
Accounts payable 388,356 598,070
Litigation settlement payable 4,250,000 4,250,000
Accrued expenses 305,064 1,497,056
Debt - current portion 1,340,514 0
Total current liabilities 6,283,934 6,345,126
Debt - non-current portion 8,724,452 0
Total liabilities 15,008,386 6,345,126
Commitments and contingencies (notes 7 and 10)
Stockholders' equity:    
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized; zero issued and outstanding 0 0
Common stock, par value $0.0001 per share, 100,000,000 shares authorized; 21,270,249 and 21,270,249 issued and 21,264,539 and 21,264,539 outstanding 2,127 2,127
Additional paid-in capital 145,850,292 145,423,012
Treasury stock at cost, 5,710 shares (40,712) (40,712)
Accumulated other comprehensive loss (19,651) (4,616)
Accumulated deficit (129,119,794) (126,399,823)
Total stockholders' equity 16,672,262 18,979,988
Total liabilities and stockholders' equity $ 31,680,648 $ 25,325,114
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets [Parenthetical] - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (in dollars) $ 1,111,366 $ 1,121,080
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, issued 0 0
Preferred stock, outstanding 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 21,270,249 21,270,249
Common stock, shares outstanding 21,264,539 21,264,539
Treasury Stock, Shares 5,710 5,710
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Revenues:    
License revenue $ 428,031 $ 0
Total revenues 428,031 0
Operating expenses:    
Research and development 1,377,527 3,083,739
General and administrative 1,687,490 1,825,176
Total operating expenses 3,065,017 4,908,915
Operating loss (2,636,986) (4,908,915)
Other income (expense):    
Interest and investment income 110,181 48,355
Interest expense (192,466) 0
Total other income (expense), net (82,285) 48,355
Loss before income tax expense (2,719,271) (4,860,560)
Income tax expense (700) (700)
Net loss $ (2,719,971) $ (4,861,260)
Basic loss per share attributable to common stock $ (0.13) $ (0.26)
Weighted average common shares outstanding, basic 21,264,539 18,711,239
Diluted loss per share attributable to common stock $ (0.13) $ (0.26)
Weighted average common shares outstanding, diluted 21,264,539 18,711,239
Comprehensive loss:    
Net loss $ (2,719,971) $ (4,861,260)
Net unrealized gain (loss) on available-for-sale securities (15,035) 2,707
Comprehensive loss $ (2,735,006) $ (4,858,553)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Cash flows from operating activities:    
Net loss $ (2,719,971) $ (4,861,260)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation expense 5,261 7,093
Loss on disposition of property and equipment 37,478 0
Stock-based compensation expense 427,280 632,290
Non-cash interest expense 64,966 0
Amortization of discount on marketable investment securities (48,863) (6,169)
Changes in operating assets and liabilities:    
Accrued interest income (24,182) 2,997
Prepaid and other current assets 160,248 67,509
Accounts payable (209,714) 607,595
Litigation insurance recovery (246,722) 0
Accrued expenses (1,191,992) 411,194
Cash used in operating activities (3,746,211) (3,138,751)
Cash flows from investing activities:    
Refund of rental deposit 7,000 0
Purchases of marketable investment securities (13,210,225) (6,972,103)
Maturities of marketable investment securities 12,300,000 8,400,000
Cash provided by (used in) investing activities (903,225) 1,427,897
Cash flows from financing activities:    
Proceeds from debt agreement 10,000,000 0
Proceeds from stock option exercises 0 388,551
Net proceeds from common stock offering 0 2,698,098
Cash provided by financing activities 10,000,000 3,086,649
Net increase in cash and cash equivalents 5,350,564 1,375,795
Cash and cash equivalents at beginning of period 3,210,749 5,560,716
Cash and cash equivalents at end of period 8,561,313 6,936,511
Supplemental disclosure of cash flow information:    
Income taxes paid 700 700
Supplemental disclosure of non-cash investing and financing activity:    
Net unrealized gain (loss) on available-for-sale securities (15,035) 2,707
Accrued final payment charge on debt $ 64,966 $ 0
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Basis of Presentation
3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
Business Description and Basis of Presentation [Text Block]
(1)
Basis of Presentation
 
The accompanying unaudited condensed consolidated financial statements included herein have been prepared by Lipocine Inc. (“Lipocine” or the “Company”) in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The unaudited condensed consolidated financial statements are comprised of the financial statements of Lipocine and its subsidiaries collectively referred to as the Company. In management's opinion, the interim financial data presented includes all adjustments (consisting solely of normal recurring items) necessary for fair presentation. All intercompany accounts and transactions have been eliminated. Certain information required by U.S. generally accepted accounting principles has been condensed or omitted in accordance with rules and regulations of the SEC. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for any future period or for the year ending December 31, 2018.
 
These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and the notes thereto for the year ended December 31, 2017.
 
The preparation of the unaudited condensed consolidated financial statements requires management to make estimates and assumptions relating to reporting of the assets and liabilities and the disclosure of contingent assets and liabilities to prepare these condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period in conformity with U.S. generally accepted accounting principles. Actual results could differ from these estimates.
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings (Loss) per Share
3 Months Ended
Mar. 31, 2018
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block]
(2)
Earnings (Loss) per Share
 
Basic earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is based on the weighted average number of common shares outstanding plus, where applicable, the additional potential common shares that would have been outstanding related to dilutive options and unvested restricted stock units to the extent such shares are dilutive.
 
The following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the three months ended March 31, 2018 and 2017:
 
 
 
Three Months Ended March 31,
 
 
 
2018
 
2017
 
Basic loss per share attributable to common stock:
 
 
 
 
 
 
 
Numerator
 
 
 
 
 
 
 
Net loss
 
$
(2,719,971)
 
$
(4,861,260)
 
 
 
 
 
 
 
 
 
Denominator
 
 
 
 
 
 
 
Weighted avg. common shares outstanding
 
 
21,264,539
 
 
18,711,239
 
 
 
 
 
 
 
 
 
Basic loss per share attributable to common stock
 
$
(0.13)
 
$
(0.26)
 
 
 
 
 
 
 
 
 
Diluted loss per share attributable to common stock:
 
 
 
 
 
 
 
Numerator
 
 
 
 
 
 
 
Net loss
 
$
(2,719,971)
 
$
(4,861,260)
 
 
 
 
 
 
 
 
 
Denominator
 
 
 
 
 
 
 
Weighted avg. common shares outstanding
 
 
21,264,539
 
 
18,711,239
 
 
 
 
 
 
 
 
 
Diluted loss per share attributable to common stock
 
$
(0.13)
 
$
(0.26)
 
 
The computation of diluted loss per share for the three months ended March 31, 2018 and 2017 does not include the following stock options and unvested restricted stock units to purchase shares in the computation of diluted loss per share because these instruments were antidilutive:
 
 
 
March 31,
 
 
 
2018
 
2017
 
Stock options
 
 
2,374,449
 
 
2,070,076
 
Unvested restricted stock units
 
 
203,998
 
 
287,000
 
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Marketable Investment Securities
3 Months Ended
Mar. 31, 2018
Investments, Debt and Equity Securities [Abstract]  
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]
(3)       Marketable Investment Securities
 
The Company has classified its marketable investment securities as available-for-sale securities. These securities are carried at fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend income is recognized on the ex-dividend date and interest income is recognized on an accrual basis. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at March 31, 2018 and December 31, 2017 were as follows:
  
March 31, 2018
 
Amortized
Cost
 
Gross
unrealized
holding
gains
 
Gross
unrealized
holding
losses
 
Aggregate
fair value
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Government bonds and notes
 
$
2,992,811
 
$
-
 
$
(2,891)
 
$
2,989,920
 
Corporate bonds, notes and commercial paper
 
 
16,228,256
 
 
-
 
 
(16,802)
 
 
16,211,454
 
 
 
$
19,221,067
 
$
-
 
$
(19,693)
 
$
19,201,374
 
 
December 31, 2017
 
Amortized
Cost
 
Gross
unrealized
holding
gains
 
Gross
unrealized
holding
losses
 
Aggregate
fair value
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Government bonds and notes
 
$
4,744,566
 
$
-
 
$
(2,876)
 
$
4,741,690
 
Corporate bonds, notes and commercial paper
 
 
13,517,371
 
 
-
 
 
(1,740)
 
 
13,515,631
 
 
 
$
18,261,937
 
$
-
 
$
(4,616)
 
$
18,257,321
 
 
Maturities of debt securities classified as available-for-sale securities at March 31, 2018 are as follows:
 
March 31, 2018
 
Amortized
Cost
 
Aggregate
fair value
 
Due within one year
 
$
19,221,067
 
$
19,201,374
 
 
 
$
19,221,067
 
$
19,201,374
 
 
There were no sales of marketable investment securities during the three months ended March 31, 2018 and 2017 and therefore no realized gains or losses. Additionally, $12.3 million and $8.4 million of marketable investment securities matured during the three months ended March 31, 2018 and 2017, respectively. The Company determined there were no other-than-temporary impairments for the three months ended March 31, 2018 and 2017.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value
3 Months Ended
Mar. 31, 2018
Fair Value Disclosures [Abstract]  
Fair Value Disclosures [Text Block]
(4)
Fair Value
 
The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:
 
 
Level 1 Inputs: Quoted prices for identical instruments in active markets.
 
 
Level 2 Inputs: Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuation in which all significant inputs and significant value drivers are observable in active markets.
 
 
Level 3 Inputs: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
 
All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For accrued interest income, prepaid and other current assets, accounts payable, and accrued expenses, the carrying amounts approximate fair value because of the short maturity of these instruments. The following table presents the placement in the fair value hierarchy of assets and liabilities that are measured at fair value on a recurring basis at March 31, 2018 and December 31, 2017:
 
 
 
 
 
 
Fair value measurements at reporting date using
 
 
 
March 31,
2018
 
Level 1 inputs
 
Level 2 inputs
 
Level 3 inputs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents - money market funds, commercial paper, and treasury bills
 
$
7,793,612
 
$
5,247,856
 
$
2,545,756
 
$
-
 
Government bonds and notes
 
 
2,989,920
 
 
2,989,920
 
 
-
 
 
-
 
Corporate bonds, notes and commercial paper
 
 
16,211,454
 
 
-
 
 
16,211,454
 
 
-
 
 
 
$
26,994,986
 
$
8,237,776
 
$
18,757,210
 
$
-
 
 
 
 
 
 
 
Fair value measurements at reporting date using
 
 
 
December 31,
2017
 
Level 1 inputs
 
Level 2 inputs
 
Level 3 inputs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents - money market funds
 
$
2,171,814
 
$
2,171,814
 
$
-
 
$
-
 
Government bonds and notes
 
 
4,741,690
 
 
4,741,690
 
 
-
 
 
-
 
Corporate bonds, notes and commercial paper
 
 
13,515,631
 
 
-
 
 
13,515,631
 
 
-
 
 
 
$
20,429,135
 
$
6,913,504
 
$
13,515,631
 
$
-
 
 
The following methods and assumptions were used to determine the fair value of each class of assets and liabilities recorded at fair value in the balance sheets:
 
Cash equivalents: Cash equivalents primarily consist of highly-rated money market funds, commercial paper and treasury bills with original maturities to the Company of three months or less and are purchased daily at par value with specified yield rates. Cash equivalents related to money market funds and treasury bills are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices or broker or dealer quotations for similar assets. Cash equivalents related to commercial paper are classified within Level 2 of the fair value hierarchy because they are valued using broker/dealer quotes, bids and offers, benchmark yields and credit spreads and other observable inputs.
 
Government bonds and notes: The Company uses a third-party pricing service to value these investments. United States Treasury bonds and notes are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets for identical assets and reportable trades. Other United States government agency bonds are classified within Level 2 of the fair value hierarchy because they are valued using broker/dealer quotes, bids and offers, benchmark yields and credit spreads and other observable inputs.
 
Corporate bonds, notes, and commercial paper: The Company uses a third-party pricing service to value these investments. The pricing service utilizes broker/dealer quotes, bids and offers, benchmark yields and credit spreads and other observable inputs.
 
The Company’s accounting policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 1 or Level 2 for the three months ended March 31, 2018.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Loan and Security Agreement
3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Debt Disclosure [Text Block]
(5)
Loan and Security Agreement
 
On January 5, 2018, the Company entered into a Loan and Security Agreement (the “Loan and Security Agreement”) with Silicon Valley Bank (“SVB”) pursuant to which SVB agreed to lend the Company $10.0 million. The principal borrowed under the Loan and Security Agreement bears a fixed interest rate equal to the Prime Rate, as reported in money rates section of The Wall Street Journal or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum, which interest is payable monthly. The loan matures on December 1, 2021. The Company is only required to make monthly interest payments until December 31, 2018, following which the Company will be required to also make equal monthly payments of principal and interest for the remainder of the term; provided, however, that if on or prior to May 31, 2018, the Company receives evidence reasonably satisfactory to SVB that the Company has received FDA approval for TLANDOTM, the interest-only payment period will be extended to June 30, 2019. The Company will also be required to pay an additional final payment at maturity equal to $650,000 (the “Final Payment Charge”). The Final Payment Charge will be due on the scheduled maturity date and is being recognized as an increase to the principal balance with a corresponding charge to interest expense over the term of the facility using the effective interest method. At its option, the Company may prepay all amounts owed under the Loan and Security Agreement (including all accrued and unpaid interest and the Final Payment Charge), subject to a prepayment charge if the loan has been outstanding for less than two years, which prepayment charge is determined based on the date the loan is prepaid.
 
In connection with the Loan and Security Agreement, the Company and the Subsidiary granted to SVB a security interest in substantially all of the Company’s assets now owned or hereafter acquired, excluding intellectual property and certain other assets. In addition, if TLANDO is not approved by the FDA on or prior to May 31, 2018, the Company will be required to maintain $5.0 million of cash collateral at SVB until such time as TLANDO is approved by the FDA.
 
While any amounts are outstanding under the Loan and Security Agreement, the Company is subject to a number of affirmative and negative covenants, including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness and transactions with affiliates, among other customary covenants. The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus 5.0% and would provide SVB, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including foreclosure against the property securing the credit facilities, including its cash. These events of default include, among other things, any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, the Company’s insolvency, a material adverse change, and one or more judgments against the Company in an amount greater than $100,000 individually or in the aggregate.
 
Principal payments on debt at March 31, 2018, are as follows:
 
(in thousands)
 
 
 
 
Years Ending December 31,
 
Amount
 
2018
 
$
 
2019
 
 
3,144
 
2020
 
 
3,330
 
2021
 
 
3,526
 
Thereafter
 
 
 
 
 
$
10,000
 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes
3 Months Ended
Mar. 31, 2018
Income Tax Disclosure [Abstract]  
Income Tax Disclosure [Text Block]
(6)
Income Taxes
 
The tax provision for interim periods is determined using an estimate of the Company’s effective tax rate for the full year adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter the Company updates its estimate of the annual effective tax rate, and if the estimated tax rate changes, the Company makes a cumulative adjustment.
 
At March 31, 2018 and December 31, 2017, the Company had a full valuation allowance against its deferred tax assets, net of expected reversals of existing deferred tax liabilities, as it believes it is more likely than not that these benefits will not be realized.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Contractual Agreements
3 Months Ended
Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business and Contractual Arrangements [Text Block]
(7)
Contractual Agreements
 
(a)
Abbott Products, Inc.
 
On March 29, 2012, the Company terminated its collaborative agreement with Solvay Pharmaceuticals, Inc. (later acquired by Abbott Products, Inc.) for TLANDO. As part of the termination, the Company reacquired the rights to the intellectual property from Abbott. All obligations under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual 1% royalty on net sales. Such royalties are limited to $1.0 million in the first two calendar years following product launch, after which period there is not a cap on royalties and no maximum aggregate amount. If generic versions of any such product are introduced, then royalties are reduced by 50%. The Company did not incur any royalties during the three months ended March 31, 2018 and 2017.
 
(b)
Contract Research and Development
 
The Company has entered into agreements with various contract organizations that conduct preclinical, clinical, analytical and manufacturing development work on behalf of the Company as well as a number of independent contractors, primarily clinical researchers, who serve as advisors to the Company. The Company incurred expenses of $732,000 and $2.4 million for the three months ended March 31, 2018 and 2017 under these agreements and has recorded these expenses in research and development expenses.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Leases
3 Months Ended
Mar. 31, 2018
Leases [Abstract]  
Leases of Lessee Disclosure [Text Block]
(8)
Leases
 
On August 6, 2004, the Company assumed a non-cancelable operating lease for office space and laboratory facilities in Salt Lake City, Utah. On May 6, 2014, the Company modified and extended the lease through February 28, 2018. On February 8, 2018, the Company extended the lease through February 28, 2019. Additionally, on December 28, 2015, the Company entered into an operating lease for office space in Lawrenceville, New Jersey through January 31, 2018. The Company vacated the Lawrenceville, New Jersey office on January 31, 2018. Future minimum lease payments under non-cancellable operating leases (with initial or remaining lease terms in excess of one year) as of March 31, 2018 are:
 
 
 
Operating
 
 
 
leases
 
Year ending December 31:
 
 
 
 
2018
 
 
240,570
 
2019
 
 
53,460
 
Total minimum lease payments
 
$
294,030
 
 
The Company’s rent expense was $83,000 and $95,000 for the three months ended March 31, 2018 and 2017.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2018
Stockholders Equity Note [Abstract]  
Stockholders Equity Note Disclosure [Text Block]
(9)
Stockholders’ Equity
 
(a)
Issuance of Common Stock
 
In March 2017, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), to sell shares of our common stock, with aggregate gross sales proceeds of up to $20.0 million, from time to time, through an “at the market” (“ATM”), equity offering program, under which Cantor acts as sales agent. The shares of common stock to be sold under the Sales Agreement will be sold and issued pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-199093) (the “Existing Form S-3”), which was previously declared effective by the Securities and Exchange Commission, and the related prospectus and one or more prospectus supplements. As of March 31, 2018, we had sold an aggregate of 2,518,109 shares at a weighted-average sales price of $4.40 per share under the ATM for aggregate gross proceeds of $11.1 million and net proceeds of $10.6 million, after deducting sales agent commission and discounts and our other offering costs. We sold no shares in the three months ended March 31, 2018 and 666,853 shares at a weighted-average sales price of $4.33 per share under the ATM for aggregate gross proceeds of $2.9 million and $2.7 million in net proceeds in the three months ended March 31, 2017.
 
On October 13, 2017, the Company filed a Form S-3 (File No. 333-220942) (the “New Form S-3”) to replace the Existing Form S-3.  The New Form S-3 has been declared effective by the Securities and Exchange Commission.  The New Form S-3 registered the sale of up to $150.0 million of any combination of common stock, preferred stock, debt securities, warrants and units pursuant to a shelf registration statement.  The New Form S-3 also contains a prospectus pursuant to which we may sell, from time to time, shares of our common stock having an aggregate offering price of up to $25.0 million through Cantor as our sales agent, pursuant to the Sales Agreement.  Pursuant to Rule 415(a)(6) of the Securities Act of 1933, as amended, the offering of securities on the Existing Form S-3 are deemed terminated as of the date of effectiveness of the New Form S-3. 
 
(b)
Rights Agreement
 
On November 13, 2015, the Company and American Stock Transfer & Trust Company, LLC, as Rights Agent, entered into a Rights Agreement. Also on November 12, 2015, the board of directors of the Company authorized and the Company declared a dividend of one preferred stock purchase right (each a “Right” and collectively, the “Rights”) for each outstanding share of common stock of the Company. The dividend was payable to stockholders of record as of the close of business on November 30, 2015 and entitles the registered holder to purchase from the Company one one-thousandth of a fully paid non-assessable share of Series A Junior Participating Preferred Stock of the Company at a price of $63.96 per one-thousandth share (the “Purchase Price”). The Rights will generally become exercisable upon the earlier to occur of (i) 10 business days following a public announcement that a person or group of affiliated or associated persons has become an Acquiring Person (as defined below) or (ii) 10 business days (or such later date as may be determined by action of the board of directors prior to such time as any person or group of affiliated or associated persons becomes an Acquiring Person) following the commencement of, or announcement of an intention to make, a tender offer or exchange offer the consummation of which would result in the beneficial ownership by a person or group of 15% or more of the outstanding common stock of the Company. Except in certain situations, a person or group of affiliated or associated persons becomes an “Acquiring Person” upon acquiring beneficial ownership of 15% or more of the outstanding shares of common stock of the Company.
 
In general, in the event a person becomes an Acquiring Person, then each Right not owned by such Acquiring Person will entitle its holder to purchase from the Company, at the Right’s then current exercise price, in lieu of shares of Series A Junior Participating Preferred Stock, common stock of the Company with a market value of twice the Purchase Price.
 
In addition, if after any person has become an Acquiring Person, (a) the Company is acquired in a merger or other business combination, or (b) 50% or more of the Company’s assets, or assets accounting for 50% or more of its earning power, are sold, leased, exchanged or otherwise transferred (in one or more transactions), proper provision shall be made so that each holder of a Right (other than the Acquiring Person, its affiliates and associates and certain transferees thereof, whose Rights became void) shall thereafter have the right to purchase from the acquiring corporation, for the Purchase Price, that number of shares of common stock of the acquiring corporation which at the time of such transaction would have a market value of twice the Purchase Price.
 
The Company will be entitled to redeem the Rights at $0.001 per Right at any time prior to the time an Acquiring Person becomes such. The terms of the Rights are set forth in the Rights Agreement, which is summarized in the Company's Current Report on Form 8-K dated November 13, 2015. The rights plan will expire on November 12, 2018, unless the rights are earlier redeemed or exchanged by the Company.
 
(c)
Share-Based Payments
 
The Company recognizes stock-based compensation expense for grants of stock option awards, restricted stock units and restricted stock under the Company’s Incentive Plan to employees and nonemployee members of the Company’s board of directors based on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over the award’s requisite service period. In addition, the Company grants stock options to nonemployee consultants from time to time in exchange for services performed for the Company. Equity instruments granted to nonemployees are subject to periodic revaluation over their vesting terms.
 
The Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of the Company’s common stock price, (ii) the periods of time over which employees and members of the board of directors are expected to hold their options prior to exercise (expected term), (iii) expected dividend yield on the Common Stock, and (iv) risk-free interest rates. Stock-based compensation expense also includes an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation cost that has been expensed in the statements of operations amounted to $427,000 and $632,000 for the three months ended March 31, 2018 and 2017, allocated as follows:
 
 
 
Three Months Ended
March 31,
 
 
 
2018
 
 
2017
 
 
 
 
 
 
 
 
Research and development
 
$
149,588
 
 
$
207,380
 
General and administrative
 
 
277,692
 
 
 
424,910
 
 
 
 
 
 
 
 
 
 
 
 
$
427,280
 
 
$
632,290
 
 
The Company did not issue any stock options during the three months ended March 31, 2018 and 2017. Additionally, the Company issued 287,000 restricted stock units during three months ended March 31, 2017 and did not issue any restricted stock units during the three months ended March 31, 2018.
 
Key assumptions used in the determination of the fair value of stock options granted are as follows:
 
Expected Term: The expected term represents the period that the stock-based awards are expected to be outstanding. Due to limited historical experience of similar awards, the expected term was estimated using the simplified method in accordance with the provisions of Staff Accounting Bulletin (“SAB”) No. 107, Share-Based Payment, for awards with stated or implied service periods. The simplified method defines the expected term as the average of the contractual term and the vesting period of the stock option. For awards with performance conditions, and that have the contractual term to satisfy the performance condition, the contractual term was used.
 
Risk-Free Interest Rate: The risk-free interest rate used was based on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term.
 
Expected Dividend: The expected dividend assumption is based on management’s current expectation about the Company’s anticipated dividend policy. The Company does not anticipate declaring dividends in the foreseeable future.
 
Expected Volatility: Since the Company did not have sufficient trading history, the volatility factor was based on the average of similar public companies through August 2014. When selecting similar companies, the Company considered the industry, stage of life cycle, size, and financial leverage. Beginning in August 2014, the volatility factor is based on a combination of the Company's trading history since March 2014 and the average of similar public companies. Beginning in July 2017, the volatility factor is based solely on the Company’s trading history since March 2014.
 
FASB ASC 718, Stock Compensation, requires the Company to recognize compensation expense for the portion of options that are expected to vest. Therefore, the Company applied estimated forfeiture rates that were derived from historical employee termination behavior. If the actual number of forfeitures differs from those estimated by management, additional adjustments to compensation expense may be required in future periods.
 
As of March 31, 2018, there was $2.4 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the Company’s stock plans. That cost is expected to be recognized over a weighted average period of 1.85 years and will be adjusted for subsequent changes in estimated forfeitures. Additionally, as of March 31, 2018, there was $736,000 of total unrecognized compensation cost related to unvested restricted stock units that have performance vesting.
 
(d)
Stock Option Plan
 
In April 2014, the board of directors adopted the 2014 Stock and Incentive Plan ("2014 Plan") subject to shareholder approval which was received in June 2014. The 2014 Plan provides for the granting of nonqualified and incentive stock options, stock appreciation rights, restricted stock units, restricted stock and dividend equivalents. An aggregate of 1,000,000 shares are authorized for issuance under the 2014 Plan. Additionally, 271,906 remaining authorized shares under the 2011 Equity Incentive Plan ("2011 Plan") were issuable under the 2014 Plan at the time of the 2014 Plan adoption. Upon receiving shareholder approval in June 2016, the 2014 Plan was amended and restated to increase the authorized number of shares of common stock of the Company issuable under all awards granted under the 2014 Plan from 1,271,906 to 2,471,906. The board of directors, on an option-by-option basis, determines the number of shares, exercise price, term, and vesting period. Options granted generally have a ten-year contractual life. The Company issues shares of common stock upon the exercise of options with the source of those shares of common stock being either newly issued shares or shares held in treasury. An aggregate of 2,471,906 shares are authorized for issuance under the 2014 Plan, with 573,108 shares remaining available for grant as of March 31, 2018.
 
A summary of stock option activity is as follows:
 
 
 
Outstanding stock options
 
 
 
Number of
shares
 
 
Weighted average
exercise price
 
Balance at December 31, 2017
 
 
2,374,449
 
 
$
5.64
 
Options granted
 
 
-
 
 
 
-
 
Options exercised
 
 
-
 
 
 
-
 
Options forfeited
 
 
-
 
 
 
-
 
Options cancelled
 
 
-
 
 
 
-
 
Balance at March 31, 2018
 
 
2,374,449
 
 
 
5.64
 
 
The following table summarizes information about stock options outstanding and exercisable at March 31, 2018:
 
Options outstanding
 
Options exercisable
 
Number
outstanding
 
Weighted
average
remaining
contractual
life
(Years)
 
 
Weighted
average
exercise
price
 
 
Aggregate
intrinsic
value
 
 
Number
exerciseable
 
 
Weighted
average
remaining
contractual
life
(Years)
 
 
Weighted
average
exercise
price
 
 
Aggregate
intrinsic
value
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,374,449
 
 
7.20
 
 
$
5.64
 
 
$
-
 
 
 
1,522,295
 
 
 
6.10
 
 
$
6.20
 
 
$
-
 
 
The intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value of stock options exercised during the three months ended March 31, 2018 and 2017 was zero and $131,000. There were no stock options exercised during the three months ended March 31, 2018 and 138,274 stock options exercised during the three months ended March 31, 2017.
 
(e)
Restricted Stock Units
 
A summary of restricted stock unit activity is as follows:
 
 
 
Number of
unvested restricted
shares
 
 
 
 
 
Balance at December 31, 2017
 
 
203,998
 
Granted
 
 
-
 
Vested
 
 
-
 
Cancelled
 
 
-
 
Balance at March 31, 2018
 
 
203,998
 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block]
(10)             
Commitments and Contingencies
 
Litigation
 
The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business. The Company records a liability when a particular contingency is probable and estimable.
 
On February 15, 2018, the Company and the other defendants entered into a memorandum of understanding to settle the purported securities class action litigation captioned In re Lipocine Inc. Securities Litigation, 2:17CV00182 DB (D. Utah) which was originally filed against the Company on July 1, 2016. The memorandum of understanding contemplates that the parties will enter into a settlement agreement, which, if entered into, will be subject to customary conditions including court approval following notice to our stockholders, and a hearing at which time the court will consider the fairness, reasonableness and adequacy of the settlement.  If a settlement is finally approved by the court, it will resolve all of the claims that were or could have been brought in the action being settled. The Company continues to believe that the claims in the lawsuits are without merit and, to the extent the parties do not enter into a settlement agreement or the court does not approve a settlement, the Company will defend against them vigorously. The Company maintains insurance for claims of this nature. As a result of signing the memorandum of understanding and the potential liability becoming probable and estimable, the Company has recorded a litigation settlement liability for $4.3 million as of March 31, 2018. Additionally, the Company has recorded a litigation insurance settlement recovery receivable of $3.6 million as of March 31, 2018 which represents the estimated insurance claims proceeds from our insurance carrier in excess of the Company’s retention.
 
Beyond In re Lipocine Inc. Securities Litigation, 2:17CV00182 DB (D. Utah), management does not currently believe that any other matter, individually or in the aggregate, will have a material adverse effect on our financial condition, liquidity or results of operations.
 
Guarantees and Indemnifications
 
In the ordinary course of business, the Company enters into agreements, such as lease agreements, licensing agreements, clinical trial agreements, and certain services agreements, containing standard guarantee and / or indemnifications provisions. Additionally, the Company has indemnified its directors and officers to the maximum extent permitted under the laws of the State of Delaware.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Spriaso, LLC
3 Months Ended
Mar. 31, 2018
Agreement With Spriaso LLC [Abstract]  
Agreement With Spriaso LLC [Text Block]
(11)
Spriaso, LLC
 
On July 23, 2013, the Company entered into an assignment/license and a services agreement with Spriaso, a related-party that is majority-owned by certain current and former directors of Lipocine Inc. and their affiliates. Under the license agreement, the Company assigned and transferred to Spriaso all of the Company’s rights, title and interest in its intellectual property to develop products for the cough and cold field. In addition, Spriaso received all rights and obligations under the Company’s product development agreement with a third-party. In exchange, the Company will receive a royalty of 20 percent of the net proceeds received by Spriaso, up to a maximum of $10.0 million. Spriaso also granted back to the Company an exclusive license to such intellectual property to develop products outside of the cough and cold field. Under the service agreement, the Company provided facilities and up to 10 percent of the services of certain employees to Spriaso for a period of 18 months which expired January 23, 2015. Effective January 23, 2015, the Company entered into an amended services agreement with Spriaso in which the Company agreed to continue providing up to 10 percent of the services of certain employees to Spriaso at a rate of $230/hour for a period of six months. The agreement was further amended on July 23, 2015, on January 23, 2016, on July 23, 2016, on January 23, 2017, on July 23, 2017 and again on January 23, 2018 to extend the term of the agreement for an additional six months. The agreement may be extended upon written agreement of Spriaso and the Company. The Company did not receive any reimbursements during the three months ended March 31, 2018 and 2017, respectively. Additionally, during the three months ended March 31, 2018 and 2017, the Company received $428,000 and zero in royalty payments from Spriaso. Spriaso filed its first NDA and as an affiliated entity of the Company, it used up the one-time waiver for user fees for a small business submitting its first human drug application to the FDA. Spriaso is considered a variable interest entity under the FASB ASC Topic 810-10, Consolidations, however the Company is not the primary beneficiary and has therefore not consolidated Spriaso.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Recent Accounting Pronouncements
3 Months Ended
Mar. 31, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]
(12)
Recent Accounting Pronouncements
 
Accounting Pronouncements Not Yet Adopted
 
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses. The new standard amends guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019; early adoption is permitted for interim and annual reporting periods beginning after December 15, 2018. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (i.e., modified retrospective approach). The Company plans to adopt this pronouncement effective January 1, 2019 and does not believe it will have a material effect on the Company's financial position or results of operations.
 
In February 2016, FASB issued ASU 2016-02, Leases, which provides new guidance for lease accounting including recognizing most leases on-balance sheet. The standard becomes effective for annual and interim periods in fiscal years beginning after December 15, 2018. ASU 2016-02 mandates a modified retrospective transition method for all entities. The Company does not have any lease that extends beyond December 31, 2018 other that its facility lease that was extended in February 2018 for a period of one-year until February 28, 2019. The Company plans to adopt this pronouncement effective January 1, 2019 and does not believe it will have a material effect on the Company's financial position or results of operations.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings (Loss) per Share (Tables)
3 Months Ended
Mar. 31, 2018
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
The following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the three months ended March 31, 2018 and 2017:
 
 
 
Three Months Ended March 31,
 
 
 
2018
 
2017
 
Basic loss per share attributable to common stock:
 
 
 
 
 
 
 
Numerator
 
 
 
 
 
 
 
Net loss
 
$
(2,719,971)
 
$
(4,861,260)
 
 
 
 
 
 
 
 
 
Denominator
 
 
 
 
 
 
 
Weighted avg. common shares outstanding
 
 
21,264,539
 
 
18,711,239
 
 
 
 
 
 
 
 
 
Basic loss per share attributable to common stock
 
$
(0.13)
 
$
(0.26)
 
 
 
 
 
 
 
 
 
Diluted loss per share attributable to common stock:
 
 
 
 
 
 
 
Numerator
 
 
 
 
 
 
 
Net loss
 
$
(2,719,971)
 
$
(4,861,260)
 
 
 
 
 
 
 
 
 
Denominator
 
 
 
 
 
 
 
Weighted avg. common shares outstanding
 
 
21,264,539
 
 
18,711,239
 
 
 
 
 
 
 
 
 
Diluted loss per share attributable to common stock
 
$
(0.13)
 
$
(0.26)
 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
The computation of diluted loss per share for the three months ended March 31, 2018 and 2017 does not include the following stock options and unvested restricted stock units to purchase shares in the computation of diluted loss per share because these instruments were antidilutive:
 
 
 
March 31,
 
 
 
2018
 
2017
 
Stock options
 
 
2,374,449
 
 
2,070,076
 
Unvested restricted stock units
 
 
203,998
 
 
287,000
 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Marketable Investment Securities (Tables)
3 Months Ended
Mar. 31, 2018
Investments, Debt and Equity Securities [Abstract]  
Available-for-sale Securities [Table Text Block]
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at March 31, 2018 and December 31, 2017 were as follows:
  
March 31, 2018
 
Amortized
Cost
 
Gross
unrealized
holding
gains
 
Gross
unrealized
holding
losses
 
Aggregate
fair value
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Government bonds and notes
 
$
2,992,811
 
$
-
 
$
(2,891)
 
$
2,989,920
 
Corporate bonds, notes and commercial paper
 
 
16,228,256
 
 
-
 
 
(16,802)
 
 
16,211,454
 
 
 
$
19,221,067
 
$
-
 
$
(19,693)
 
$
19,201,374
 
 
December 31, 2017
 
Amortized
Cost
 
Gross
unrealized
holding
gains
 
Gross
unrealized
holding
losses
 
Aggregate
fair value
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Government bonds and notes
 
$
4,744,566
 
$
-
 
$
(2,876)
 
$
4,741,690
 
Corporate bonds, notes and commercial paper
 
 
13,517,371
 
 
-
 
 
(1,740)
 
 
13,515,631
 
 
 
$
18,261,937
 
$
-
 
$
(4,616)
 
$
18,257,321
 
Schedule Of Available For Sale Securities Debt Maturities [Table Text Block]
Maturities of debt securities classified as available-for-sale securities at March 31, 2018 are as follows:
 
March 31, 2018
 
Amortized
Cost
 
Aggregate
fair value
 
Due within one year
 
$
19,221,067
 
$
19,201,374
 
 
 
$
19,221,067
 
$
19,201,374
 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value (Tables)
3 Months Ended
Mar. 31, 2018
Fair Value Disclosures [Abstract]  
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
 
 
 
 
 
 
Fair value measurements at reporting date using
 
 
 
March 31,
2018
 
Level 1 inputs
 
Level 2 inputs
 
Level 3 inputs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents - money market funds, commercial paper, and treasury bills
 
$
7,793,612
 
$
5,247,856
 
$
2,545,756
 
$
-
 
Government bonds and notes
 
 
2,989,920
 
 
2,989,920
 
 
-
 
 
-
 
Corporate bonds, notes and commercial paper
 
 
16,211,454
 
 
-
 
 
16,211,454
 
 
-
 
 
 
$
26,994,986
 
$
8,237,776
 
$
18,757,210
 
$
-
 
 
 
 
 
 
 
Fair value measurements at reporting date using
 
 
 
December 31,
2017
 
Level 1 inputs
 
Level 2 inputs
 
Level 3 inputs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents - money market funds
 
$
2,171,814
 
$
2,171,814
 
$
-
 
$
-
 
Government bonds and notes
 
 
4,741,690
 
 
4,741,690
 
 
-
 
 
-
 
Corporate bonds, notes and commercial paper
 
 
13,515,631
 
 
-
 
 
13,515,631
 
 
-
 
 
 
$
20,429,135
 
$
6,913,504
 
$
13,515,631
 
$
-
 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Loan and Security Agreement (Tables)
3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Schedule of Maturities of Long-term Debt [Table Text Block]
Principal payments on debt at March 31, 2018, are as follows:
 
(in thousands)
 
 
 
 
Years Ending December 31,
 
Amount
 
2018
 
$
 
2019
 
 
3,144
 
2020
 
 
3,330
 
2021
 
 
3,526
 
Thereafter
 
 
 
 
 
$
10,000
 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Leases (Tables)
3 Months Ended
Mar. 31, 2018
Leases [Abstract]  
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
 
 
 
Operating
 
 
 
leases
 
Year ending December 31:
 
 
 
 
2018
 
 
240,570
 
2019
 
 
53,460
 
Total minimum lease payments
 
$
294,030
 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2018
Stockholders Equity Note [Abstract]  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Stock-based compensation cost that has been expensed in the statements of operations amounted to $427,000 and $632,000 for the three months ended March 31, 2018 and 2017, allocated as follows:
 
 
 
Three Months Ended
March 31,
 
 
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Research and development
 
$
149,588
 
$
207,380
 
General and administrative
 
 
277,692
 
 
424,910
 
 
 
 
 
 
 
 
 
 
 
$
427,280
 
$
632,290
 
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
A summary of stock option activity is as follows:
 
 
Outstanding stock options
 
 
Number of
shares
 
Weighted average
exercise price
 
Balance at December 31, 2017
 
 
2,374,449
 
$
5.64
 
Options granted
 
 
-
 
 
-
 
Options exercised
 
 
-
 
 
-
 
Options forfeited
 
 
-
 
 
-
 
Options cancelled
 
 
-
 
 
-
 
Balance at March 31, 2018
 
 
2,374,449
 
 
5.64
 
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]
The following table summarizes information about stock options outstanding and exercisable at March 31, 2018:
 
Options outstanding
 
Options exercisable
 
Number
outstanding
 
Weighted average remaining contractual life (Years)
 
Weighted
average
exercise
price
 
Aggregate
intrinsic
value
 
Number exerciseable
 
Weighted average remaining contractual life (Years)
 
Weighted
average
exercise
price
 
Aggregate
intrinsic
value
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,374,449
 
 
7.20
 
$
5.64
 
$
-
 
 
1,522,295
 
 
6.10
 
$
6.20
 
$
-
 
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]
 
 
 
 
Number of
unvested restricted
shares
 
 
 
 
 
 
Balance at December 31, 2017
 
 
203,998
 
Granted
 
 
-
 
Vested
 
 
-
 
Cancelled
 
 
-
 
Balance at March 31, 2018
 
 
203,998
 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings (Loss) per Share (Details) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Basic loss per share attributable to common stock: Numerator    
Net loss $ (2,719,971) $ (4,861,260)
Denominator    
Weighted avg. common shares outstanding (in shares) 21,264,539 18,711,239
Basic loss per share attributable to common stock (in dollars per share) $ (0.13) $ (0.26)
Diluted loss per share attributable to common stock: Numerator    
Net loss $ (2,719,971) $ (4,861,260)
Denominator    
Weighted avg. common shares outstanding (in shares) 21,264,539 18,711,239
Diluted loss per share attributable to common stock (in dollars per share) $ (0.13) $ (0.26)
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings (Loss) per Share (Details 1) - shares
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Unvested restricted stock units [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 203,998 287,000
Stock options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2,374,449 2,070,076
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Marketable Investment Securities (Details) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost $ 19,221,067 $ 18,261,937
Gross unrealized holding gains 0 0
Gross unrealized holding losses (19,693) (4,616)
Aggregate fair value 19,201,374 18,257,321
Government bonds and notes [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 2,992,811 4,744,566
Gross unrealized holding gains 0 0
Gross unrealized holding losses (2,891) (2,876)
Aggregate fair value 2,989,920 4,741,690
Corporate bonds, notes and commercial paper [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 16,228,256 13,517,371
Gross unrealized holding gains 0 0
Gross unrealized holding losses (16,802) (1,740)
Aggregate fair value $ 16,211,454 $ 13,515,631
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Marketable Investment Securities (Details 1)
Mar. 31, 2018
USD ($)
Amortized Cost  
Due within one year $ 19,221,067
Amortized Cost, Total 19,221,067
Aggregate fair value  
Due within one year 19,201,374
Aggregate fair value, Total $ 19,201,374
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Marketable Investment Securities (Details Textual) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Proceeds from Sale and Maturity of Marketable Securities, Total $ 12.3 $ 8.4
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value (Details) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Assets:    
Marketable Investment Securities $ 19,201,374 $ 18,257,321
Assets, Fair Value 26,994,986 20,429,135
Money Market Funds [Member]    
Assets:    
Cash equivalents-money market funds   2,171,814
Money Market Funds, Commercial Paper, And Government Notes [Member]    
Assets:    
Cash equivalents-money market funds 7,793,612  
Corporate bonds, notes and commercial paper [Member]    
Assets:    
Marketable Investment Securities 16,211,454 13,515,631
Government Notes [Member]    
Assets:    
Marketable Investment Securities 2,989,920 4,741,690
Level 1 inputs [Member]    
Assets:    
Assets, Fair Value 8,237,776 6,913,504
Level 1 inputs [Member] | Money Market Funds [Member]    
Assets:    
Cash equivalents-money market funds   2,171,814
Level 1 inputs [Member] | Money Market Funds, Commercial Paper, And Government Notes [Member]    
Assets:    
Cash equivalents-money market funds 5,247,856  
Level 1 inputs [Member] | Corporate bonds, notes and commercial paper [Member]    
Assets:    
Marketable Investment Securities 0 0
Level 1 inputs [Member] | Government Notes [Member]    
Assets:    
Marketable Investment Securities 2,989,920 4,741,690
Level 2 inputs [Member]    
Assets:    
Assets, Fair Value 18,757,210 13,515,631
Level 2 inputs [Member] | Money Market Funds [Member]    
Assets:    
Cash equivalents-money market funds   0
Level 2 inputs [Member] | Money Market Funds, Commercial Paper, And Government Notes [Member]    
Assets:    
Cash equivalents-money market funds 2,545,756  
Level 2 inputs [Member] | Corporate bonds, notes and commercial paper [Member]    
Assets:    
Marketable Investment Securities 16,211,454 13,515,631
Level 2 inputs [Member] | Government Notes [Member]    
Assets:    
Marketable Investment Securities 0 0
Level 3 inputs [Member]    
Assets:    
Assets, Fair Value 0 0
Level 3 inputs [Member] | Money Market Funds [Member]    
Assets:    
Cash equivalents-money market funds   0
Level 3 inputs [Member] | Money Market Funds, Commercial Paper, And Government Notes [Member]    
Assets:    
Cash equivalents-money market funds 0  
Level 3 inputs [Member] | Corporate bonds, notes and commercial paper [Member]    
Assets:    
Marketable Investment Securities 0 0
Level 3 inputs [Member] | Government Notes [Member]    
Assets:    
Marketable Investment Securities $ 0 $ 0
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Loan and Security Agreement (Details)
$ in Thousands
Mar. 31, 2018
USD ($)
2018 $ 0
2019 3,144
2020 3,330
2021 3,526
Thereafter 0
Long-term Debt $ 10,000
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Loan and Security Agreement (Details Textual) - Loan and Security Agreement [Member] - Silicon Valley Bank [Member] - USD ($)
Jan. 05, 2018
Mar. 31, 2018
Debt Instrument, Face Amount $ 10,000,000  
Debt Instrument, Maturity Date Dec. 01, 2021  
Debt Instrument, Basis Spread on Variable Rate 1.00%  
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid $ 650,000  
Debt Instrument, Basis Spread On Interest Rate On Debt Default 5.00%  
Cash Collateral for Borrowed Securities   $ 5,000,000
Debt Instrument, Interest Rate Terms a fixed interest rate equal to the Prime Rate, as reported in money rates section of The Wall Street Journal or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum, which interest is payable monthly.  
Debt Instrument, Payment Terms The Company is only required to make monthly interest payments until December 31, 2018, following which the Company will be required to also make equal monthly payments of principal and interest for the remainder of the term; provided, however, that if on or prior to May 31, 2018, the Company receives evidence reasonably satisfactory to SVB that the Company has received FDA approval for TLANDOTM, the interest-only payment period will be extended to June 30, 2019.  
Debt Instrument, Debt Default, Description of Violation or Event of Default These events of default include, among other things, any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, the Companys insolvency, a material adverse change, and one or more judgments against the Company in an amount greater than $100,000 individually or in the aggregate.  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Contractual Agreements (Details Textual) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Schedule of Contractual Agreements [Line Items]    
Collaborative Arrangement, Rights and Obligations All obligations under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual 1% royalty on net sales.  
Contract Research And Development [Member]    
Schedule of Contractual Agreements [Line Items]    
Other Research and Development Expense $ 732,000 $ 2,400,000
Abbott Products, Inc. [Member] | Collaborative Arrangement [Member]    
Schedule of Contractual Agreements [Line Items]    
Collaborative Arrangement, Termination Date Mar. 29, 2012  
Collaborative Arrangement, Royalties, Maximum Amount $ 1,000,000  
Collaborative Arrangement, Royalties, Percentage of Reduction 50.00%  
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Leases (Details)
Mar. 31, 2018
USD ($)
Year ending December 31:  
2018 $ 240,570
2019 53,460
Total minimum lease payments $ 294,030
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Leases (Details Textual) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Operating Leased Assets [Line Items]    
Operating Leases, Rent Expense $ 83,000 $ 95,000
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity (Details) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Allocated Share-based Compensation Expense $ 427,280 $ 632,290
Research and development [Member]    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Allocated Share-based Compensation Expense 149,588 207,380
General and administrative [Member]    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Allocated Share-based Compensation Expense $ 277,692 $ 424,910
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity (Details 1) - Employee Stock Option [Member]
3 Months Ended
Mar. 31, 2018
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of Shares, Balance at beginning of the period (in shares) | shares 2,374,449
Number of Shares, Options granted (in shares) | shares 0
Number of Shares, Options exercised (in shares) | shares 0
Number of Shares, Options forfeited (in shares) | shares 0
Number of Shares, Options cancelled (in shares) | shares 0
Number of Shares, Balance at end of the period (in shares) | shares 2,374,449
Weighted average exercise price, Balance at beginning of the period (in dollars per share) | $ / shares $ 5.64
Weighted average exercise price, Options granted (in dollars per share) | $ / shares 0
Weighted average exercise price, Options exercised (in dollars per share) | $ / shares 0
Weighted average exercise price, Options forfeited (in dollars per share) | $ / shares 0
Weighted average exercise price, Options cancelled (in dollars per share) | $ / shares 0
Weighted average exercise price, Balance at end of the period (in dollars per share) | $ / shares $ 5.64
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity (Details 2) - Employee Stock Option [Member] - USD ($)
3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of options outstanding 2,374,449 2,374,449
Options outstanding, Weighted average remaining contractual life (Years) 7 years 2 months 12 days  
Options outstanding, Weighted average exercise price (in dollars per share) $ 5.64 $ 5.64
Options outstanding, Aggregate intrinsic value $ 0  
Number of options exerciseable 1,522,295  
Options exercisable, Weighted average remaining contractual life (Years) 6 years 1 month 6 days  
Options exercisable, Weighted average exercise price (in dollars per share) $ 6.20  
Options exercisable, Aggregate intrinsic value $ 0  
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity (Details 3) - Restricted Stock [Member]
3 Months Ended
Mar. 31, 2018
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of shares, Balance at beginning of the period 203,998
Number of shares, Granted 0
Number of shares, Vested 0
Number of shares, Cancelled 0
Number of shares, Balance at end of the period 203,998
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity (Details Textual) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Oct. 13, 2017
Jun. 30, 2016
Jun. 29, 2016
Nov. 13, 2015
Apr. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Allocated Share-based Compensation Expense $ 427,280 $ 632,290          
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total 2,400,000            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 0 $ 131,000          
Stock Issued During Period, Shares, New Issues   666,853          
Proceeds from Issuance of Common Stock $ 0 $ 2,698,098          
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 1 year 10 months 6 days            
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.001         $ 63.96  
Stock Issued During Period, Value, New Issues   $ 2,900,000          
Shares Issued, Price Per Share   $ 4.33          
Common Stock,Preferred Stock,Debt Securities,Warrants and Units To be Sold,Amount,Maximum     $ 150,000,000        
Common Stock, Additional Amount Authorized     $ 25,000,000        
Common Stock [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period   138,274          
At The Market Offering [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock Issued During Period, Shares, New Issues 2,518,109            
Proceeds from Issuance of Common Stock $ 10,600,000            
Controlled Equity Offering Sales Agreement, Maximum Amount Authorized   $ 20,000,000          
Stock Issued During Period, Value, New Issues $ 11,100,000            
Shares Issued, Price Per Share $ 4.40            
2014 Equity Incentive Plans [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized       2,471,906 1,271,906   1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 573,108            
2011 Equity Incentive Plan [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant             271,906
Restricted Stock Units (RSUs) [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total $ 736,000            
Stock Issued During Period, Shares, Restricted Stock Award, Gross   287,000          
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Details Textual) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Estimated Litigation Liability, Current $ 4,250,000 $ 4,250,000
Insurance Settlements Receivable, Current 3,566,649 $ 3,319,927
Settled Litigation [Member]    
Estimated Litigation Liability, Current 4,300,000  
Insurance Settlements Receivable, Current $ 3,600,000  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Spriaso, LLC (Details Textual) - USD ($)
1 Months Ended 3 Months Ended
Jul. 23, 2013
Mar. 31, 2018
Mar. 31, 2017
Related Party Transaction [Line Items]      
Percentage Of Fee To Be Received 20.00%    
Maximum Proceeds From Affiliates Under License Agreement $ 10,000,000    
Description Of Terms Of Service Agreement   Under the service agreement, the Company provided facilities and up to 10 percent of the services of certain employees to Spriaso for a period of 18 months which expired  
Service Fee $ 230    
Proceeds from License Fees Received   $ 428,000 $ 0
EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $! ITP?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ 0$"G3&;S"V"" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " ! 0*=,O> ("^X K @ $0 &1O8U!R;W!S+V-O M&ULS9+!2L0P$(9?17)O)]FB+J&;B^))07!!\1:2V=U@DX9DI-VWMXV[ M740?P&-F_GSS#4QKHC1]PN?41TSD,%^-O@M9FKAA!Z(H ;(YH->YGA)A:N[Z MY#5-S[2'J,V'WB.L.+\!CZ2M)@TSL(H+D:G6&FD2:NK3"6_-@H^?J2LP:P [ M]!@H@Z@%,#5/C,>Q:^$"F&&$R>?O MJ%6*I_8DL'V"DY9K>DAF&HAZ;DIAT$ MO#T]OI1U*Q621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( $! ITQX6YJL8P( !4( 8 >&PO=V]R:W-H965T&UL?5;;CILP$/T5Q ($M 93VPG; MOZ]M6):U35_BVSES9LR,)WG/^(NH")'!:T-;L0LK*;MM%(FR(@T63ZPCK3JY M,MY@J9;\%HF.$WPQI(9&,(ZSJ,%U&Q:YV3OQ(F=W2>N6G'@@[DV#^=\#H:S? MA2!\VWBN;Y74&U&1=_A&?A#YLSMQM8HF*Y>Z(:VH61MP[ ]@D03#.)7 M37HQFP5*@U^'L6[-V \G"1AI?@(<"7 B@/5_"6@DH'<",L$/GIE0/V&) MBYRS/N##U^JP3@JP1>HR2[UI[LZ^.F)EYX8>C*CI]8%N(C,+Y!Z!5*'OK($ M7,3:+Y!Y!3*'OK$$7 2(_0HKK\+*Y0-+8H"D!M(.GSD&"V&LO2)K5\3*E,, MR>:0A539>"4VKD1B27@@J5\"Q/Z"BET+F5U2L7-;($7I)EV26JA=X$K9N>7# M+'P6X"W@/8"N!3O!/!BXD&' 7\4 N1;L'/-AX(**O]B!6\L06<_1B/F0R@!F M28HVEE8T>V0;PF^F'XF@9/?6-,/9[M3S]M \TN_PH6%^Q_Q6MR(X,ZF>>O,@ M7QF31#D4/RE7*M6CIP4E5ZFG*S7G0Z,:%I)U8Q..IG\"Q3]02P,$% @ M0$"G3#T7M3SZ P ^1$ !@ !X;"]W;W)K %+Q:)5(BC39*!%7E M&2[P@;^Z_^K#1]GS<]W\:'T[1=[\*A;+_4IW",OVSK MYE!V\;)Y2=M3$\K-$'2H4E3*I8=R?TR6\^'>4[.9% \G[C^_YEU_4WTN7\5+Z$/T/WU^FIB5?IM97-_A".[;X^SIJP722_ MP&.!>1\P*/[>AW-[![;?P^3 W ,P&L MF \#]!B@24!Z<3:D^K7LRN6\J<^SYC);I[)?%/"HXV"N^YO#V V_Q6S;>/=M MB6:>OO7MC)+518*WDGM%(2CL59+&_J\F4#2!0[R^C7=RO!;C]1!O;N,SDL1% MD@V2XR#QUH$&35+A.HV@,I/+?HSHQW _GOBY2.Q-/Y"C IV1T2\$H4>;15>R M(RLZLMQ13AQ9UI')T!!5P56HE5QRHT7W7CNAFRWE>=9@T-C'5T[7(@6XSK+)]9. M+CK*N2.R:U8Y=X2:CF+!59E5F9*]@))YI;@;!BPE+-+,TJTNR+2ZE=W[F> G M<#^6^@%IPKQRQE-+7(E6HP4P$ZYDH (GJIX@*LA(!(2N0=*LE$CS^*8RD>2>Q\R49$3E?)_ MA9R4"+26+3Y3W;N1:8JQKKK<*<;@-9:F)M"#CA2R8J1EPNNOHTOFA)KV][EO\#4$L#!!0 ( $! ITPQUQ?: M8 ( )8( 8 >&PO=V]R:W-H965T&ULC99MKYL@%,>_ MBO$#5/"YC359798MV9+F+KM[35M:S55Q0-N[;S] ZQ2X;7TA#_[/.;\#"&17 M0M]8B3%WWINZ96NWY+Q;>1[;E[A!;$$ZW(HO1T(;Q$63GCS648P.RJBI/1^ MV&M0U;IYIOJV-,_(F==5B[?48>>F0?3O!M?DNG:A>^MXJ4XEEQU>GG7HA']B M_JO;4M'R1B^'JL$MJTCK4'Q*WQED[HC4]D1\B8;WPYK%T@B M7.,]ERZ0*"ZXP'4M/0F./X-3=XPI#:?UF_> MC^A<\Q=R_8J'A"+7&;+_CB^X%G))(F+L2K0W)1P%4@!G,O.]78 MJ6\B6R9Z+WD49=Y%^ADDFU[B3R3^7%%8%/^=>"+^".%;(7QE'TXA8@VBER1* MTBH)%$\0:[K"IO,A2(&=)[#R!"9/HO'TDG02!RP %##>2B;T816FM"D236: M7A)-LP;]H_$\(9P115:BR"1::D21$4A'N:>8,<16AMA@B+4(F_@APSW%C"&Q M,B0F@[8 -LESZ^2A;$:36FE2DT;[43?IA].OC\PSRAG3TLJT-)D"C6EI1/*A MGP _U)94\81P1@2!?<<#)E.H;WG %BL.HT"'>D8YI_I@'X8FE;$10R-6E$!] MYAZI>AIOJ9ZW8M"U4$KT2';=OO]1/7(S9565C'MNH.]=UT?Y:F\I>EC&/7R:^E(>CZR>2U>)4',R_QGT] M/;9^E%Q7V96U:;K2-E%K]LOX@=]O0/8!@^);:2[=S7O4I_)D[8]^\/=N&;/> MD:G,UO5+%/[Q;#:FJOJ5O(__ID7CZYY]X.W[R^J?AN1],D]%9S:V^E[NW'$9 MZSC:F7UQKMP7>_G+3 G).)JR_\<\F\K+>R=^CZVMNN%OM#UWSM;3*MY*7?P< MGV4S/"_3^B]A= !, 7 -X/+- #$%B-\!Z9#\Z&Q(]6/ABM6BM9>H'4_K5/1? M"GXO?#&W_>10N^$SGVWG9Y]76;9(GOMU)LEZE,"-A%\5B5_\N@-0.ZP!AT:P;,9(1AK)4$75S)DK,E[A1()#7RODD NE)*@@$ZP33 LE M.."\5)@7 MX"/EC.OP3A&Z5 LYEQ+-*BZP(1T:$KA\/(U>[(Z+ MT!(I@[F;3R.68\;JD+$6@)*[E6G,/<_R&@.0N8L^%%6D^:]ZI$ MR^:J!#1A@6,_X>^_2?,'52*4[U2)IC8 XKZ>^44(-&8!8Q;=D4GS!W>$4KYY M1X#&+6#K+.]TY#A[.WUAEOE-UYHT??]%X'E=F[_E7Y]W;L_,:!LZ>IJTVNK?7J?U!+ M P04 " ! 0*=,JFF(*6@$ 8% & 'AL+W=OWIOW2G:WM5U^KLNXVT;GOK\]QW.W/MBJZ M3\W5UNZ?8]-61>\NVU/<75M;',:@JHQ1"!U7Q:6.MNOQWFN[73?O?7FI[6N[ MZMZKJFC_W=FRN6TBB+[=^'PYG?OA1KQ=7XN3_F M7K7VN(E>X#F7:@@8%7]=[*U;_%X-J;PUS9?AXM?#)A*#(UO:?3\T4;BO#YO; MLAQ:4S>)?-6=#9ORK\OA_Z\B=)H=;#'XKWL/S>W M7^R96G)6J^#I]7^KQ^S;]8W . MXP-P#L![ *@?!L@Y0'X/2,;D)V=CJC\5?;%=M\UMU4Y/ZUH,DP*>I1O,_7!S M'+OQ/Y=MY^Y^;#.QCC^&=F;);I+@0@)W1>P:O_> 7 \[).'XV$%.%=KP/4@V M!SG&RV4. 8<)&Y^,\&=6*HD\1S8D@GTB0F]:Q056!$ M4]9'2GTHST=*>DC08.HMAYS*M$3, FXRUDU&W6C/34:[23+MJ7*J"O@ P2]_ M09T8?_T+THF;TZGV9E3.Z33H+& HP".@4S\-M,#RY@60I(29GQ)2JYB O^QS M1H=9%H 3\'0"2?Q(\/U(T@]H@8F_"!B=-DJ$AIC''5#>2?+,$V: A,-=XCNB M0BV,6BRN1TL\[T!12Z0,*>Z9:8/DH5%A:%'P] 2*3TEF$$7C$T#F2@*Q0Y4) M.&D2\,1S%!B0$D^4D4\.I1K!YSJK!)D:%2B>3@BA2.( MU'=#F4?<4 GJ+!6A:H\\%Y%R$80/1J2X"STL9C,J4NVV7@%7/!>1;CII!)*^S66$8(TRH2*+/*D18:T?F78(67HP#:39+XI*E3*E7[0O"G)(UA %D2QZ.DH&COWG:2S01>D!DH0F#R2!Z*DGE)]E>]9#:-H(3T4<_HT(C0*S\/1\^F0ZGLS MTYG9[T5[NM3=ZJWI^Z8:SV2.3=-;YU!\<@[/MCC<+TI[[(>?QOUNI[.JZ:)O MKO,Y7'P_#-S^!U!+ P04 " ! 0*=,53C4Q;8! #2 P & 'AL+W=O M)W\?0%['2?U"S##G#-GAB$;M'FU+8!#;U(HF^/6N6Y/B"U; MD,Q>Z0Z4OZFUD *C@;97DIF MW@\@])#C%%\<3[QI77"0(NM8 [_!_>F.QEMD9JFX!&6Y5LA G>/;='_8AO@8 M\,QAL(LS"I627/D1:OT'FPT!M0O'&W\VXYB-AM/= M](/(_(V+?U!+ P04 " ! 0*=,_>$5E[4! #2 P & 'AL+W=OBSXT&VG0\.5N:#:.$[^!_#V:+%5I9::NB=-#VQT!3T+CF>LA ? WY* MF-SF3$(E%V,>@_&E+N@A" (%E0\, K. MO:F",[8BWJ%XA]YKF? D9]= M,2BA/_!\[WX>FNPC3" MTU<*_T.0[1)DD2![19"^*7$O)GN3A&UZJL&V<9H>->!O8N/R%[" MYVG_)FPK>T&PO=V]R:W-H965T M&UL;5-M;Z,P#/XK47[ TJ;=BRI 6C=--VDG53MM]SD% ]$2 MS"6A[/[])8$RUN,+L8V?QX\=)^G1?-@:P)%/K1J;TMJY=L>8S6O0PEYA"XW_ M4Z+1PGG75,RV!D0105HQOEK=,"UD0[,DQ@XF2[!S2C9P,,1V6@OS=P\*^Y2N MZ3GP*JO:A0#+DE94\ O<6WLPWF,32R$U-%9B0PR4*;U?[_;;D!\3WB7T=F:3 MT,D1\2,XST5*5T$0*,A=8!#^.,$#*!6(O(P_(R>=2@;@W#ZS/\7>?2]'8>$! MU6]9N#JE=Y044(I.N5?L?\#8SS4E8_,O< +ETX,27R-'9>.7Y)UUJ$<6+T6+ MS^&433S[D?\,6P;P$< O &PH%)4_"B>RQ&!/S##[5H0K7N^XGTT>@G$4\9\7 M;WWTE*WY=<).@6C,V0\Y?)XS93#//I7@2R7V_#\X7X9O%A5N(GSS3>'-,L%V MD6 ;";;?"&XO6ES*N;LHPF8SU6"JN$V6Y-@U<9-GT6EA[WF\DZ_T8=M_"E/) MQI(C.G^S-L.:#8[#=GQ!;'K&V3]02P,$ M% @ 0$"G3&! "]&U 0 T@, !@ !X;"]W;W)K=&J=P7MO!^.C+FJ RW?2=;9F;T2O9P]D2-VHM[.\3*#,5-*6OCD?9=CXX M6)D/HH7OX'\,9XL66UEJJ:%WTO3$0E/0^_1X.H3X&/ D87*;,PF57(QY#L:7 MNJ!)$ 0**A\8!&Y7> "E A'*^+5PTC5E &[/K^R?8NU8RT4X>##JIZQ]5] [ M2FIHQ*C\HYD^PU+/.TJ6XK_"%12&!R68HS+*Q954H_-&+RPH18N7>9=]W*?Y M)KM=8/L O@#X"KB+>=B<*"K_*+PH#R(\<7KDV)LJ.&,KXAV*=^B] MEBG_D+-K(%IB3G,,W\:L$0S9UQ1\+\6)_P?G^_!L5V$6X=DV>Y;L$QQV"0Z1 MX/ /0?JFQ+V8MRK9IJ<:;!NGR9'*C'VSS;>M\?&'-E"UJX*]-#AS>UL5IX-&W#7&]! M5!&D%>.[W0W30G:TR*+O9(O,#%[)#DZ6N$%K8?\<09DQIWOZYGB43>N#@Q59 M+QKX"?Y7?[)HL86EDAHZ)TU'+-0YO=L?CFF(CP%/$D:W.I-0R=F8YV!\JW*Z M"X) 0>D#@\#M O>@5"!"&2\S)UU2!N#Z_,;^$&O'6L["P;U1OV7EVYS>4E)! M+0;E'\WX%>9ZKBF9B_\.%U 8'I1@CM(H%U=2#LX;/;.@%"U>IUUV<1^G&_YY MAFT#^ S@"^ VYF%3HJC\B_"BR*P9B9UZWXOPQ/L#Q]Z4P1E;$>]0O$/OI=@G M2<8N@6B..4XQ?!VS1#!D7U+PK11'_A^<;\.3385)A"?O%*;;!.DF01H)TG<$ MUQ]*W(JY^9"$K7JJP39QFAPIS=#%25YYEX&]X_%-_H5/T_Y#V$9VCIR-QY>- M_:^-\8!2=E&UL M;5/;;MP@$/T5Q <$+W::[6;ML8W"Q0&\3O^^@!W'2?T" MS##GS)EAR$=MGFT'X-"K%,H6N'.N/Q!BJPXDLU>Z!^5O&FTD<]XT+;&] 59' MD!2$)LD7(AE7N,RC[V3*7 ].< 4G@^P@)3-_CR#T6. =?G,\\+9SP4'*O&82E.5:(0--@6]WAV,6XF/ (X?1KLXH5'+6^CD8/^H")T$0 M"*A<8&!^N\ ="!&(O(R7F1,O*0-P?7YC_QYK][6YGFN,YN)_P@6$#P]*?(Y*"QM75 W6:3FS>"F2O4X[5W$?IYOT>H9M M ^@,H M@'_.0*5%4_HTY5N9&C\A,O>]9>.+=@?K>5,$96Q'OO'CKO9=RE][D MY!*(YICC%$/7,4L$\>Q+"KJ5XDC_@]-M>+JI,(WP](/"_39!MDF018+L \'7 M3R5NQ&3)IR1DU5,)IHW39%&E!Q4G>>5=!O:6QC=Y#Y^F_1GQTG&XU]<2V )Z]:=2ZGK??]@3%7MJ"%NS,]=/BG-E8+CZYMF.LMB"J" MM&)\MWO'M) =+;(8.]DB,X-7LH.3)6[06MC?1U!FS&E"KX%GV;0^!%B1]:*! M;^"_]R>+'EM8*JFA<])TQ$*=TX?D<$Q#?DSX(6%T*YN$3L[&O 3G%W@$I0(1RO@U<]*E9 "N[2O[Q]@[]G(6#AZ-^BDKW^;T R45U&)0 M_MF,GV#NYYZ2N?DO< &%Z4$)UBB-4,KN M#E>HQ0>V. IJ'\SW:-MIS2;'FWY^06QYQL4?4$L#!!0 ( $! ITP'Q0M> MM@$ -(# 9 >&PO=V]R:W-H965TVT-]J#]38-&<>=-TS+;&^!U!"G)TMWNCBDN M-"WSZ#N;,L?!2:'A;(@=E.+F[PDDC@5-Z*OC2;2="PY6YCUOX0>XG_W9>(LM M++50H*U 30PT!7U(CJ 7P)&NSJ34,D%\3D87^N"[H(@D%"YP,#]=H5' MD#(0>1E_9DZZI S ]?F5_7.LW==RX18>4?X6M>L*>J"DAH8/TCWA^ 7F>FXI MF8O_!E>0/CPH\3DJE#:NI!JL0S6S>"F*OTR[T'$?IYLLF6';@'0&I O@$/.P M*5%4_HD[7N8&1V*FWO<\/'%R3'UOJN",K8AW7KSUWFN99+8TQ:3K MF"6">?8E1;J5XI3^!T^WX?M-A?L(W[]3>+=-D&T29)$@>T=P_Z'$K9C#AR1L MU5,%IHW39$F%@XZ3O/(N _N0QC=Y"Y^F_3LWK="67-#YEXW];Q =>"F[&S]" MG?]@BR&A<>%X[\]F&K/)<-C//X@MW[C\!U!+ P04 " ! 0*=,]%?WHK8! M #2 P &0 'AL+W=OS\<&7-U#XJ[&S. QIO66,4]FK9C;K# FPA2DF5)\HXI+C2M MBN@[VZHPHY="P]D2-RK%[>\32#.5-*6OCB?1]3XX6%4,O(-OX+\/9XL66UD: MH4 [832QT);T(3V>\A ? WX(F-SF3$(E%V.>@_&Y*6D2!(&$V@<&CML5'D'* M0(0R?BV<=$T9@-OS*_O'6#O6X@L3PH 1SU$:ZN))Z=-ZHA06E*/XR[T+'?9IO\OL%M@_(%D"V NYB'C8G MBLH_<,^KPIJ)V+GW P]/G!XS[$T=G+$5\0[%._1>JS2_+]@U$"TQISDFV\:L M$0S9UQ397HI3]A\\VX(ORPS7Z;[!/DNP1Y),C_(4C?E+@7\U8EV_14 M@>WB-#E2FU''2=YXUX%]R.*;_ V?I_TKMYW0CER,QY>-_6^-\8!2DALSG<=L-KP9EA_$UF]<_0%02P,$% @ 0$"G3!/*>7>W 0 MT@, !D !X;"]W;W)K&UL;5/;;MLP#/T501]0 M)8[3%8%MH.E0=, *!"VV/2LV;0O5Q9/DN/W[4K+KN9U?))'B.3RDJ&PP]L6U M )Z\*JE=3EOONP-CKFQ!<7=E.M!X4QNKN$?3-LQU%G@504JR9+.Y9HH+38LL M^DZVR$SOI=!PLL3U2G'[=@1IAIQNZ8?C232M#PY69!UOX!G\K^YDT6(S2R44 M:">,)A;JG-YN#\ WP(&MSB34,G9F)=@_*ARN@F"0$+I P/'[0)W(&4@ M0AE_)TXZIPS Y?F#_3[6CK6O:43,7_ MA M(# ]*,$=II(LK*7OGC9I84(KBK^,N=-R'\6:?3K!U0#(!DAEP$_.P,5%4 M_IU[7F36#,2.O>]X>.+M(<'>E,$96Q'O4+Q#[Z78[G<9NP2B*>8XQB3+F#F" M(?N<(EE+<4S^@R?K\-VJPEV$[SXI3-<)TE6"-!*DGPCV7TIJK M-G&:'"E-K^,D+[SSP-XF\4W^A8_3_LAM([0C9^/Q96/_:V,\H)3-%8Y0BQ]L M-B34/AR_X=F.8S8:WG33#V+S-R[> 5!+ P04 " ! 0*=,G>[;Z+UTG\0LPPYPS9X8A&[1YM2V M0^]2*)OCUKEN3X@M6Y#,7ND.E+^IM9',>=,TQ'8&6!5!4A":)#=$,JYPD47? MT129[IW@"HX&V5Y*9OX>0.@AQQM\<3SSIG7!08JL8PW\ O>[.QIOD9FEXA*4 MY5HA W6.[S;[0QKB8\ ?#H-=G%&HY*3U:S"^5SE.@B 04+K P/QVAGL0(A!Y M&6\3)YY3!N#R?&%_C+7[6D[,PKT6+[QR;8YW&%50LUZX9ST\P53/-493\3_@ M#,*'!R4^1ZF%C2LJ>^NTG%B\%,G>QYVKN _C37J!K0/H!* S8!";Y]*7(FY23XE(8N>2C!- MG":+2MVK.,D+[SRP=S2^R?_P<=I_,M-P9=%)._^RL?^UU@Z\E.3*CU#K/]AL M"*A=.-[ZLQG';#2<[J8?1.9O7/P#4$L#!!0 ( $! ITS$@HHUL@$ -(# M 9 >&PO=V]R:W-H965T MO"BI74$[[_L#8Z[J0'%W9WK0^*8R= M;)F;P4NAX62)&Y3B]L\1I!D+FM!KX$FTG0\!5N8];^$[^!_]R:+'%I9:*-!. M&$TL- 5]2 ['+.3'A)\"1K>R2>CD;,QS<+[4!=T%02"A\H&!XW&!1Y R$*&, MWS,G74H&X-J^LG^*O6,O9^[@T43(W_Q4N M(#$]*,$:E9$N?DDU.&_4S()2%'^93J'C.<[\5]@V()T!Z0V 386B\H_<\S*W M9B1VFGW/PQ4GAQ1G4X5@'$7\A^(=1B]E;"O<1OG^C\#\$V29!%@FR-P3[FQ:WSN<(4Z?&"+(Z'QP7R/ MMIW6;'*\Z><7Q)9G7/X%4$L#!!0 ( $! ITS;JY:&PO=V]R:W-H965TM4M1IVV]B7W^H?+B X_;M!]CQO(S]"=SK<\\Y%[A)!Z7?3 -@T8?@TF2X ML;;;$V**!@0S-ZH#Z;Y42@MF7:AK8CH-K Q%@A.Z6NV(8*W$>1IR1YVGJK>\ ME7#4R/1",/UY *Z&#*_Q)?':UHWU"9*G':OA.]@?W5&[B,PL92M FE9)I*'* M\/UZ?T@\/@!^MC"8Q1[Y3DY*O?G@:YGAE3<$' KK&9A;SO G'LB9^-]XL2S MI"]<[B_L3Z%WU\N)&7A0_%=;VB;#=QB54+&>VUS M[YB_XO6>NK,I?#(<1?CFS!N7/>?K79*2LR>:,(<10Y>8&4$<^RQ!8Q('^D\Y MC9=OH@XWH7RS5*?_(=A&";:!8/M7B[NK%F.8V[A($A5)(@1W5R(QS)N>3[CD2BD+SLKJQGEI MW!3/ 8?*^NVMV^OQ+8^!5=TTIF3^K\A_ U!+ P04 " ! 0*=,BX$:/L4! M W! &0 'AL+W=OMO8E]_J'RX@./N[0?8==V,_3%P.?><H$2-,IB334.;Y/#\>=QP? [PY&LYHC7\E9J1>_^%;E./&&@$-I/0-SPP4> M@'-/Y&R\SIQXD?2)Z_D[^]=0NZOES P\*/[<5;;-\1U&%=1LX/9)C8\PU[/# M:"[^.UR .[AWXC1*Q4WXHG(P5HF9Q5D1[&T:.QG&<=K9[^>T> *=$^B2J#N;$H?#$<1]IQYXZ*7(MTG&;EXHAESG#!T MC5D0Q+$O$C0F<:3_I--X^B;JALGV$8)MH%@^ZG$]*K$&.8_+G=1 MD5V$8',E$L-LKT3(ZN($Z"8\68-*-S[ADFNE+#@KR8WSTKHN7A8<:NNG>S?7TUN>%E;U&UL;5/;;MP@$/T5Q <$+[O9C5:VI6RJ*I5::96H[3-KCR\*%P?P.OW[#-AQ MW=0OP SGG+DPI(.Q+ZX!\.1-2>TRVGC?'1ES10-*N!O3@<:;RE@E/)JV9JZS M(,I(4I+Q)-DS)5I-\S3ZSC9/3>]EJ^%LB>N5$O;/":09,KJA'XZGMFY\<+ \ M[40-S^!_=F>+%IM5RE:!=JW1Q$*5T?O-\;0+^ CXU<+@%F<2*KD8\Q*,;V5& MDY 02"A\4!"X7>$!I Q"F,;KI$GGD(&X/'^H?XVU8RT7X>#!R-]MZ9N,WE%2 M0B5ZZ9_,\ A3/;>43,5_ARM(A(=,,$9AI(LK*7KGC9I4,!4EWL:]U7$?QIO] M?J*M$_A$X#/A+L9A8Z"8^1?A19Y:,Q []KX3X8DW1XZ]*8(SMB+>8?(.O==\ M<[A-V34(39C3B.%+S(Q@J#Z'X&LA3OP_.E^G;UE!XTUCK.(>3=LRUUO@ M=20IR=(DN6>*"TW+//K.MLS-X*70<+;$#4IQ^_L$THP%W=&;XUFTG0\.5N8] M;^$;^._]V:+%%I5:*-!.&$TL- 5]W!U/643(7_P6N(!$>,L$8E9$NKJ0:G#=J5L%4%'^==J'C/DXW]S?: M-B&=">E".$0"FP+%S#]PS\OMT(Y7 MC?UOC/& J21W.$(=?K#%D-#X<'S LYW&;#*\Z>&PO=V]R:W-H965TDD8K0,HFJEJIE5:IVCY[80 K-J:V6=*_[]BPE&YY MP3/#.6CL6^N!?#D7:O.Y;3UOC\PYLH6M'!WIH<._]3&:N'1M0USO051 M19)6C.]V#TP+V=$BB[&3+3(S>"4[.%GB!JV%_7T$9<:<)O0:>)5-ZT. %5DO M&O@&_GM_LNBQ1:62&CHG34$T:UL$CHY&_,6G,]53G>A M(%!0^J @\+C ,R@5A+",7[,F75(&XMJ^JG^,O6,O9^'@V:B?LO)M3A\IJ: 6 M@_*O9OP$-LRA",HXC_L'B'T4N1/"89NP2A M&7.<,'R-61 ,U9<4?"O%D?]'Y]OT_6:%^TC?K[.G#]L"Z:9 &@72?UKD-RUN M8?8W2=AJIAIL$[?)D=(,7=SD5719V"<>[^0O?-KVK\(VLG/D;#S>;)Q_;8P' M+&5WARO4X@-;' 6U#^8'M.VT9I/C33^_(+8\X^(/4$L#!!0 ( $! ITQY M,U3 W0$ $% 9 >&PO=V]R:W-H965TMC:EMPO;O:QM"*75?L&=\YIR9 MP>-T%/)--0 :O7/6J0PW6OVDJL0;];X7&8XL D!@T); M!FJ6&SP#8Y;(I/%SYL2+I U<[^_L'UWMII8K5? LV(^VU$V&CQB54-&!Z1U[=PZSOSW,'] - =$ MFP R";G,/U!-\U2*$'O M,-$:LR"(85\D(I_$.?HG//*'[[P9[ESX;JT>!WZ"O9=@[PCV?Y48;TKT80Y^ MD=@K$GL(DHV(#W/TBQR\(@

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�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
XML 54 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 77 187 1 false 26 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.marathonbarcorp.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.marathonbarcorp.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] Sheet http://www.marathonbarcorp.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets [Parenthetical] Statements 3 false false R4.htm 104 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.marathonbarcorp.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 105 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.marathonbarcorp.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 106 - Disclosure - Basis of Presentation Sheet http://www.marathonbarcorp.com/role/BasisOfPresentation Basis of Presentation Notes 6 false false R7.htm 107 - Disclosure - Earnings (Loss) per Share Sheet http://www.marathonbarcorp.com/role/EarningsLossPerShare Earnings (Loss) per Share Notes 7 false false R8.htm 108 - Disclosure - Marketable Investment Securities Sheet http://www.marathonbarcorp.com/role/MarketableInvestmentSecurities Marketable Investment Securities Notes 8 false false R9.htm 109 - Disclosure - Fair Value Sheet http://www.marathonbarcorp.com/role/FairValue Fair Value Notes 9 false false R10.htm 110 - Disclosure - Loan and Security Agreement Sheet http://www.marathonbarcorp.com/role/LoanAndSecurityAgreement Loan and Security Agreement Notes 10 false false R11.htm 111 - Disclosure - Income Taxes Sheet http://www.marathonbarcorp.com/role/IncomeTaxes Income Taxes Notes 11 false false R12.htm 112 - Disclosure - Contractual Agreements Sheet http://www.marathonbarcorp.com/role/ContractualAgreements Contractual Agreements Notes 12 false false R13.htm 113 - Disclosure - Leases Sheet http://www.marathonbarcorp.com/role/Leases Leases Notes 13 false false R14.htm 114 - Disclosure - Stockholders' Equity Sheet http://www.marathonbarcorp.com/role/StockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 115 - Disclosure - Commitments and Contingencies Sheet http://www.marathonbarcorp.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 116 - Disclosure - Spriaso, LLC Sheet http://www.marathonbarcorp.com/role/SpriasoLlc Spriaso, LLC Notes 16 false false R17.htm 117 - Disclosure - Recent Accounting Pronouncements Sheet http://www.marathonbarcorp.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 17 false false R18.htm 118 - Disclosure - Earnings (Loss) per Share (Tables) Sheet http://www.marathonbarcorp.com/role/EarningsLossPerShareTables Earnings (Loss) per Share (Tables) Tables http://www.marathonbarcorp.com/role/EarningsLossPerShare 18 false false R19.htm 119 - Disclosure - Marketable Investment Securities (Tables) Sheet http://www.marathonbarcorp.com/role/MarketableInvestmentSecuritiesTables Marketable Investment Securities (Tables) Tables http://www.marathonbarcorp.com/role/MarketableInvestmentSecurities 19 false false R20.htm 120 - Disclosure - Fair Value (Tables) Sheet http://www.marathonbarcorp.com/role/FairValueTables Fair Value (Tables) Tables http://www.marathonbarcorp.com/role/FairValue 20 false false R21.htm 121 - Disclosure - Loan and Security Agreement (Tables) Sheet http://www.marathonbarcorp.com/role/LoanAndSecurityAgreementTables Loan and Security Agreement (Tables) Tables http://www.marathonbarcorp.com/role/LoanAndSecurityAgreement 21 false false R22.htm 122 - Disclosure - Leases (Tables) Sheet http://www.marathonbarcorp.com/role/LeasesTables Leases (Tables) Tables http://www.marathonbarcorp.com/role/Leases 22 false false R23.htm 123 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.marathonbarcorp.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.marathonbarcorp.com/role/StockholdersEquity 23 false false R24.htm 124 - Disclosure - Earnings (Loss) per Share (Details) Sheet http://www.marathonbarcorp.com/role/EarningsLossPerShareDetails Earnings (Loss) per Share (Details) Details http://www.marathonbarcorp.com/role/EarningsLossPerShareTables 24 false false R25.htm 125 - Disclosure - Earnings (Loss) per Share (Details 1) Sheet http://www.marathonbarcorp.com/role/EarningsLossPerShareDetails1 Earnings (Loss) per Share (Details 1) Details http://www.marathonbarcorp.com/role/EarningsLossPerShareTables 25 false false R26.htm 126 - Disclosure - Marketable Investment Securities (Details) Sheet http://www.marathonbarcorp.com/role/MarketableInvestmentSecuritiesDetails Marketable Investment Securities (Details) Details http://www.marathonbarcorp.com/role/MarketableInvestmentSecuritiesTables 26 false false R27.htm 127 - Disclosure - Marketable Investment Securities (Details 1) Sheet http://www.marathonbarcorp.com/role/MarketableInvestmentSecuritiesDetails1 Marketable Investment Securities (Details 1) Details http://www.marathonbarcorp.com/role/MarketableInvestmentSecuritiesTables 27 false false R28.htm 128 - Disclosure - Marketable Investment Securities (Details Textual) Sheet http://www.marathonbarcorp.com/role/MarketableInvestmentSecuritiesDetailsTextual Marketable Investment Securities (Details Textual) Details http://www.marathonbarcorp.com/role/MarketableInvestmentSecuritiesTables 28 false false R29.htm 129 - Disclosure - Fair Value (Details) Sheet http://www.marathonbarcorp.com/role/FairValueDetails Fair Value (Details) Details http://www.marathonbarcorp.com/role/FairValueTables 29 false false R30.htm 130 - Disclosure - Loan and Security Agreement (Details) Sheet http://www.marathonbarcorp.com/role/LoanAndSecurityAgreementDetails Loan and Security Agreement (Details) Details http://www.marathonbarcorp.com/role/LoanAndSecurityAgreementTables 30 false false R31.htm 131 - Disclosure - Loan and Security Agreement (Details Textual) Sheet http://www.marathonbarcorp.com/role/LoanAndSecurityAgreementDetailsTextual Loan and Security Agreement (Details Textual) Details http://www.marathonbarcorp.com/role/LoanAndSecurityAgreementTables 31 false false R32.htm 132 - Disclosure - Contractual Agreements (Details Textual) Sheet http://www.marathonbarcorp.com/role/ContractualAgreementsDetailsTextual Contractual Agreements (Details Textual) Details http://www.marathonbarcorp.com/role/ContractualAgreements 32 false false R33.htm 133 - Disclosure - Leases (Details) Sheet http://www.marathonbarcorp.com/role/LeasesDetails Leases (Details) Details http://www.marathonbarcorp.com/role/LeasesTables 33 false false R34.htm 134 - Disclosure - Leases (Details Textual) Sheet http://www.marathonbarcorp.com/role/LeasesDetailsTextual Leases (Details Textual) Details http://www.marathonbarcorp.com/role/LeasesTables 34 false false R35.htm 135 - Disclosure - Stockholders' Equity (Details) Sheet http://www.marathonbarcorp.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.marathonbarcorp.com/role/StockholdersEquityTables 35 false false R36.htm 136 - Disclosure - Stockholders' Equity (Details 1) Sheet http://www.marathonbarcorp.com/role/StockholdersEquityDetails1 Stockholders' Equity (Details 1) Details http://www.marathonbarcorp.com/role/StockholdersEquityTables 36 false false R37.htm 137 - Disclosure - Stockholders' Equity (Details 2) Sheet http://www.marathonbarcorp.com/role/StockholdersEquityDetails2 Stockholders' Equity (Details 2) Details http://www.marathonbarcorp.com/role/StockholdersEquityTables 37 false false R38.htm 138 - Disclosure - Stockholders' Equity (Details 3) Sheet http://www.marathonbarcorp.com/role/StockholdersEquityDetails3 Stockholders' Equity (Details 3) Details http://www.marathonbarcorp.com/role/StockholdersEquityTables 38 false false R39.htm 139 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.marathonbarcorp.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://www.marathonbarcorp.com/role/StockholdersEquityTables 39 false false R40.htm 140 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://www.marathonbarcorp.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://www.marathonbarcorp.com/role/CommitmentsAndContingencies 40 false false R41.htm 141 - Disclosure - Spriaso, LLC (Details Textual) Sheet http://www.marathonbarcorp.com/role/SpriasoLlcDetailsTextual Spriaso, LLC (Details Textual) Details http://www.marathonbarcorp.com/role/SpriasoLlc 41 false false All Reports Book All Reports lpcn-20180331.xml lpcn-20180331.xsd lpcn-20180331_cal.xml lpcn-20180331_def.xml lpcn-20180331_lab.xml lpcn-20180331_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 59 0001144204-18-025522-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-18-025522-xbrl.zip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end